<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757300</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5-13</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30081-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.003</ELocationID>
            <Abstract>
                <AbstractText>The best predictors of response to intravesical immunotherapy are tumor grade and stage, tumor recurrence pattern, nomograms, panels of urinary cytokines, and fluorescent in situ hybridization patterns of urine cytology examinations. Future investigations on predictors of Bacillus Calmette-Guérin efficacy are needed to better select those patients who will really benefit from a conservative treatment. Hardly any of the proposed nomograms were designed to precisely predict the outcome of Bacillus Calmette-Guérin immunotherapy. A new nomogram for NMIBC recurrence and progression based on all non-muscle-invasive bladder cancer subgroups would include factors already proven in cancer prognosis and prediction.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Faba</LastName>
                    <ForeName>Óscar Rodríguez</ForeName>
                    <Initials>ÓR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pisano</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krajewski</LastName>
                    <ForeName>Wojciech</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology and Oncological Urology, Wroclaw Medical University, Ludwika Pasteura 1, 50-367 Wrocław, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breda</LastName>
                    <ForeName>Alberto</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Palou</LastName>
                    <ForeName>Joan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fundacion Puigvert, carrer de Cartagena 340-350, 08025, Barcelona, Universitata Autonoma de Barcelona, Spain. Electronic address: jpalou@fundacio-puigvert.es.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001500" MajorTopicYN="N">BCG Vaccine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049451" MajorTopicYN="N">Nomograms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BCG</Keyword>
            <Keyword MajorTopicYN="N">Bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Nomograms</Keyword>
            <Keyword MajorTopicYN="N">Non-muscle invasive</Keyword>
            <Keyword MajorTopicYN="N">Predictors</Keyword>
            <Keyword MajorTopicYN="N">Recurrence</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757300</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30081-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31764822</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>47</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e18035</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000018035</ELocationID>
            <Abstract>
                <AbstractText>Chronic obstructive pulmonary disease (COPD) patients are at a higher risk of development of lung cancer. Frequent exacerbations of COPD trigger the disease course to chronic inflammation which likely plays a role in the pathogenesis of lung cancer. Previous studies showed influenza virus infection is one of important causes for exacerbations of COPD. Therefore, the aim of this study was to know whether influenza vaccination could reduce the incidence of lung cancer in patients with COPD.This cohort study enrolled patients (≥55 years old) with a recorded diagnosis of COPD between January 1, 2000 and December 31, 2012 by using the Taiwan Health Insurance Database. A propensity score was calculated to reduce vaccine therapy selection bias. Cox proportional hazard regressions were used to investigate the association between the influenza vaccination and lung cancer incidence after adjusting for known confounding factors. Besides, we categorized the patients into 4 groups according to vaccination status (unvaccinated, total number of vaccinations: 1, 2-3, ≥4) to evaluate the dose-dependent effect on reducing lung cancer occurrence of lung cancer in COPD patients.Our study comprised of 28,752 eligible individuals from the COPD cohort database. Among them, 51% (14,630) received influenza vaccination; the rest (49%) of the COPD patients did not receive influenza vaccination. We observed that COPD patients receiving influenza vaccination had a lower risk of lung cancer (adjusted HR = 0.40, 95% CI (0.35-0.45), P &lt; .001). We also founded comparable protective effect in both sexes and all age groups (55-64, 65-74, ≥75) regardless of influenza seasonality. Furthermore, dose-dependent protective effect could be seen after stratifying patients according to the total number vaccinations, the adjusted HRs for lung cancer risk were 0.48 (0.40-0.54) and 0.24 (0.20-0.29) for patients who received 2 to 3 and ≥4 vaccinations during the follow-up period.This population-based cohort study demonstrated that annual influenza vaccination administration could reduce incidence of lung cancer in COPD patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Kuan-Yuan</ForeName>
                    <Initials>KY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Sheng-Ming</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ju-Chi</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cardiovascular Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Kang-Yun</ForeName>
                    <Initials>KY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Pulmonary Medicine, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31764822</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000018035</ArticleId>
            <ArticleId IdType="pii">00005792-201911220-00053</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757298</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>35-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30084-9</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.006</ELocationID>
            <Abstract>
                <AbstractText>Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.</AbstractText>
                <CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cooley</LastName>
                    <ForeName>Lauren Folgosa</ForeName>
                    <Initials>LF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLaughlin</LastName>
                    <ForeName>Kimberly A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA; Department of Biochemistry, Northwestern University, Feinberg School of Medicine, Polsky Urologic Cancer Institute, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meeks</LastName>
                    <ForeName>Joshua J</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 16-703, Chicago, IL 60611, USA; Department of Biochemistry, Northwestern University, Feinberg School of Medicine, Polsky Urologic Cancer Institute, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. Electronic address: joshua.meeks@northwestern.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001500" MajorTopicYN="N">BCG Vaccine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BCG</Keyword>
            <Keyword MajorTopicYN="N">Bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Genomics</Keyword>
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Mutation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757298</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30084-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31764821</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>47</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association between TGF-β1 rs1982073/rs1800469 polymorphism and lung cancer susceptibility: An updated meta-analysis involving 7698 cases and controls.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e18028</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000018028</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There have been several case-control studies to assess the relationship between the transforming growth factor-β1 (TGF-β1) T + 869C (rs1982073)/C-509T (rs1800469) gene polymorphism and lung cancer in recent years; however, the results remain controversial. In this study, we investigated the potential correlation between the TGF-β1 T + 869C/C-509T polymorphism and increased risk of lung cancer through meta-analysis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We searched the Cochrane Library database, Embase, PubMed, Web of Science, China National Knowledge Infrastructure, and the Wanfang Data Information Service platform to identify relevant case-control studies in strict accordance with the inclusion and exclusion criteria. The odds ratio (OR) and its 95% confidence interval (95% CI) were used to evaluate the correlation between TGF-β1 gene polymorphism and lung tumor risk. Sensitivity analysis and Egger test were used to evaluate the stability of the results and possible publication bias.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 8 studies, with 3680 patients and 4018 controls, were included. The meta-analysis revealed that there was no conspicuous correlation between the TGF-β1 T + 869C (rs1982073)/C-509T (rs1800469) variant and lung cancer in the overall population. For TGF-β1 C-509T, a significant decreased risk was identified in patients with nonsmall-cell lung cancer (NSCLC) in the analysis stratified by disease (TT vs CT + CC: P = .02, OR = 0.49, 95% CI 0.27-0.90). However, for TGF-β1 T + 869C, subgroup analysis showed no correlation between the T + 869C polymorphism and lung cancer susceptibility in patients with NSCLC. In the subgroup analysis by ethnicity, no distinct association was observed between T + 869C (rs1982073)/C-509T (rs1800469) polymorphism and lung cancer susceptibility in the Asian and Caucasian groups. Moreover, no significant association was found in the analysis of groups stratified by age, sex, and smoking history.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The TGF-β1 T + 869C (rs1982073) and C-509T (rs1800469) polymorphisms are not implicated in lung cancer susceptibility in the overall population. However, our analysis indicated that the C-509T (rs1800469) polymorphism decreases the risk of lung cancer in patients with NSCLC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Guangyuan</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Cong</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Penghui</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Yuxuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Tianjin Medical University General Hospital, Tianjin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiu</LastName>
                    <ForeName>Mengxi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Haifei</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yiling</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Second Clinical Medical School, Nanchang University, Nanchang, Jiangxi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Evidence-based Medicine.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Jiangxi Province Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C508960">TGFB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31764821</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000018028</ArticleId>
            <ArticleId IdType="pii">00005792-201911220-00052</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757295</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.</ArticleTitle>
            <Pagination>
                <MedlinePgn>119-128</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30092-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.014</ELocationID>
            <Abstract>
                <AbstractText>Bacillus Calmette-Guerin (BCG)-refractory high-grade non-muscle-invasive bladder cancer remains a challenging problem. Radical cystectomy is standard of care, but carries significant morbidity. Therefore, there is a need for effective treatments. Previous salvage intravesical therapies have had disappointing results with long-term follow-up; however, a wide array of novel agents is currently under investigation. These include novel combinations of existing intravesical agents, novel modes of delivery such as hyperthermia, viral mediated therapies, and immunotherapy. We review the need for novel treatment with existing agents and their long-term results, and discuss novel intravesical therapies and the data currently available on these therapies.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khaled</LastName>
                    <ForeName>Dunia</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Holzbeierlein</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3016, Kansas City, KS 66160, USA. Electronic address: jholzbeierlein@kumc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001500">BCG Vaccine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001500" MajorTopicYN="N">BCG Vaccine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BCG failure</Keyword>
            <Keyword MajorTopicYN="N">Intravesical therapy</Keyword>
            <Keyword MajorTopicYN="N">Non–muscle-invasive bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Novel agents</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757295</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30092-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.014</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31764811</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>47</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Safety and efficacy of laparoscopic gastrectomy in obese patients with gastric cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17991</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017991</ELocationID>
            <Abstract>
                <AbstractText>The present study aimed to investigate the safety and short-term outcome of laparoscopy-assisted distal radical gastrectomy in treating gastric cancer among obese patients.Perioperative outcomes were compared between 67 gastric cancer patients with a body mass index (BMI) ≥25 kg/m (obese group) and 198 ones with BMI &lt;25 kg/m (non-obese group). All the cases underwent laparoscopic radical resection between April 2009 and October 2013.The value of BMI was 27.3 ± 2.67 kg/m in the obese group and 21.3 ± 2.64 kg/m in non-obese group. There were no significant differences between 2 groups in age, sex, presence of diabetes, tumor size, number of metastatic lymph nodes, or metastatic lymph node ratio. Postoperative complications did not differ between the 2 groups (P &gt; .05). There were significant differences between the 2 groups in operation time (non-obese: [234.2 ± 67.1] minutes vs obese group: [259.4 ± 78.5]; P = .017), postoperative hospital stay (obese group [19.7 ± 14.8] day vs non-obese [15.4 ± 7.1], P = .002), and retrieved lymph nodes ([27.6 ± 11.0] day vs non-obese [31.9 ± 12.5] day, P = .002).Obesity may prolong operation time and postoperative hospital stay, and cause less retrieved lymph nodes, but does not increase the incidence of postoperative complications. The experienced center can properly conduct laparoscopic assisted radical gastrectomy in obese patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Maoxing</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery IV, Peking University Cancer Hospital &amp; Institute, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xing</LastName>
                    <ForeName>Jiadi</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arslan</LastName>
                    <ForeName>Ahmet</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Yingcong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Xinyu</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Zhendan</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Nan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Chenghai</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cui</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Xiangqian</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005743" MajorTopicYN="N">Gastrectomy</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31764811</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017991</ArticleId>
            <ArticleId IdType="pii">00005792-201911220-00042</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757294</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>111-118</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30091-6</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.013</ELocationID>
            <Abstract>
                <AbstractText>Due to significant risks of cancer recurrence and progression, and limited options after intravesical Bacillus Calmette Guerin (BCG) therapy, there is a critical unmet need to identify novel treatments for those patients with BCG-unresponsive bladder cancer. There is active investigation of immunotherapies which provide both biologic and clinical rationales for indoleamine-2,3- dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>Carissa E</ForeName>
                    <Initials>CE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of California, San Francisco, 550 16th Street, 6th Floor, San Francisco, CA 94143, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Porten</LastName>
                    <ForeName>Sima P</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of California, San Francisco, 550 16th Street, 6th Floor, San Francisco, CA 94143, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grossfeld</LastName>
                    <ForeName>Gary D</ForeName>
                    <Initials>GD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville, New Jersey 08648, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meng</LastName>
                    <ForeName>Maxwell V</ForeName>
                    <Initials>MV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of California, San Francisco, 550 16th Street, 6th Floor, San Francisco, CA 94143, USA. Electronic address: max.meng@ucsf.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010091">Oximes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0A7729F42K</RegistryNumber>
                <NameOfSubstance UI="C000630574">linrodostat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71596A9R13</RegistryNumber>
                <NameOfSubstance UI="C000613752">epacadostat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8DUH1N11BX</RegistryNumber>
                <NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.11.11</RegistryNumber>
                <NameOfSubstance UI="D014366">Tryptophan Oxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XD0FY1J13B</RegistryNumber>
                <NameOfSubstance UI="C525396">1-methyltryptophan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014366" MajorTopicYN="N">Tryptophan Oxygenase</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BCG-unresponsive</Keyword>
            <Keyword MajorTopicYN="N">IDO inhibitors</Keyword>
            <Keyword MajorTopicYN="N">Non–muscle invasive bladder cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757294</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30091-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.013</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31758539</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1189</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cancer Immunotherapy Targeting Co-signal Molecules.</ArticleTitle>
            <Pagination>
                <MedlinePgn>313-326</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-981-32-9717-3_11</ELocationID>
            <Abstract>
                <AbstractText>Great success of immune checkpoint blockade represented by anti-PD-1 monoclonal antibodies (mAbs) has changed a landscape of cancer immunotherapy. There is no doubt about an importance of co-signal molecules as one of the most promising targets in anti-cancer drugs. However, it should be noted that the proportion of patients who have objective and durable responses to immune checkpoint blockade remains less than 30% in majority of cancers. Thus, in addition to refine the usage of existing drugs for checkpoint blockade, identification and characterization of novel checkpoint molecules other than CTLA-4 and PD-1 is a highly anticipated research subject. In addition, agonists of stimulatory co-signal molecules have a potential to further improve anti-tumor effects, rendering them attractive in research and drug development. In this chapter, functions of co-signal molecules in anti-tumor immunity in terms of pre-clinical animal models as well as clinical trials are described.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nakajima</LastName>
                    <ForeName>Masao</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamada</LastName>
                    <ForeName>Koji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan. ktamada@yamaguchi-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="Y">Immunotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Agonistic antibody</Keyword>
            <Keyword MajorTopicYN="N">Immune checkpoint blockade</Keyword>
            <Keyword MajorTopicYN="N">Inhibitory co-signals</Keyword>
            <Keyword MajorTopicYN="N">Stimulatory co-signals</Keyword>
            <Keyword MajorTopicYN="N">T cell exhaustion</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31758539</ArticleId>
            <ArticleId IdType="doi">10.1007/978-981-32-9717-3_11</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757293</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>103-110</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30090-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.012</ELocationID>
            <Abstract>
                <AbstractText>This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non-muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non-muscle-invasive bladder cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sathianathen</LastName>
                    <ForeName>Niranjan J</ForeName>
                    <Initials>NJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Minnesota, 420 Delaware Street Southeast, MMC 394, Minneapolis, MN, USA; Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia. Electronic address: nsathian@umn.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Regmi</LastName>
                    <ForeName>Subodh</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Minnesota, 420 Delaware Street Southeast, MMC 394, Minneapolis, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Shilpa</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Konety</LastName>
                    <ForeName>Badrinath R</ForeName>
                    <Initials>BR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, University of Minnesota, 420 Delaware Street Southeast, MMC 394, Minneapolis, MN, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016879" MajorTopicYN="N">Salvage Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Non–muscle-invasive bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Oncology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757293</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30090-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
        <PMID Version="1">31752898</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1743-8977</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Particle and fibre toxicology</Title>
                <ISOAbbreviation>Part Fibre Toxicol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Commentary: the chronic inhalation study in rats for assessing lung cancer risk may be better than its reputation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>44</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12989-019-0330-4</ELocationID>
            <Abstract>
                <AbstractText>Recently, Borm and Driscoll published a commentary discussing grouping of Poorly Soluble particles of Low Toxicity (PSLTs) and the use of rats as an animal model for human hazard assessment of PSLTs (Particle and Fibre Toxicology (2019) 16(1):11). The commentary was based on the scientific opinion of several international experts on these topics. The general conclusion from the authors was a cautious approach towards using chronic inhalation studies in rats for human hazard assessment of PSLTs. This was based on evidence of inhibition of particle clearance leading to overload in the rats after high dose exposure, and a suggested over reactivity of rat lung cancer responses compared to human risk.As a response to the commentary, we here discuss evidence from the scientific literature showing that a) diesel exhaust particles, carbon black nanoparticles and TiO<sub>2</sub> nanoparticles have similar carcinogenic potential in rats, and induce lung cancer at air concentrations below the air concentrations that inhibit particle clearance in rats, and b) chronic inhalation studies of diesel exhaust particles are less sensitive than epidemiological studies, leading to higher risk estimates for lung cancer. Thus, evidence suggests that the chronic inhalation study in rats can be used for assessing lung cancer risk insoluble nanomaterials.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saber</LastName>
                    <ForeName>Anne T</ForeName>
                    <Initials>AT</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Research Centre for the Working Environment, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poulsen</LastName>
                    <ForeName>Sarah S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Research Centre for the Working Environment, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hadrup</LastName>
                    <ForeName>Niels</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Research Centre for the Working Environment, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobsen</LastName>
                    <ForeName>Nicklas R</ForeName>
                    <Initials>NR</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Research Centre for the Working Environment, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vogel</LastName>
                    <ForeName>Ulla</ForeName>
                    <Initials>U</Initials>
                    <Identifier Source="ORCID">0000-0001-6807-1524</Identifier>
                    <AffiliationInfo>
                        <Affiliation>National Research Centre for the Working Environment, Copenhagen, Denmark. ubv@nfa.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016422">Letter</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D016420">Comment</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Part Fibre Toxicol</MedlineTA>
            <NlmUniqueID>101236354</NlmUniqueID>
            <ISSNLinking>1743-8977</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053260">Soot</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001335">Vehicle Emissions</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentOn">
                <RefSource>Part Fibre Toxicol. 2019 Feb 21;16(1):11</RefSource>
                <PMID Version="1">30791931</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053260" MajorTopicYN="N">Soot</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001335" MajorTopicYN="N">Vehicle Emissions</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31752898</ArticleId>
            <ArticleId IdType="doi">10.1186/s12989-019-0330-4</ArticleId>
            <ArticleId IdType="pii">10.1186/s12989-019-0330-4</ArticleId>
            <ArticleId IdType="pmc">PMC6873684</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Scand J Work Environ Health. 2015 Sep 1;41(5):467-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26153779</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Environ Mol Mutagen. 2007 Oct;48(8):682-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17896790</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Environ Health Perspect. 2014 Feb;122(2):172-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24273233</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>IARC Monogr Eval Carcinog Risks Hum. 2010;93:1-413</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21449489</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Occup Environ Med. 2014 Jan;71(1):30-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24186945</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Res Rep Health Eff Inst. 1994 Oct;(68 Pt 1):1-75; discussion 77-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7530965</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Environ Mol Mutagen. 2007 Jul;48(6):451-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17584883</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Toxicol Sci. 2005 Dec;88(2):614-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16177241</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Toxicol Appl Pharmacol. 1996 Feb;136(2):372-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8619246</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Inhal Toxicol. 2005 Oct;17(11):549-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16033752</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Fundam Appl Toxicol. 1991 Aug;17(2):280-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1662648</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Environ Mol Mutagen. 2011 May;52(4):331-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20963790</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Toxicol Appl Pharmacol. 1985 Jun 30;79(2):179-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4002222</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Appl Toxicol. 1989 Feb;9(1):23-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2466883</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Part Fibre Toxicol. 2019 Feb 21;16(1):11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30791931</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31748017</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1550-7033</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of biomedical nanotechnology</Title>
                <ISOAbbreviation>J Biomed Nanotechnol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A Humanized Cancer-Bone Metastasis Mouse Model Based on Silica Nanoparticles-Incorporated Human Demineralized Bone Matrix.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2363-2375</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1166/jbn.2019.2860</ELocationID>
            <Abstract>
                <AbstractText>Breast cancer tends to spread to other organs and bone metastasis has the highest frequency in breast cancer metastasis, while its mechanisms are not clear and the current treatments are not very effective. To better study the mechanisms and facilitate drug screening for breast cancer bone metastasis, an <i>in vivo</i> mouse model needs to be constructed. However, the construction of the humanized mouse model for cancer bone metastasis which will mimick real interactions between cancer tissue and bone tissue in the human microenvironment remains a challenge. In this study, we constructed a human engineering bone tissue composed with the human osteoblast-like cells (SaOS-2 cells) and the silica nanoparticlesincorporated human demineralized bone matrix (Si/DBM). The engineered bone was then transplanted into a nude mouse to build a humanized bone microenvironment. The human breast cancer cells were then injected into the fat pads of the nude mouse to form an orthotopic tumor. The results showed that the engineered bone tissue-constructed humanized bone microenvironment had significant advantages when inducing human cancer cells to metastasize into the engineered bone tissue. Further, the SaOS-2/Si/DBM had a stronger ability to entice cancer-bone metastasis through promoting osteogenesis compared to the SaOS-2/DBM. Accordingly, this study highlights a novel, facile and effective mouse model for human cancer-bone metastasis, which will provide a platform to explore the mechanisms and anti-tumor drug screening for cancer-bone metastasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Genlan</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chuangkun</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Xiaoliang</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Leyu</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Xiaozhong</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biomed Nanotechnol</MedlineTA>
            <NlmUniqueID>101230869</NlmUniqueID>
            <ISSNLinking>1550-7033</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7631-86-9</RegistryNumber>
                <NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001857" MajorTopicYN="N">Bone Matrix</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001859" MajorTopicYN="Y">Bone Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023822" MajorTopicYN="N">Tissue Engineering</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31748017</ArticleId>
            <ArticleId IdType="doi">10.1166/jbn.2019.2860</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31748012</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1550-7033</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of biomedical nanotechnology</Title>
                <ISOAbbreviation>J Biomed Nanotechnol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intercellular Crosstalk of Mesenchymal Stem Cells with Prostate Cancer Cells via Microvesicles Loaded with Magnetic Nanocubes for Targeted Magnetic Hyperthermia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2291-2304</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1166/jbn.2019.2868</ELocationID>
            <Abstract>
                <AbstractText>The targeted delivery of nanomedicines into solid tumors remains challenging in cancer treatment. Stem cells with tumortropic migration ability are promising as biocarriers to transport nanomedicines. The transportation of nanomedicines into cancer cells is the key step for tumor targeted delivery via stem cells. In this study, we designed a magnetic nanocube (scMNP) loaded in mesenchymal stem cells for magnetic hyperthermia of prostate cancer, and the delivery and transportation pathways into the cancer cells were fully investigated. The MSCs acted as the carrier of the loaded scMNPs along with the upregulation of CXCR4 for the migration to cancer cells. The therapeutic effect was mainly due to scMNPs via magnetic hyperthermia. Stem cell-derived microvesicles containing scMNPs played an essential role in the crosstalk between stem cells and cancer cells for targeted delivery. Both <i>in vitro</i> and <i>in vivo</i> studies demonstrated that the system showed satisfactory therapeutic efficiency under magnetic hyperthermia therapy. Our investigation presents a comprehensive study of magnetic nanoparticles in combination with MSCs and their extracellular microvesicles and is promising as an effective strategy for magnetic hyperthermia therapy of prostate cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Liqun</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Mengwei</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Chang</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Qishuai</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jiaojiao</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ning</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>Xiaofei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biomed Nanotechnol</MedlineTA>
            <NlmUniqueID>101230869</NlmUniqueID>
            <ISSNLinking>1550-7033</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006979" MajorTopicYN="Y">Hyperthermia, Induced</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008280" MajorTopicYN="N">Magnetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31748012</ArticleId>
            <ArticleId IdType="doi">10.1166/jbn.2019.2868</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31757302</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1558-318X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>47</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Urologic clinics of North America</Title>
                <ISOAbbreviation>Urol. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?</ArticleTitle>
            <Pagination>
                <MedlinePgn>73-82</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0094-0143(19)30087-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ucl.2019.09.009</ELocationID>
            <Abstract>
                <AbstractText>Apaziquone is an interesting drug for intravesical use in patients with nonmuscle invasive bladder cancer; however, more research is needed to prove its actual benefit. Although the apaziquone trials demonstrate the potential of this new drug, the singular phase 3 trials did not reach their primary endpoint. To date, no new trials are recruiting, so the development of apaziquone seems to have stopped.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Arends</LastName>
                    <ForeName>Tom J H</ForeName>
                    <Initials>TJH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alfred Witjes</LastName>
                    <ForeName>Johannes</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Radboud University Nijmegen Medical Centre, Geert Groote plein zuid 10, 6525 GA Nijmegen, The Netherlands. Electronic address: fred.witjes@radboudumc.nl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Urol Clin North Am</MedlineTA>
            <NlmUniqueID>0423221</NlmUniqueID>
            <ISSNLinking>0094-0143</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001388">Aziridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D045563">Indolequinones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>H464ZO600O</RegistryNumber>
                <NameOfSubstance UI="C060817">apaziquone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000283" MajorTopicYN="N">Administration, Intravesical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001388" MajorTopicYN="N">Aziridines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002295" MajorTopicYN="N">Carcinoma, Transitional Cell</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045563" MajorTopicYN="N">Indolequinones</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apaziquone</Keyword>
            <Keyword MajorTopicYN="N">Bladder cancer</Keyword>
            <Keyword MajorTopicYN="N">Experimental</Keyword>
            <Keyword MajorTopicYN="N">Nonmuscle invasive</Keyword>
            <Keyword MajorTopicYN="N">Therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31757302</ArticleId>
            <ArticleId IdType="pii">S0094-0143(19)30087-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ucl.2019.09.009</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31767027</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">0717-6287</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biological research</Title>
                <ISOAbbreviation>Biol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gramicidin inhibits human gastric cancer cell proliferation, cell cycle and induced apoptosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>57</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s40659-019-0264-1</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastric cancer is a common malignant tumor with high morbidity and mortality worldwide, which seriously affects human health. Gramicidin is a short peptide antibiotic which could be used for treating infection induced by bacteria or fungi. However, the anti-cancer effect of gramicidin on gastric cancer cells and its underlying mechanism remains largely unknown.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Gastric cancer cells SGC-7901, BGC-823 and normal gastric mucosal cells GES-1 were treated with different concentrations of gramicidin respectively. The results of CCK-8 experiment revealed cellular toxicity of gramicidin to cancer cells while cell colony formation assay showed that gramicidin significantly inhibited the proliferation of gastric cancer cells, but had little effect on normal gastric mucosal cells. In addition, the wound healing assay showed that gramicidin inhibited the migration of SGC-7901 cell. Meanwhile, apoptosis and cell cycle analysis revealed that gramicidin induced cell apoptosis with G2/M cell cycle inhibition. Furthermore, western blot analysis demonstrated that gramicidin down-regulated the expression of cyclinD1 and Bcl-2 as well as the FoxO1 phosphorylation.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current study illustrated the anti-tumor activity of gramicidin on gastric cancer cells, providing a possibility for gramicidin to be applied in clinical practice for the treatment of gastric cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Tingting</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Zhoupu Hospital affiliated to Shanghai Health Medical College, Shanghai, 201318, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Kaikai</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Engineering Research Center of Cell &amp; Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cao</LastName>
                    <ForeName>Xiangliao</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Huanbai</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Yongde</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology and Metabolism, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Yudong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Engineering Research Center of Cell &amp; Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China. ydhfighting@alumni.sjtu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qian</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China. fengqian@sjtu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Engineering Research Center of Cell &amp; Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, People's Republic of China. fengqian@sjtu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Zishu</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Anhui Province Key Laboratory of Translational Cancer Research (Bengbu Medical College), 287 Changhuai Road, Bengbu, 233004, Anhui Province, People's Republic of China. wzshahbb@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2017YFC0908500</GrantID>
                    <Agency>The National Key Research and Development Program of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81573438</GrantID>
                    <Agency>National Natural Science Foundation of China (CN)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81773741</GrantID>
                    <Agency>National Natural Science Foundation of China (CN)</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>16CR4025A</GrantID>
                    <Agency>Three-year Action Plan for Promoting Clinical Skills and Innovation in Municipal Hospitals</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Biol Res</MedlineTA>
            <NlmUniqueID>9308271</NlmUniqueID>
            <ISSNLinking>0716-9760</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000595707">BCL2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071161">Forkhead Box Protein O1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>136601-57-5</RegistryNumber>
                <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1405-97-6</RegistryNumber>
                <NameOfSubstance UI="D006096">Gramicidin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071161" MajorTopicYN="N">Forkhead Box Protein O1</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006096" MajorTopicYN="N">Gramicidin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Cell cycle arrest</Keyword>
            <Keyword MajorTopicYN="N">Gramicidin</Keyword>
            <Keyword MajorTopicYN="N">Proliferation</Keyword>
            <Keyword MajorTopicYN="N">SGC-7901</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31767027</ArticleId>
            <ArticleId IdType="doi">10.1186/s40659-019-0264-1</ArticleId>
            <ArticleId IdType="pii">10.1186/s40659-019-0264-1</ArticleId>
            <ArticleId IdType="pmc">PMC6878685</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Mol Med. 2016 Jul;22(7):534-544</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27260398</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2017 Aug 1;28(8):1767-1775</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28184417</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Jul;66(4):271-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27253694</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 2011 Nov;1813(11):1978-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21440011</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Membr Biol. 1996 Oct-Dec;13(4):225-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9116761</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 1991 Feb 25;1062(2):206-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1706202</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2015 Mar 1;136(5):E359-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25220842</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Cell Biol. 2018 Nov;28(11):911-925</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30061045</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):686-699</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28161329</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Toxicol Pathol. 2007 Jun;35(4):495-516</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17562483</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 2007 Sep;1768(9):2011-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17572379</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Biochem. 2005 Dec 1;96(5):906-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16163738</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 2014 Oct;1843(10):2240-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24768714</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2018 Sep 21;9(74):34022-34029</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30338043</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2011 Oct 14;147(2):275-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22000009</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Cycle. 2014;13(5):807-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24407358</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Semin Cell Dev Biol. 2017 Dec;72:152-162</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28396106</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Cell. 2017 Jan 9;31(1):2-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28073002</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>In Vivo. 2018 Jan-Feb;32(1):1-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29275292</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13150-13155</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27799526</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncogene. 2005 Nov 14;24(50):7410-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16288288</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Clin Microbiol Infect Dis. 2016 May;35(5):763-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26886453</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Pathol. 2012 Aug;227(4):470-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22450659</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 Apr;13(4):788-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24493697</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Cancer. 2017 Dec;3(12):857-870</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29198441</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 1989 Sep 28;976(2-3):241-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2477065</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Exp Clin Cancer Res. 2016 Sep 27;35(1):153</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27670139</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Res. 2017 Apr;15(4):489-497</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28096479</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Lett. 2004 Jan 8;203(1):1-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14670612</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2008 Mar 21;319(5870):1665-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18356527</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Virol. 1997;142(11):2225-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9672588</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Ther. 2013 Nov;12(11):2296-307</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24006494</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2012 Mar;13(3):239-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22285168</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2011 Jun 22;11:264</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21696576</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biomed Pharmacother. 2017 Nov;95:477-486</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28865368</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31739375</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-7803</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>57</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zeitschrift fur Gastroenterologie</Title>
                <ISOAbbreviation>Z Gastroenterol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunoglobulin G4 (IgG4)-related disease of the stomach - a challenging differential diagnosis in suspected gastric cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1298-1303</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1055/a-1013-4437</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND"> Immunoglobulin G4-related disease (IgG4-RD) can involve different organs and is diagnosed by a combination of clinicopathological features, including storiform fibrosclerosis infiltrated by numerous IgG4-positive plasma cells that frequently forms tumor-like lesions with or without associated obliterative phlebitis. Involvement of the stomach is rare and can occur as part of a multiorgan involvement of IgG4-RD or as isolated gastric involvement.</AbstractText>
                <AbstractText Label="CASE REPORT" NlmCategory="METHODS"> We report 2 female patients with therapy-refractory gastric ulcers associated with gastric wall thickening and lymphadenopathy that were highly suggestive of gastric cancer or lymphoma. Biopsies failed to confirm a diagnosis, and IgG4-RD was diagnosed only after surgical resection in both patients. The previous literature on gastric IgG4-RD is summarized and shows different characteristics in patients with multiorgan IgG4-RD and isolated gastric IgG4-RD. As reported for autoimmune pancreatitis type 1, patients with multiorgan IgG4-RD are mainly elderly men with frequently elevated serum IgG4 concentrations. In contrast, isolated gastric IgG4-RD predominantly affects female patients with normal serum IgG4 levels. Surgical resection is commonly performed due to the clinical suspicion of malignancy and the absence of findings indicative of IgG4-RD on biopsy. Today, diagnosis is confirmed histopathologically only after resection.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS"> IgG4-RD should be taken into account when gastric malignancy is suspected endoscopically or radiologically and biopsies fail to confirm the presence of a malignancy (especially subepithelial tumors or refractory gastric ulcers). Serum IgG4 concentrations are insufficient to confirm localized gastric IgG4-RD. Diagnostic workups need to be improved to avoid unnecessary surgical resections with the attendant potential morbidity and mortality.</AbstractText>
                <CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Probst</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Universitätsklinikum Augsburg, Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Schaller</LastName>
                    <ForeName>Tina</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Universitätsklinikum Augsburg, Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Sommer</LastName>
                    <ForeName>Florian</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Geissler</LastName>
                    <ForeName>Bernd</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Agaimy</LastName>
                    <ForeName>Abbas</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Universitätsklinikum Erlangen, Erlangen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Messmann</LastName>
                    <ForeName>Helmut</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Universitätsklinikum Augsburg, Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="N">
                    <LastName>Märkl</LastName>
                    <ForeName>Bruno</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Pathology, Universitätsklinikum Augsburg, Augsburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Immunglobulin G4 (IgG4)-assoziierte Erkrankung des Magens – eine seltene Differenzialdiagnose bei klinischem Verdacht auf Magenkarzinom.</VernacularTitle>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Z Gastroenterol</MedlineTA>
            <NlmUniqueID>0033370</NlmUniqueID>
            <ISSNLinking>0044-2771</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077733" MajorTopicYN="N">Immunoglobulin G4-Related Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072281" MajorTopicYN="N">Lymphadenopathy</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010950" MajorTopicYN="N">Plasma Cells</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherAbstract Type="Publisher" Language="ger">
            <AbstractText Label="HINTERGRUND" NlmCategory="UNASSIGNED"> Immunglobulin-G4-assoziierte Erkrankungen (IgG4-related diseases, IgG4-RD) werden durch eine Kombination klinischer und histopathologischer Kriterien diagnostiziert (storiforme Fibrosklerose, Infiltration IgG4-positiver Plasmazellen, Bildung von tumor-like lesions, obliterative Phlebitis). Eine gastrale Manifestation ist selten. Bisher sind nur wenige Fallberichte publiziert.</AbstractText>
            <AbstractText Label="FALLDARSTELLUNG" NlmCategory="UNASSIGNED"> Wir berichten über zwei Patientinnen mit therapierefraktären Magenulzera, Magenwandverdickung und paragastraler Lymphadenopathie. Wiederholte Biopsien waren nicht wegweisend. Aufgrund des hohen Malignomverdachts erfolgte bei beiden Patientinnen eine Gastrektomie. Erst am chirurgischen Resektat wurde eine IgG4-RD diagnostiziert. Die vorliegende Literatur beschreibt eine gastrale Mitbeteiligung im Rahmen einer Multiorganerkrankung, aber auch Fälle mit isoliertem Magenbefall. Klinisch unterscheiden sich beide Gruppen. Ähnlich der Typ-1-Autoimmunpankreatitis handelt es sich bei Patienten mit Multiorganerkrankung um ältere Männer mit erhöhtem Serum-IgG4. Demgegenüber dominiert bei isoliertem Magenbefall das weibliche Geschlecht. Serum-IgG4 ist bei ihnen nicht erhöht. Die Diagnosestellung erfolgt meist erst nach einer chirurgischen Resektion, die aufgrund eines klinischen Malignomverdachts und unergiebiger Biopsie erfolgt.</AbstractText>
            <AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED"> Eine IgG4-assoziierte Genese sollte als Differenzialdiagnose in Erwägung gezogen werden, wenn endoskopische und radiologische Befunde ein Malignom des Magens vermuten lassen, Biopsien aber nicht wegweisend sind (Magenwandverdickung, refraktäre Magenulzera, Lymphadenopathie). Serum-IgG4-Spiegel sind bei isoliertem Magenbefall nicht verlässlich erhöht. Eine verbesserte Diagnostik muss angestrebt werden, um unnötige chirurgische Resektionen mit ihrer Morbidität und Mortalität zu vermeiden.</AbstractText>
        </OtherAbstract>
        <CoiStatement>Andreas Probst, Tina Schaller, Florian Sommer, Bernd Geissler, Abbas Agaimy, Helmut Messmann, and Bruno Märkl declare no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31739375</ArticleId>
            <ArticleId IdType="doi">10.1055/a-1013-4437</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31738207</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1532-3145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>43</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2019 Nov/Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of computer assisted tomography</Title>
                <ISOAbbreviation>J Comput Assist Tomogr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Associations Between Apparent Diffusion Coefficient Values and the Prognostic Factors of Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>931-936</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/RCT.0000000000000936</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Breast imaging can offer great information about breast cancer heterogeneity. The purpose of this study was to analyze the relationship between apparent diffusion coefficient (ADC) values and various prognostic factors and investigate whether ADC values are useful for breast cancer diagnosis, evaluation of treatment response, and determination of prognosis.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 111 cases of breast cancer were included in this study. Magnetic resonance findings were recorded according to the Breast Imaging Reporting and Data System magnetic resonance imaging lexicon. Diffusion-weighted imaging rim sign and minimum, maximum, and difference ADC values (ADCdiff) were also evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">ADCdiff was related to all prognostic factors such as histological grade, Ki-67, tumor size, molecular subtype, axillary node metastasis, lymphvascular invasion, internal enhancement pattern, intratumoral high T2 signal, peritumoral edema, and diffusion-weighted imaging rim sign, whereas minimum and maximum ADC values showed variable associations.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Apparent diffusion coefficient values were shown to be correlated with many proven or possible prognostic factors of breast cancer. In particular, ADCdiff can reflect tumor heterogeneity and showed higher correlation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Bo Bae</ForeName>
                    <Initials>BB</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Chungnam University Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Comput Assist Tomogr</MedlineTA>
            <NlmUniqueID>7703942</NlmUniqueID>
            <ISSNLinking>0363-8715</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011857" MajorTopicYN="N">Radiographic Image Interpretation, Computer-Assisted</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31738207</ArticleId>
            <ArticleId IdType="doi">10.1097/RCT.0000000000000936</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31738203</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1532-3145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>43</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2019 Nov/Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of computer assisted tomography</Title>
                <ISOAbbreviation>J Comput Assist Tomogr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Surveillance Magnetic Resonance Imaging in Detecting the Second Breast Cancer in Women With a Personal History of Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>937-942</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/RCT.0000000000000931</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to evaluate the diagnostic performance of magnetic resonance imaging (MRI) in detecting the secondary breast cancer among women with a personal history of the lesion.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We retrospectively reviewed breast MRI examinations performed between 2007 and 2011. A total of 798 women with a history of breast cancer were included in the study. Cancer detection rate, positive predictive value (PPV), recall rate, sensitivity, and specificity were assed. Cancer detection rate was stratified by interval after surgery of the primary breast cancer. Also, we derived 1 comparison group from the women for comparing the performance of x-ray mammography, ultrasound, and MRI in detecting the second breast cancer.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 798 patients, 47 of the 49 secondary breast carcinomas were detected by MRI. The sensitivity and specificity of MRI in detecting the secondary lesions were 95.9% and 96.3%, respectively. The recall rate was 9.5%, and the PPV was 61.8%. Cancer detection rate of MRI examinations performed at more than 36 months after initial surgery was significantly higher than that at 36 months or less after initial surgery (13.7% vs 3.6, P &lt; 0.001). In comparison group, the sensitivity and specificity of MRI, mammography, and ultrasound were 96.7% and 96.1%, 48.4% and 93.9%, and 77.4% and 96.1%, respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Surveillance MRI for women with a personal history of breast cancer has high sensitivity in finding the secondary malignancies with a reasonable recall rate and PPV.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Haiquan</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Huadong Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hua</LastName>
                    <ForeName>Yanqing</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Radiology, Huadong Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Weijun</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Ultrasound, Cancer Center, Fudan University, Shanghai, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Comput Assist Tomogr</MedlineTA>
            <NlmUniqueID>7703942</NlmUniqueID>
            <ISSNLinking>0363-8715</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008327" MajorTopicYN="N">Mammography</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016609" MajorTopicYN="N">Neoplasms, Second Primary</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016217" MajorTopicYN="N">Ultrasonography, Mammary</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31738203</ArticleId>
            <ArticleId IdType="doi">10.1097/RCT.0000000000000931</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31738199</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1532-3145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>43</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <MedlineDate>2019 Nov/Dec</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of computer assisted tomography</Title>
                <ISOAbbreviation>J Comput Assist Tomogr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Value of Dual-Energy Computed Tomography for Diagnosing Cervical Lymph Node Metastasis in Patients With Papillary Thyroid Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>970-975</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/RCT.0000000000000927</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to determine the value of dual-energy computed tomography (DECT) for the diagnosis of cervical lymph node metastasis in papillary thyroid cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The normalized iodine concentration (NIC) and the slope of the spectral Hounsfield unit curve (λHU) in the arterial and venous phases were measured using iodine-overlay images and spectral curves. Quantitative DECT data and qualitative conventional CT data were analyzed by radiologists.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The best qualitative parameter for lymph node metastasis detection was obvious node enhancement, and the best quantitative parameter for detection was arterial-phase NIC, which showed high sensitivity, specificity, and accuracy values at an optimal threshold of 25.8%. The best combination of qualitative and quantitative parameters consisted of obvious enhancement and arterial-phase NIC; this combination showed a sensitivity of 90.8% and a specificity of 80.5%.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The DECT quantitative parameters NIC and λHU can be an additional tool to diagnose cervical lymph node metastasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Muzhen</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Radiology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Cailing</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Oncological Surgery, Provincial Clinical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Radiology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Siemens Healthcare Ltd.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Shengjian</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Cancer Hospital/Institute.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Mingping</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Radiology.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Comput Assist Tomogr</MedlineTA>
            <NlmUniqueID>7703942</NlmUniqueID>
            <ISSNLinking>0363-8715</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009333" MajorTopicYN="N">Neck</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011857" MajorTopicYN="N">Radiographic Image Interpretation, Computer-Assisted</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077273" MajorTopicYN="N">Thyroid Cancer, Papillary</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31738199</ArticleId>
            <ArticleId IdType="doi">10.1097/RCT.0000000000000927</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31727279</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0423-2607</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>The Enzymes</Title>
                <ISOAbbreviation>Enzymes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patient-derived tumor models of esophageal cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>97-111</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1874-6047(19)30029-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.enz.2019.10.003</ELocationID>
            <Abstract>
                <AbstractText>Tumor models are powerful tools to plan preclinical therapeutic strategies that cannot be conducted on humans. Recently, patient-derived tumor models such as patient-derived xenograft (PDX) and/or patient-derived organoid (PDO), are widely used to investigate the antitumor effects of various drugs, because those tumors resemble original tumors at the physiological and molecular level. In this chapter, we describe patient-derived tumor models of esophageal cancers and outline the latest research as well as the molecular pathology of esophageal cancers.</AbstractText>
                <CopyrightInformation>© 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saito</LastName>
                    <ForeName>Tomoki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohashi</LastName>
                    <ForeName>Shinya</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizumoto</LastName>
                    <ForeName>Ayaka</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; KBBM Inc., Kyoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muto</LastName>
                    <ForeName>Manabu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: mmuto@kuhp.kyoto-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Enzymes</MedlineTA>
            <NlmUniqueID>101637215</NlmUniqueID>
            <ISSNLinking>1874-6047</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Esophageal cancer</Keyword>
            <Keyword MajorTopicYN="N">Patient-derived organoid (PDO)</Keyword>
            <Keyword MajorTopicYN="N">Patient-derived xenograft (PDX)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31727279</ArticleId>
            <ArticleId IdType="pii">S1874-6047(19)30029-0</ArticleId>
            <ArticleId IdType="doi">10.1016/bs.enz.2019.10.003</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31722875</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1756-1833</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>367</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                        <Day>13</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMJ (Clinical research ed.)</Title>
                <ISOAbbreviation>BMJ</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>l6090</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.l6090</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES">To quantify post-colonoscopy colorectal cancer (PCCRC) rates in England by using recent World Endoscopy Organisation guidelines, compare incidence among colonoscopy providers, and explore associated factors that could benefit from quality improvement initiatives.</AbstractText>
                <AbstractText Label="DESIGN">Population based cohort study.</AbstractText>
                <AbstractText Label="SETTING">National Health Service in England between 2005 and 2013.</AbstractText>
                <AbstractText Label="POPULATION">All people undergoing colonoscopy and subsequently diagnosed as having colorectal cancer up to three years after their investigation (PCCRC-3yr).</AbstractText>
                <AbstractText Label="MAIN OUTCOME MEASURES">National trends in incidence of PCCRC (within 6-36 months of colonoscopy), univariable and multivariable analyses to explore factors associated with occurrence, and funnel plots to measure variation among providers.</AbstractText>
                <AbstractText Label="RESULTS">The overall unadjusted PCCRC-3yr rate was 7.4% (9317/126 152), which decreased from 9.0% in 2005 to 6.5% in 2013 (P&lt;0.01). Rates were lower for colonoscopies performed under the NHS bowel cancer screening programme (593/16 640, 3.6%), while they were higher for those conducted by non-NHS providers (187/2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory bowel disease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Wide variation exists in PCCRC-3yr rates across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowel cancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectal cancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.</AbstractText>
                <CopyrightInformation>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Burr</LastName>
                    <ForeName>Nicholas E</ForeName>
                    <Initials>NE</Initials>
                    <Identifier Source="ORCID">0000-0003-1988-2982</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Epidemiology Group, Institute of Cancer and Pathology and Institute of Data Analytics, University of Leeds, Leeds LS2 9JT, UK nick.burr@nhs.net.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Mid Yorkshire Hospitals NHS Trust, Pinderfields General Hospital, Wakefield, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Derbyshire</LastName>
                    <ForeName>Edmund</ForeName>
                    <Initials>E</Initials>
                    <Identifier Source="ORCID">0000-0002-0591-1458</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0002-2518-5799</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Epidemiology Group, Institute of Cancer and Pathology and Institute of Data Analytics, University of Leeds, Leeds LS2 9JT, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Whalley</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">0000-0003-3643-4129</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Epidemiology Group, Institute of Cancer and Pathology and Institute of Data Analytics, University of Leeds, Leeds LS2 9JT, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Subramanian</LastName>
                    <ForeName>Venkataraman</ForeName>
                    <Initials>V</Initials>
                    <Identifier Source="ORCID">0000-0003-3603-0861</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finan</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                    <Identifier Source="ORCID">0000-0003-0731-1541</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Epidemiology Group, Institute of Cancer and Pathology and Institute of Data Analytics, University of Leeds, Leeds LS2 9JT, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>John Goligher Colorectal Unit, St James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rutter</LastName>
                    <ForeName>Matthew D</ForeName>
                    <Initials>MD</Initials>
                    <Identifier Source="ORCID">0000-0001-9507-0295</Identifier>
                    <AffiliationInfo>
                        <Affiliation>University Hospital of North Tees, Hardwick, Stockton on Tees, UK.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Northern Institute for Cancer Research, Newcastle University, Newcastle, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valori</LastName>
                    <ForeName>Roland</ForeName>
                    <Initials>R</Initials>
                    <Identifier Source="ORCID">0000-0002-9068-018X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morris</LastName>
                    <ForeName>Eva J A</ForeName>
                    <Initials>EJA</Initials>
                    <Identifier Source="ORCID">0000-0002-1075-6544</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Cancer Epidemiology Group, Institute of Cancer and Pathology and Institute of Data Analytics, University of Leeds, Leeds LS2 9JT, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <Acronym>CRUK_</Acronym>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMJ</MedlineTA>
            <NlmUniqueID>8900488</NlmUniqueID>
            <ISSNLinking>0959-8138</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>BMJ. 2019 Nov 13;367:l6384</RefSource>
                <PMID Version="1">31722874</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055088" MajorTopicYN="Y">Early Detection of Cancer</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName>
                <QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013222" MajorTopicYN="N">State Medicine</DescriptorName>
                <QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the Bobby Moore Fund, Cancer Research UK, Yorkshire Cancer Research, and Crohn’s and Colitis UK for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31722875</ArticleId>
            <ArticleId IdType="doi">10.1136/bmj.l6090</ArticleId>
            <ArticleId IdType="pmc">PMC6849511</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ Evid Based Med. 2018 Feb;23(1):1-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29367314</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Frontline Gastroenterol. 2019 Apr;10(2):93-106</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">31210174</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Endoscopy. 2018 Jan;50(1):40-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28753700</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2016 Dec;65(12):1923-1929</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27531829</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2014 Jun;63(6):964-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23955527</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2012 Jul;61(7):1050-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21940723</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Frontline Gastroenterol. 2010 Apr;1(1):52-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28839544</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Gastroenterol Hepatol. 2015 Sep;13(9):1656-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25956835</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg. 2009 Mar;249(3):376-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19247021</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2018 Sep;155(3):909-925.e3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29958856</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastrointest Endosc. 2019 Jan;89(1):168-176.e3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30144415</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2011 Jun 28;105(1):170-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21559016</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2010 May;59(5):666-89</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20427401</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Chronic Dis. 1987;40(5):373-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3558716</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2012 Oct 9;107(8):1220-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22996611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Gastroenterol Hepatol. 2017 Jul;29(7):855-860</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28410353</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2006 Apr;130(4):1030-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16618396</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2010 May 8;375(9726):1624-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20430429</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Endoscopy. 2018 Sep;50(9):878-885</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30036893</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2012 Nov;61(11):1576-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22200840</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2014 Aug 28;371(9):799-807</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25162886</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Gastroenterol. 2013 Aug;108(8):1332-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23774154</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2013 Nov 16;382(9905):1674-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23831144</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Colorectal Dis. 2018 Sep;20(9):O283-O285</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30192079</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2012 Jun 15;118(12):3044-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21989586</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Public Health (Oxf). 2012 Mar;34(1):138-48</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21795302</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastrointest Endosc. 2018 May;87(5):1324-1334.e4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29317271</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2015 Aug;64(8):1248-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25416064</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 1993 Dec 30;329(27):1977-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8247072</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2019 Jul 11;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">31302144</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2019 Jul 31;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">31376388</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2013 Feb;62(2):242-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22661458</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2010 May 13;362(19):1795-803</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20463339</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gut. 2012 Oct;61(10):1439-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22156981</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stat Med. 2005 Apr 30;24(8):1185-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15568194</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31722283</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>201</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of photochemistry and photobiology. B, Biology</Title>
                <ISOAbbreviation>J. Photochem. Photobiol. B, Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthesis of Zinc oxide nanoparticles from Marsdenia tenacissima inhibits the cell proliferation and induces apoptosis in laryngeal cancer cells (Hep-2).</ArticleTitle>
            <Pagination>
                <MedlinePgn>111624</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1011-1344(19)31086-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jphotobiol.2019.111624</ELocationID>
            <Abstract>
                <AbstractText>Biosynthesis of Zinc oxide nanoparticles (ZnONPs) from natural plants stands as a promising nanodrug delivery system in cancer therapeutics. Marsdenia tenacissima (M.t), a Chinese medicinal plant has been extensively used as clinical remedy for treating several types of cancer. In this present study, ZnONPs were synthesized from Marsdenia tenacissima and its anti cancer potency was assessed against in vitro laryngeal cancer cell line Hep-2. The biosynthesized Marsdenia tenacissima Zinc Oxide Nanoparticles [M.t-ZnONPs] was characterized using UV-visible Spec, SEM, TEM and EDAX analysis. The cytotoxic and apoptotic inducing potential of M.t-ZnONPs was assessed by MTT assay and staining such as DCFH-DA, AO/EtBr, Rhodamine 123, DAPI and comet assay. The anticancer potential of M.t-ZnONPs was analysed by Real time PCR analysis of proapoptotic, antiapoptotic and caspases proteins. Our present findings showed characteristic and morphological representation of synthesized M.t-ZnONPs by UV-visible Spec, SEM, TEM and EDAX analysis. M.t-ZnONPs exhibits its cytotoxicity by inhibiting the viability of Hep-2 cells and IC<sub>50</sub> value was obtained by MTT assay. The results of apoptotic staining techniques in M.t-ZnONPs treated Hep-2 cells confirm with excess ROS generation, disruption of mitochondrial membrane potential and nuclear damage. The apoptotic inducing potential of M.t-ZnONPs was also evidenced by upregulation of proapoptotic proteins Bax, Caspase 3 &amp; 9 and downregultion of antiapoptotic protein Bcl-2 by RT-PCR analysis. Finally, these results suggested that biosynthesized M.t-ZnONPs is an effective anticancer agent which induces apoptosis in Hep-2 laryngeal cell line and thus conclude that M.t-ZnONPs, a valid anticancer strategy in treating various cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yayuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Jianguang</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Veeraraghavan</LastName>
                    <ForeName>Vishnu Priya</ForeName>
                    <Initials>VP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai 600 077, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mohan</LastName>
                    <ForeName>Surapaneni Krishna</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biochemistry, College of Applied Medical Sciences - Jubail (CAMSJ), Imam Abdulrahman Bin Faisal University, P.O. Box 4030, Al Ansar Rd, Deffi, Jubail Industrial City, Al Jubail 35816, Kingdom of Saudi Arabia (KSA).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Chao</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China. Electronic address: entwc73@sina.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Xiaoguang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang 150081, China. Electronic address: fzswyxg@sina.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>J Photochem Photobiol B</MedlineTA>
            <NlmUniqueID>8804966</NlmUniqueID>
            <ISSNLinking>1011-1344</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SOI2LOH54Z</RegistryNumber>
                <NameOfSubstance UI="D015034">Zinc Oxide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055772" MajorTopicYN="N">Green Chemistry Technology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007822" MajorTopicYN="N">Laryngeal Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D031101" MajorTopicYN="N">Marsdenia</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015034" MajorTopicYN="N">Zinc Oxide</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Hep-2 cell line</Keyword>
            <Keyword MajorTopicYN="N">Laryngeal cancer</Keyword>
            <Keyword MajorTopicYN="N">Marsdenia tenacissima</Keyword>
            <Keyword MajorTopicYN="N">Nanoparticles</Keyword>
            <Keyword MajorTopicYN="N">Zinc oxide</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31722283</ArticleId>
            <ArticleId IdType="pii">S1011-1344(19)31086-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2019.111624</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31722153</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1533-4406</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>381</Volume>
                    <Issue>20</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The New England journal of medicine</Title>
                <ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1929-1939</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1902626</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube (&quot;ovarian&quot;) cancer is widely practiced but has not been evaluated in phase 3 investigation.</AbstractText>
                <AbstractText Label="METHODS">We randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Adjuvant chemotherapy (paclitaxel-carboplatin or gemcitabine-carboplatin) and use of bevacizumab were at the discretion of the investigator. The primary end point was overall survival.</AbstractText>
                <AbstractText Label="RESULTS">A total of 485 patients underwent randomization, 240 to secondary cytoreduction before chemotherapy and 245 to chemotherapy alone. The median follow-up was 48.1 months. Complete gross resection was achieved in 67% of the patients assigned to surgery who underwent the procedure. Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to 84% of the patients overall and was equally distributed between the two groups. The hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1.72; P = 0.08), which corresponded to a median overall survival of 50.6 months and 64.7 months, respectively. Adjustment for platinum-free interval and chemotherapy choice did not alter the effect. The hazard ratio for disease progression or death (surgery vs. no surgery) was 0.82 (95% CI, 0.66 to 1.01; median progression-free survival, 18.9 months and 16.2 months, respectively). Surgical morbidity at 30 days was 9%; 1 patient (0.4%) died from postoperative complications. Patient-reported quality of life decreased significantly after surgery but did not differ significantly between the two groups after recovery.</AbstractText>
                <AbstractText Label="CONCLUSIONS">In this trial involving patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone. (Funded by the National Cancer Institute and others; GOG-0213 ClinicalTrials.gov number, NCT00565851.).</AbstractText>
                <CopyrightInformation>Copyright © 2019 Massachusetts Medical Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Coleman</LastName>
                    <ForeName>Robert L</ForeName>
                    <Initials>RL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spirtos</LastName>
                    <ForeName>Nick M</ForeName>
                    <Initials>NM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Enserro</LastName>
                    <ForeName>Danielle</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herzog</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabbatini</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Armstrong</LastName>
                    <ForeName>Deborah K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jae-Weon</ForeName>
                    <Initials>JW</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Sang-Yoon</ForeName>
                    <Initials>SY</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Byoung-Gie</ForeName>
                    <Initials>BG</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Joo-Hyun</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujiwara</LastName>
                    <ForeName>Keiichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walker</LastName>
                    <ForeName>Joan L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Casey</LastName>
                    <ForeName>Ann C</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alvarez Secord</LastName>
                    <ForeName>Angeles</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubin</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>John K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DiSilvestro</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidson</LastName>
                    <ForeName>Susan A</ForeName>
                    <Initials>SA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohn</LastName>
                    <ForeName>David E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tewari</LastName>
                    <ForeName>Krishnansu S</ForeName>
                    <Initials>KS</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Basen-Engquist</LastName>
                    <ForeName>Karen</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Helen Q</ForeName>
                    <Initials>HQ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brady</LastName>
                    <ForeName>Mark F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mannel</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the University of Texas M.D. Anderson Cancer Center, Houston (R.L.C., K.B.-E.); Women's Cancer Center of Nevada, Las Vegas (N.M.S.); NRG Oncology Statistical and Data Management Center, Roswell Park Cancer Institute, Buffalo (D.E., H.Q.H., M.F.B.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (P.S.) - both in New York; the University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati (T.J.H.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (D.K.A.); Seoul National University College of Medicine (J.-W.K.), Samsung Medical Center, Sungkyunkwan University School of Medicine (B.-G.K.), and Asan Medical Center, University of Ulsan College of Medicine (J.-H.N.), Seoul, and the Research Institute and Hospital, National Cancer Center, Goyang (S.-Y.P.) - all in South Korea; Saitama Medical University International Medical Center, Hidaka, Japan (K.F.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.L.W., R.S.M.); National Surgical Adjuvant Breast and Bowel Project/NRG Oncology, U.S. Oncology Research, and Metro-Minnesota Community Oncology Research Consortium, Minneapolis (A.C.C.); Duke Cancer Institute, Duke University Medical Center, Durham, NC (A.A.S.); Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.R.); Gynecologic Cancer Program, California Pacific-Palo Alto Medical Foundation, Sutter Research Institute, San Francisco (J.K.C.); Women and Infants Hospital, Providence, RI (P.D.); the University of Colorado School of Medicine, Aurora, and Denver Health Medical Center, Denver (S.A.D.); Ohio State University, Columbus (D.E.C.); and the University of California, Irvine, Orange (K.S.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00565851</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>U10 CA180868</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UG1 CA189867</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA016672</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA 37517</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10CA180868</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UG1 CA233193</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>1U10 CA180822</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U10 CA180822</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>CA 27469</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>N Engl J Med</MedlineTA>
            <NlmUniqueID>0255562</NlmUniqueID>
            <ISSNLinking>0028-4793</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
                <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BG3F62OND5</RegistryNumber>
                <NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065426" MajorTopicYN="Y">Cytoreduction Surgical Procedures</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31722153</ArticleId>
            <ArticleId IdType="doi">10.1056/NEJMoa1902626</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31721221</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mechanotechnical faults and particular issues of anastomotic complications following robot-assisted anterior resection in 968 rectal cancer patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1436-1445</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25765</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As most risk factors for anastomotic complications (AC) in rectal cancer patients appear to be noncorrectable, it is needed to find the correctable causes. Additionally, the outcomes of indocyanine-green fluorescence imaging (IFI) and robot-stapled anastomosis have yet been undetermined.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">This study retrospectively analyzed 968 consecutive patients with rectal cancer, who underwent curative robot-assisted anterior resections between 2010 and 2018. IFI parameters and stapling features in the surgical records were reviewed, and reconfirmed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">AC occurred in 54 patients (5.6%), 34 (3.5%) with anastomotic leakage (AL) and 24 (2.5%) with anastomotic stenosis (AS). Mechanotechnical faults including defective stapling configurations, including angles lesser than or equal to 150° and outer deviation (more than half from the center of the circle) of linear staples, between the two linear staples were independently associated with AL (P &lt; .001 each). IFI significantly reduced AL rate (2.5% vs 5.3%, P = .029) and AS rate (2% vs 18.8%, P = .006), respectively. Robot linear stapling enabled to maintain the obtuse angle during consecutive staplings and reduced console time. AL and AS were independent risk factors for disease-free survival (P = .02) and local recurrence (P = .03), respectively.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AC were associated with some correctable causes, namely, mechanotechnical errors and lack of use of IFI.</AbstractText>
                <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jin C</ForeName>
                    <Initials>JC</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4823-8619</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jong L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Chan W</ForeName>
                    <Initials>CW</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2382-0939</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Seok-Byung</ForeName>
                    <Initials>SB</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8824-4808</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alsaleem</LastName>
                    <ForeName>Hassan A</ForeName>
                    <Initials>HA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Seong H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2016R1E1A1A02919844</GrantID>
                    <Agency>The Korea Research Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IX6J1063HV</RegistryNumber>
                <NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003251" MajorTopicYN="N">Constriction, Pathologic</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004733" MajorTopicYN="N">Enema</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017792" MajorTopicYN="N">Surgical Stapling</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">anastomotic leakage</Keyword>
            <Keyword MajorTopicYN="N">anastomotic stricture</Keyword>
            <Keyword MajorTopicYN="N">anterior resection</Keyword>
            <Keyword MajorTopicYN="N">rectal cancer</Keyword>
            <Keyword MajorTopicYN="N">robot-assisted</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31721221</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25765</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31721218</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of metabolic syndrome on functional outcomes and complications of surgical treatment of prostate cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1505-1507</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25762</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metabolic syndrome (MetS) has a negative impact on functional recovery and complications after many surgical procedures.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To assess the role of Mets on functional outcomes and complications after radical prostatectomy (RP) for prostate cancer.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Complete data were collected from 5758 patients, undergoing RP at a single referral centers in a 10-year period and the presence of MetS before surgery was ascertained in 17.7% of them using a modified version of the IDF-AHA/NHLBI criteria. Outcomes included 1-year continence and potency rates, early (≤90 days) and late (&gt;90 days) complications.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Postoperative continence (no pads) was significantly less likely in MetS patients (75.4% vs 82.6%, P &lt; .01), despite no difference in preoperative continence. Erections with or without therapy were reached in 55.8% of non-MetS and 41.8% of MetS patients (P &lt; .01), in this case a significant difference in preoperative function was seen. No differences in early and late complications, except for wound infections (5.8% vs 3.9%, P &lt; .01) were observed.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the present study RP was safe from the complications standpoint in MetS patients, but the presence of the syndrome was a significant risk factor for post-RP incontinence and impotence.</AbstractText>
                <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morlacco</LastName>
                    <ForeName>Alessandro</ForeName>
                    <Initials>A</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0201-0758</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Urology Clinic - Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moro</LastName>
                    <ForeName>Fabrizio Dal</ForeName>
                    <Initials>FD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Urology Clinic, University Hospital &quot;Santa Maria della Misericordia&quot;, Udine, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rangel</LastName>
                    <ForeName>Laureano J</ForeName>
                    <Initials>LJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carlson</LastName>
                    <ForeName>Rachel E</ForeName>
                    <Initials>RE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soligo</LastName>
                    <ForeName>Matteo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Urology Clinic - Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karnes</LastName>
                    <ForeName>Robert Jeffrey</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Mayo Clinic, Rochester, Minnesota.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D007172" MajorTopicYN="N">Erectile Dysfunction</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011468" MajorTopicYN="Y">Prostatectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014549" MajorTopicYN="N">Urinary Incontinence</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">impotence</Keyword>
            <Keyword MajorTopicYN="N">incontinence</Keyword>
            <Keyword MajorTopicYN="N">metabolic syndrome</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
            <Keyword MajorTopicYN="N">surgical treatment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31721218</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25762</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31720813</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0851</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer immunology, immunotherapy : CII</Title>
                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2067-2080</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-019-02429-2</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Tumor-associated macrophages (TAMs) exist as heterogeneous subsets and have dichotomous roles in cancer-immune evasion. This study aims to assess the clinical effects of Galectin-9<sup>+</sup> tumor-associated macrophages (Gal-9<sup>+</sup>TAMs) in muscle-invasive bladder cancer (MIBC).</AbstractText>
                <AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">We identified Gal-9<sup>+</sup>TAMs by immunohistochemistry (IHC) analysis of a tumor microarray (TMA) (n = 141) from the Zhongshan Hospital and by flow cytometric analysis of tumor specimens (n = 20) from the Shanghai Cancer Center. The survival benefit of platinum-based chemotherapy in this subpopulation was evaluated. The effect of the tumor-immune microenvironment with different percentages of Gal-9<sup>+</sup>TAMs was explored.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of Gal-9<sup>+</sup>TAMs increased with tumor stage and grade. Gal-9<sup>+</sup>TAMs predicted poor overall survival (OS) and recurrence-free survival (RFS) and were better than Gal-9<sup>-</sup>TAMs and TAMs to discriminate prognostic groups. In univariate and multivariate Cox regression analyses, patients with high percentages of Gal-9<sup>+</sup>TAMs showed the prominent survival benefit after receiving adjuvant chemotherapy (ACT). High Gal-9<sup>+</sup>TAM infiltration correlated with increasing numbers of regulatory T cells (Tregs) and mast cells and decreasing numbers of CD8<sup>+</sup>T and dendritic cells (DCs). Dense infiltration of Gal-9<sup>+</sup>TAMs was related to reduced cytotoxic molecules, enhanced immune checkpoints or immunosuppressive cytokines expressed by immune cells, as well as active proliferation of tumor cells. Additionally, the subpopulation accumulated was strongly associated with PD-1<sup>+</sup>TIM-3<sup>+</sup>CD8<sup>+</sup>T cells.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Gal-9<sup>+</sup>TAMs predicted OS and RFS and response to ACT in MIBC patients. High Gal-9<sup>+</sup>TAMs were associated with a pro-tumor immune contexture concomitant with T cell exhaustion.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Yangyang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Basic Medical Sciences, Fudan University, Building West 13, No. 138 Yixueyuan Road, Shanghai, 200032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Zewei</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Lingli</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Yunyi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Peipei</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Zheng</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Quan</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Building West 7, No. 138 Yixueyuan Road, Shanghai, 200032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yifan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Basic Medical Sciences, Fudan University, Building West 13, No. 138 Yixueyuan Road, Shanghai, 200032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jiajun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bai</LastName>
                    <ForeName>Qi</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xia</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Le</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dai</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Jianming</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yiwei</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Manufacturing Bureau Road, Shanghai, 200011, China. wang.yiwei@sh9hospital.org.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Jiejie</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-7431-9063</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Building West 7, No. 138 Yixueyuan Road, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Weijuan</ForeName>
                    <Initials>W</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3494-3114</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Immunology, School of Basic Medical Sciences, Fudan University, Building West 13, No. 138 Yixueyuan Road, Shanghai, 200032, China. weijuanzhang@fudan.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>81471621</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81472227</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81472376</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81671628</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>31770851</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81702496</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81702497</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81702805</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81772696</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81871306</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81872082</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>16ZR1406500</GrantID>
                    <Agency>Shanghai Municipal Natural Science Foundation</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>17411963100</GrantID>
                    <Agency>Guide Project of Science and Technology Commission of Shanghai Municipality</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>18YF1404500</GrantID>
                    <Agency>Shanghai Sailing Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>19YF1407900</GrantID>
                    <Agency>Shanghai Sailing Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>19YF1427200</GrantID>
                    <Agency>Shanghai Sailing Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>20174Y0042</GrantID>
                    <Agency>Shanghai Municipal Commission of Health and Family Planning Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>201840168</GrantID>
                    <Agency>Shanghai Municipal Commission of Health and Family Planning Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>20184Y0151</GrantID>
                    <Agency>Shanghai Municipal Commission of Health and Family Planning Program</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>YJYQ201802</GrantID>
                    <Agency>Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Immunol Immunother</MedlineTA>
            <NlmUniqueID>8605732</NlmUniqueID>
            <ISSNLinking>0340-7004</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D054316">Biomarkers, Pharmacological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D037161">Galectins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C105032">LGALS9 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054316" MajorTopicYN="N">Biomarkers, Pharmacological</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D037161" MajorTopicYN="N">Galectins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009132" MajorTopicYN="N">Muscles</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adjuvant chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">Galectin-9+ tumor-associated macrophages</Keyword>
            <Keyword MajorTopicYN="N">Immune contexture</Keyword>
            <Keyword MajorTopicYN="N">Muscle-invasive bladder cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31720813</ArticleId>
            <ArticleId IdType="doi">10.1007/s00262-019-02429-2</ArticleId>
            <ArticleId IdType="pii">10.1007/s00262-019-02429-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31720561</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1699-3993</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>55</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Drugs of today (Barcelona, Spain : 1998)</Title>
                <ISOAbbreviation>Drugs Today</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeted therapies for ROS1-rearranged non-small cell lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>641-652</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1358/dot.2019.55.10.3030646</ELocationID>
            <Abstract>
                <AbstractText>ROS1 gene fusions account for approximately 1-2% of all cases of non-small cell lung cancer (NSCLC). Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology. The ROS1 gene has homology to ALK and this structural similarity formed the basis for utilizing ALK inhibitors for ROS1+ NSCLC. On the basis of impressive progression-free survival of 19.2 months from the PROFILE 1001 trial, crizotinib obtained Food and Drug Administration (FDA) approval as first-line therapy for treatment of ROS1+ NSCLC. Since then, there has been a growing appreciation of the incidence of brain metastases in ROS1+ NSCLC and rates of central nervous system progression on crizotinib. Additionally, appreciation of novel resistance mechanisms to crizotinib has led to the development of newer tyrosine kinase inhibitors (TKIs). In this review, we highlight known and emerging TKIs for the management of ROS1+ NSCLC.</AbstractText>
                <CopyrightInformation>Copyright 2019 Clarivate Analytics.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Patil</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simons</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of General Internal Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mushtaq</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pacheco</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doebele</LastName>
                    <ForeName>R C</ForeName>
                    <Initials>RC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowles</LastName>
                    <ForeName>D W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. daniel.bowles@ucdenver.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Spain</Country>
            <MedlineTA>Drugs Today (Barc)</MedlineTA>
            <NlmUniqueID>101160518</NlmUniqueID>
            <ISSNLinking>1699-3993</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D000077548">Anaplastic Lymphoma Kinase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C062333">ROS1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000077548" MajorTopicYN="N">Anaplastic Lymphoma Kinase</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cabozantinib</Keyword>
            <Keyword MajorTopicYN="N">Cancer therapy</Keyword>
            <Keyword MajorTopicYN="N">Ceritinib</Keyword>
            <Keyword MajorTopicYN="N">Crizotinib</Keyword>
            <Keyword MajorTopicYN="N">DS-6051b</Keyword>
            <Keyword MajorTopicYN="N">Entrectinib</Keyword>
            <Keyword MajorTopicYN="N">Lorlatinib</Keyword>
            <Keyword MajorTopicYN="N">Non-small cell lung cancer (NSCLC)</Keyword>
            <Keyword MajorTopicYN="N">ROS1 gene fusions</Keyword>
            <Keyword MajorTopicYN="N">ROS1+ NSCLC</Keyword>
            <Keyword MajorTopicYN="N">Repotrectinib</Keyword>
            <Keyword MajorTopicYN="N">Tyrosine kinase inhibitors</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31720561</ArticleId>
            <ArticleId IdType="pii">3030646</ArticleId>
            <ArticleId IdType="doi">10.1358/dot.2019.55.10.3030646</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31718480</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1423-0380</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>41</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</Title>
                <ISOAbbreviation>Tumour Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In silico identification of microRNAs as candidate colorectal cancer biomarkers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1010428319883721</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1010428319883721</ELocationID>
            <Abstract>
                <AbstractText>The involvement of microRNA in cancers plays a significant role in their pathogenesis. Specific expressions of these non-coding RNAs also serve as biomarkers for early colorectal cancer diagnosis, but their laboratory/molecular identification is challenging and expensive. The aim of this study was to identify potential microRNAs for colorectal cancer diagnosis using in silico approach. Sequence similarity search was employed to obtain the candidate microRNA from the datasets, and three target prediction software were employed to determine their target genes. To determine the involvement of these microRNAs in colorectal cancer, the microRNA gene list obtained was used alongside with colorectal cancer expressed genes from gbCRC and CoReCG databases for gene intersection analysis. The involvement of these genes in the cancer subtype was further strengthened with the DAVID database. KEGG and Gene Ontology were used for the pathway and functional analysis, while STRING was employed for the interactions of protein network and further visualized by Cytoscape. The cBioPortal database was used to prioritize the target genes; prognostic and expression analysis were finally performed on the candidate microRNAs and the prioritized targets. This study, therefore, identified five candidate microRNAs, two hub genes (CTNNB1 and epidermal growth factor receptor), and seven significant target genes associated with colorectal cancer. The molecular validation studies are ongoing to ascertain the biological fitness of these findings.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fadaka</LastName>
                    <ForeName>Adewale Oluwaseun</ForeName>
                    <Initials>AO</Initials>
                    <Identifier Source="ORCID">https://orcid.org/0000-0002-3952-2098</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Bellville, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klein</LastName>
                    <ForeName>Ashwil</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Bellville, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pretorius</LastName>
                    <ForeName>Ashley</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Bellville, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Tumour Biol</MedlineTA>
            <NlmUniqueID>8409922</NlmUniqueID>
            <ISSNLinking>1010-4283</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495270">CTNNB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D063990" MajorTopicYN="N">Gene Ontology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BLAST</Keyword>
            <Keyword MajorTopicYN="N">CD-HIT-EST-2D</Keyword>
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">biomarkers</Keyword>
            <Keyword MajorTopicYN="N">diagnostics</Keyword>
            <Keyword MajorTopicYN="N">early detection</Keyword>
            <Keyword MajorTopicYN="N">in silico analysis</Keyword>
            <Keyword MajorTopicYN="N">microRNA</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31718480</ArticleId>
            <ArticleId IdType="doi">10.1177/1010428319883721</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31713170</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1168</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Oncobiome at the Forefront of a Novel Molecular Mechanism to Understand the Microbiome and Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>147-156</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-24100-1_10</ELocationID>
            <Abstract>
                <AbstractText>The microbiome comprises all the genetic material within a microbiota, that represents tenfold higher than that of our cells. The microbiota it includes a wide variety of microorganisms such as bacteria, viruses, protozoans, fungi, and archaea, and this ecosystem is personalized in any body space of every individual. Balanced microbial communities can positively contribute to training the immune system and maintaining immune homeostasis. Dysbiosis is a change in the normal microbiome composition that can initiate chronic inflammation, epithelial barrier breaches, and overgrowth of harmful bacteria. The next-generation sequencing methods have revolutionized the study of the microbiome. Bioinformatic tools to manage large volumes of new information, it became possible to assess species diversity and measure dynamic fluctuations in microbial communities. The burden of infections that are associated to human cancer is increasing but is underappreciated by the cancer research community. The rich content in microbes of normal and tumoral tissue reflect could be defining diverse physiological or pathological states. Genomic research has emerged a new focus on the interplay between the human microbiome and carcinogenesis and has been termed the 'oncobiome'. The interactions among the microbiota in all epithelium, induce changes in the host immune interactions and can be a cause of cancer. Microbes have been shown to have systemic effects on the host that influence the efficacy of anticancer drugs. Metagenomics allows to investigate the composition of microbial community. Metatranscriptome analysis applies RNA sequencing to microbial samples to determine which species are present. Cancer can be caused by changes in the microbiome. The roles of individual microbial species in cancer progression have been identified long ago for various tissue types. The identification of microbiomes of drug resistance in the treatment of cancer patients has been the subject of numerous microbiome studies. The complexity of cancer genetic alterations becomes irrelevant in certain cancers to explain the origin, the cause or the oncogenic maintenance by the oncogene addiction theory.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Astudillo-de la Vega</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Translational Research Laboratory in Cancer &amp; Celullar Therapy, Hospital de Oncologia, Siglo XXI, IMSS, Mexico City, Mexico. hastud2@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alonso-Luna</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratorio de NGS, Nanopharmacia Diagnostica de la Ciudad de Mexico, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali-Pérez</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratorio de Oncogenomica, Nanopharmacia Diagnostica de la Ciudad de Mexico, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>López-Camarillo</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Posgrado en Ciencias Genomicas, Universidad Autonoma de la Ciudad de Mexico, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ruiz-Garcia</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastrointestinal Medical Oncology &amp; Translational Medicine Laboratory, Instituto Nacional de Cancerologia, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056186" MajorTopicYN="N">Metagenomics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064307" MajorTopicYN="Y">Microbiota</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Dysbiosis</Keyword>
            <Keyword MajorTopicYN="N">Metagenomics</Keyword>
            <Keyword MajorTopicYN="N">Metatranscriptomics</Keyword>
            <Keyword MajorTopicYN="N">Microbiome</Keyword>
            <Keyword MajorTopicYN="N">NGS</Keyword>
            <Keyword MajorTopicYN="N">Oncobiome</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31713170</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-24100-1_10</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31713165</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1168</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>79-90</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-24100-1_5</ELocationID>
            <Abstract>
                <AbstractText>Omics technologies have revolutionised fundamental and medical research. Oncology is perhaps the field where these technologies have been most rapidly adopted and where they have had their biggest impact, dramatically transforming clinical practice guidelines over a very short period of time. Along with this transformation has come an even larger array of technologies, tools and jargon, that make following the most recent developments in the field a truly daunting task for those not involved in it. This chapter is intended to provide a general overview of evolving topics in oncology research in the era of big data analysis and precision medicine, with a specific focus on the use of tumour biomarkers, tumour biomarker tests, targeted drugs and the changing landscape of clinical trial designs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hernandez-Martinez</LastName>
                    <ForeName>Juan-Manuel</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CONACYT-Instituto Nacional de Cancerología, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sánchez-Reyes</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De la Garza-Salazar</LastName>
                    <ForeName>J G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arrieta</LastName>
                    <ForeName>Oscar</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Head of the Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. ogar@unam.mx.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008495" MajorTopicYN="Y">Medical Oncology</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Basket trials</Keyword>
            <Keyword MajorTopicYN="N">Biomarkers Guidelines</Keyword>
            <Keyword MajorTopicYN="N">Clinical trials</Keyword>
            <Keyword MajorTopicYN="N">High-throughput technologies</Keyword>
            <Keyword MajorTopicYN="N">Multi-gene panels</Keyword>
            <Keyword MajorTopicYN="N">Next Generation Sequencing</Keyword>
            <Keyword MajorTopicYN="N">Omics</Keyword>
            <Keyword MajorTopicYN="N">Personalised oncology</Keyword>
            <Keyword MajorTopicYN="N">Tumour biomarkers</Keyword>
            <Keyword MajorTopicYN="N">Umbrella trial</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31713165</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-24100-1_5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31713164</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1168</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Design and Implementing Pharmacogenomics Study in Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>43-77</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-24100-1_4</ELocationID>
            <Abstract>
                <AbstractText>The advances in technology has shifted healthcare from a &quot;one size fits all&quot; model to focus on personalized therapy. Understanding the relationship of genome variations and its effect on drug response has led to individualized drug selection, maximizing drug efficacy and improving toxicity profile. The developments in pharmacogenomics has led to the discovery of predictive and prognostic biomarkers, and has transformed cancer research leading to the creation of pharmacogenomics databases. While challenges associated with the implementation of pharmacogenomics based medicine exist, integrating data amongst collaborative networks will be crucial for researchers to identify all the functional elements of the human genome sequence. Future advances in the area of pharmacogenomics research will eventually lead to the identification of the right therapeutic drug for the right patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romero Lagunes</LastName>
                    <ForeName>María Luisa</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Center Against Cancer, Autonomous University of Nuevo Leon, Monterrey, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vera Badillo</LastName>
                    <ForeName>Francisco Emilio</ForeName>
                    <Initials>FE</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Center Against Cancer, Autonomous University of Nuevo Leon, Monterrey, Mexico. fverabadillo@ctg.queensu.ca.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Canadian Cancer Trials Group, Queen's University, Kingston, Canada. fverabadillo@ctg.queensu.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Computer-based systems</Keyword>
            <Keyword MajorTopicYN="N">Germline mutations, somatic mutations</Keyword>
            <Keyword MajorTopicYN="N">Health-care system</Keyword>
            <Keyword MajorTopicYN="N">Molecular tumor board</Keyword>
            <Keyword MajorTopicYN="N">Personalized medicine</Keyword>
            <Keyword MajorTopicYN="N">Pharmacogenetics</Keyword>
            <Keyword MajorTopicYN="N">Point-of-care method</Keyword>
            <Keyword MajorTopicYN="N">Randomized trials</Keyword>
            <Keyword MajorTopicYN="N">Whole exome sequencing</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31713164</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-24100-1_4</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31713162</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1168</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>9-30</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-24100-1_2</ELocationID>
            <Abstract>
                <AbstractText>Following the completion of the Human Genome Project in 2003, research in oncology has progressively focused on the sequencing of cancer genomes, with the aim of better understanding the genetic basis of oncogenesis and identifying actionable alterations. The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a &quot;genomic era&quot; of cancer research and treatment. NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistance mechanisms, quantification of mutational burden, germline mutations which settled the foundation of a new approach in cancer care. In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM approach and the emerging role of the research field of pharmacogenomics.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morganti</LastName>
                    <ForeName>Stefania</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tarantino</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferraro</LastName>
                    <ForeName>Emanuela</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Amico</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duso</LastName>
                    <ForeName>Bruno Achutti</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curigliano</LastName>
                    <ForeName>Giuseppe</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. giuseppe.curigliano@ieo.it.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy. giuseppe.curigliano@ieo.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="Y">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Genomic era</Keyword>
            <Keyword MajorTopicYN="N">Homologous recombination</Keyword>
            <Keyword MajorTopicYN="N">Liquid biopsy</Keyword>
            <Keyword MajorTopicYN="N">Microsatellite instability</Keyword>
            <Keyword MajorTopicYN="N">Next-generation-sequencing (NGS)</Keyword>
            <Keyword MajorTopicYN="N">Oncogenesis</Keyword>
            <Keyword MajorTopicYN="N">Personalized medicine</Keyword>
            <Keyword MajorTopicYN="N">Pharmacogenomics</Keyword>
            <Keyword MajorTopicYN="N">RNA sequencing</Keyword>
            <Keyword MajorTopicYN="N">Sequencing</Keyword>
            <Keyword MajorTopicYN="N">Tumor mutational burden</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31713162</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-24100-1_2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31713161</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1168</Volume>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmaco-Geno-Proteo-Metabolomics and Translational Research in Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-24100-1_1</ELocationID>
            <Abstract>
                <AbstractText>The diagnosis, prognosis and treatment of cancer has had a great improvement due to the &quot;omics&quot; technologies such as genomics, proteomics, epigenomics, pharmacogenomics, and metabolomics. The technological progress of these technologies has allowed precision medicine to become a clinical reality. The study of different biomolecules such as DNA, RNA and proteins has helped to detect alterations in genes, changes in gene expression profiles and loss or gain of protein function, which allows us to make associations and better understand the cancer biology. Data obtained from different &quot;omics&quot; technologies gives a complementary spectrum of information that helps us to understand and unveil new information for a better diagnosis, prognosis, prediction of new molecular targets of anticancer therapies, etc. This chapter presents a general landscape of the interaction between the Pharmaco-Geno-Proteo-Metabolomic and translational medicine research in cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fernández-Figueroa</LastName>
                    <ForeName>Edith A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Computational Genomics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City, Mexico. efernandez@inmegen.gob.mx.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Translational Medicine Laboratory, Instituto Nacional de Cancerologia, Mexico City, Mexico. efernandez@inmegen.gob.mx.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lino-Silva</LastName>
                    <ForeName>Saul</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pathology Department, Instituto Nacional de Cancerologia, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peña-Velasco</LastName>
                    <ForeName>Jorge E</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Computational Genomics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Translational Medicine Laboratory, Instituto Nacional de Cancerologia, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rangel-Escareño</LastName>
                    <ForeName>Claudia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Computational Genomics Laboratory, Instituto Nacional de Medicina Genomica, Mexico City, Mexico.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057170" MajorTopicYN="Y">Translational Medical Research</DescriptorName>
                <QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Biomarker</Keyword>
            <Keyword MajorTopicYN="N">Datases</Keyword>
            <Keyword MajorTopicYN="N">Interactome</Keyword>
            <Keyword MajorTopicYN="N">Metabolomic</Keyword>
            <Keyword MajorTopicYN="N">NGS</Keyword>
            <Keyword MajorTopicYN="N">Oncogenomic</Keyword>
            <Keyword MajorTopicYN="N">Pharmacogenomics</Keyword>
            <Keyword MajorTopicYN="N">Proteogenomics</Keyword>
            <Keyword MajorTopicYN="N">Proteomic</Keyword>
            <Keyword MajorTopicYN="N">Transcriptomic</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31713161</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-24100-1_1</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31711572</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1769-6917</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>106</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Bulletin du cancer</Title>
                <ISOAbbreviation>Bull Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>946-958</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0007-4551(19)30177-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bulcan.2019.03.012</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">A HER2-specific second-generation chimeric antigen receptor (5.137.z) was introduced into NK-92 cells, designated as NK-92/5.137.z cells. To evaluate the function and effectiveness of NK-92/5.137.z cells against gastric cancer cells and further determined whether combination with apatinib can synergize with this NK cell-based practice to better suppress gastric cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The expression of HER2 was examined in gastric cancer. The in vitro and in vivo cytotoxic activities of NK-92/5.137.z cells with or without apatinib were evaluated against gastric cancer cell lines.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">HER2 proteins were over-expressed in a considerable proportion of gastric cancer cells. NK-92/5.137.z cells specifically lysed gastric cancer cells expressing HER2 and had higher levels of cytokine production. In vivo, NK-92/5.137.z cells were particularly efficient at eliminating small tumor xenografts, whereas larger solid tumors were not effectively controlled with NK-92/5.137.z cells. Treatment with apatinib increased NK cell infiltration into large tumor xenografts and improved the therapeutic efficacy of NK-92/5.137.z cells.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NK-92/5.137.z cells could represent a novel treatment option for patients with gastric cancer, either used alone or combined with apatinib.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Xian</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wenzhou traditional Chinese medicine hospital affiliated to Zhejiang Chinese medical university, department of general surgery, Zhejiang, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Shucheng</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Zhejiang provincial hospital of traditional Chinese medicine, department of cardiothoracic surgery, Zhejiang, PR China. Electronic address: monailantian@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Bull Cancer</MedlineTA>
            <NlmUniqueID>0072416</NlmUniqueID>
            <ISSNLinking>0007-4551</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019002">CD56 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C522918">NCAM1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000632548">PECAM1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019408">Platelet Endothelial Cell Adhesion Molecule-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5S371K6132</RegistryNumber>
                <NameOfSubstance UI="C553458">apatinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019002" MajorTopicYN="N">CD56 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015550" MajorTopicYN="N">Cell Degranulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
                <QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019408" MajorTopicYN="N">Platelet Endothelial Cell Adhesion Molecule-1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000076962" MajorTopicYN="N">Receptors, Chimeric Antigen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apatinib</Keyword>
            <Keyword MajorTopicYN="N">Chimeric antigen receptor</Keyword>
            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">NK-92</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31711572</ArticleId>
            <ArticleId IdType="pii">S0007-4551(19)30177-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bulcan.2019.03.012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31710924</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2682</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>201</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of photochemistry and photobiology. B, Biology</Title>
                <ISOAbbreviation>J. Photochem. Photobiol. B, Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Indocyanine green loaded APTMS coated SPIONs for dual phototherapy of cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>111648</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1011-1344(19)30583-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jphotobiol.2019.111648</ELocationID>
            <Abstract>
                <AbstractText>Superparamagnetic iron oxide nanoparticles (SPIONs) have been recently recognized as highly efficient photothermal therapy (PTT) agents. Here, we demonstrate, for the first time to our knowledge, dose and laser intensity dependent PTT potential of small, spherical, 3-aminopropyltrimethoxysilane coated cationic superparamagnetic iron oxide nanoparticles (APTMS@SPIONs) in aqueous solutions upon irradiation at 795 nm. Indocyanine green (ICG) which has been recently used for photodynamic therapy (PDT), was loaded to APTMS@SPIONs to improve the stability of ICG and to achieve an effective mild PTT and PDT (dual therapy) combination for synergistic therapeutic effect on cancer cells via a single laser treatment in the near infrared (NIR). Neither APTMS@SPIONs nor ICG-APTMS@SPIONs showed dark toxicity on MCF7 breast and HT29 colon cancer cell lines. A safe laser procedure was determined as 10 min irradiation at 795 nm with 1.8 W/cm<sup>2</sup> of laser intensity, at which APTMS@SPION did not cause a significant cell death. However, free ICG reduced cell viability at and above 10 μg/ml under these conditions along with generation of reactive oxygen species (ROS), more effectively in MCF7. ICG-APTMS@SPION treated cells showed 2-fold increase in ROS generation and near complete cell death at and below 5 μg/ml ICG dose, even in less sensitive HT29 cells after a single laser treatment at NIR, which would be safe for the healthy tissue and provide a longer penetration depth. Besides, both components can be utilized for diagnosis and the overall composition may be used for optical-image guided phototherapy in the NIR region.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bilici</LastName>
                    <ForeName>Kubra</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School of Materials Science and Engineering, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muti</LastName>
                    <ForeName>Abdullah</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physics and Electrical-Electronics Engineering, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sennaroğlu</LastName>
                    <ForeName>Alphan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School of Materials Science and Engineering, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey; Department of Physics and Electrical-Electronics Engineering, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey; KUYTAM, Koc University Surface Science and Technology Center, 34450 Istanbul, Turkey.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yagci Acar</LastName>
                    <ForeName>Havva</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate School of Materials Science and Engineering, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey; KUYTAM, Koc University Surface Science and Technology Center, 34450 Istanbul, Turkey; Department of Chemistry, Koc University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey. Electronic address: fyagci@ku.edu.tr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>J Photochem Photobiol B</MedlineTA>
            <NlmUniqueID>8804966</NlmUniqueID>
            <ISSNLinking>1011-1344</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058185">Magnetite Nanoparticles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011437">Propylamines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012821">Silanes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>13822-56-5</RegistryNumber>
                <NameOfSubstance UI="C088294">3-aminopropyltrimethoxysilane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IX6J1063HV</RegistryNumber>
                <NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007259" MajorTopicYN="N">Infrared Rays</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058185" MajorTopicYN="N">Magnetite Nanoparticles</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011437" MajorTopicYN="N">Propylamines</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012821" MajorTopicYN="N">Silanes</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">APTMS-SPION</Keyword>
            <Keyword MajorTopicYN="N">Dual therapy</Keyword>
            <Keyword MajorTopicYN="N">Indocyanine green</Keyword>
            <Keyword MajorTopicYN="N">Photodynamic therapy</Keyword>
            <Keyword MajorTopicYN="N">Photothermal therapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31710924</ArticleId>
            <ArticleId IdType="pii">S1011-1344(19)30583-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jphotobiol.2019.111648</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31709456</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0851</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>68</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer immunology, immunotherapy : CII</Title>
                <ISOAbbreviation>Cancer Immunol. Immunother.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2029-2039</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00262-019-02422-9</ELocationID>
            <Abstract>
                <AbstractText>Interferon-stimulated gene 15 (ISG15) is a 15 kDa protein induced by type I interferons (IFN-α and IFN-β) and is a member of the ubiquitin-like superfamily of proteins. The ISG15 pathway is highly expressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), suggesting a potential role of the ISG15 pathway (free ISG15 and ISG15 conjugates) in pancreatic carcinogenesis. However, very little is known about how the ISG15 pathway may contribute to pancreatic tumorigenesis. In the current study, we demonstrate that ISG15 pathway knockdown reverses the KRAS-associated phenotypes of PDAC cells such as increased proliferation and colony formation. Furthermore, clustered regularly interspaced short palindromic repeats (CRISPR)-mediated ISG15 knockdown decreased tumor programmed death ligand-1 (PDL-1) expression leading to increased number of CD8<sup>+</sup> tumor-infiltrating lymphocytes and decreased pancreatic tumor growth. In addition, the syngeneic subcutaneous mouse model revealed that knocking down the ISG15 pathway significantly decreased the rate of tumor incidence and increased the survival rate. Interestingly, the ISG15 knockdown-mediated PDL-1 downregulation in pancreatic tumors increased the efficacy of anti-programmed cell death protein-1 (PD-1) treatment. ISG15 knockdown in combination with anti-PD-1 treatment synergistically increased the number of CD8<sup>+</sup> tumor-infiltrating lymphocytes. Additionally, ISG15 knockdown alone significantly decreased the number of tumor-infiltrating regulatory T cells (Tregs) compared to wild type tumors treated with anti-PD-1 antibody. Overall, these findings suggest that strategies to target the ISG15 pathway by itself or in combination with immunotherapy may lead to improved survival for patients diagnosed with PDAC.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Burks</LastName>
                    <ForeName>Julian</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-8760-766X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Georgetown University, Washington, DC, 20007, USA. julian.burks@nih.gov.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Vaccine Branch, Center for Cancer Research, National Cancer Institute, Building 41, Room D702, Bethesda, MD, 20892, USA. julian.burks@nih.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fleury</LastName>
                    <ForeName>Alia</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Georgetown University, Washington, DC, 20007, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Livingston</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Georgetown University, Washington, DC, 20007, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Jill P</ForeName>
                    <Initials>JP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Georgetown University, Washington, DC, 20007, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>T32CA00968</GrantID>
                    <Agency>Georgetown University Medical Center</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>PG002842</GrantID>
                    <Agency>Georgetown University Medical Center</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cancer Immunol Immunother</MedlineTA>
            <NlmUniqueID>8605732</NlmUniqueID>
            <ISSNLinking>0340-7004</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C489550">G1p2 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C491383">Pdcd1 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ISG15</Keyword>
            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">Tumor microenvironment</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31709456</ArticleId>
            <ArticleId IdType="doi">10.1007/s00262-019-02422-9</ArticleId>
            <ArticleId IdType="pii">10.1007/s00262-019-02422-9</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31705561</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Full axillary lymph node dissection and increased breast epidermal thickness 1 year after radiation therapy for breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1397-1403</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25757</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We previously reported a prospective study showing axillary lymph node dissection (ALND) is associated with increased breast skin thickening during and 6 weeks post-radiation therapy (RT), and now report ALND's long-term impact at 1 year.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Among 66 women who received whole breast RT after lumpectomy, objective ultrasound measurements of epidermal thickness over four quadrants of the treated breast were measured at five time points: before RT, week 6 of RT, and 6 weeks, 6 months, and 1 year post-RT. Skin thickness ratio (STRA) was generated by normalizing for corresponding measurements of the contralateral breast.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2,436 ultrasound images were obtained. Among 63 women with evaluable data at 1 year, mean STRA significantly increased at 6 months (absolute mean increase of 65%, SD 0.054), and remained elevated at 1 year post-RT (absolute mean increase of 44%, SD 0.048). In multivariable analysis, ALND compared to sentinel lymph node biopsy, longer interval between surgery and RT, increased baseline STRA, and Caucasian race predicted for more severe changes in STRA at 1 year compared to baseline (all P &lt; .05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the setting of whole breast RT, our findings suggest that ALND has long-term repercussions on breast skin thickening.</AbstractText>
                <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Jolinta Y</ForeName>
                    <Initials>JY</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5660-6365</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Xiaofeng</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serra</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Division of General Medicine and Geriatrics, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Andrew H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Godette</LastName>
                    <ForeName>Karen D</ForeName>
                    <Initials>KD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kahn</LastName>
                    <ForeName>Shannon T</ForeName>
                    <Initials>ST</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Henry</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Gabrielle</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Tian</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Torres</LastName>
                    <ForeName>Mylin A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Winship Cancer Institute, Emory University, Atlanta, Georgia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID> R21 CA155511</GrantID>
                    <Acronym>GF</Acronym>
                    <Agency>NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>Robbins Scholar Award</GrantID>
                    <Agency>Winship Cancer Institute of Emory University</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>R03CA183006</GrantID>
                    <Acronym>GF</Acronym>
                    <Agency>NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RTOG Community Clinical Oncology and Symptom Management Group</GrantID>
                    <Agency>Radiation Therapy Oncology Group</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>P30 CA138292</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30CA138292</GrantID>
                    <Acronym>BC</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Fred Cooper Family Foundation Breast Cancer Initiative</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004817" MajorTopicYN="N">Epidermis</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061665" MajorTopicYN="N">Time-to-Treatment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">lymph node dissection</Keyword>
            <Keyword MajorTopicYN="N">radiation therapy</Keyword>
            <Keyword MajorTopicYN="N">skin thickening</Keyword>
            <Keyword MajorTopicYN="N">toxicity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31705561</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25757</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704874</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6403-6412</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13854</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sidorkiewicz</LastName>
                    <ForeName>Iwona</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0254-3095</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland iwona.sidorkiewicz@umb.edu.pl.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piskór</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dąbrowska</LastName>
                    <ForeName>Emilia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guzińska-Ustymowicz</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pryczynicz</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zbucka-Krętowska</LastName>
                    <ForeName>Monika</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Reproduction and Gynecological Endocrinology, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ławicki</LastName>
                    <ForeName>Sławomir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000628668">CSF1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560822">TIMP1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560823">TIMP2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019715">Tissue Inhibitor of Metalloproteinase-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>127497-59-0</RegistryNumber>
                <NameOfSubstance UI="D019716">Tissue Inhibitor of Metalloproteinase-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>81627-83-0</RegistryNumber>
                <NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045726" MajorTopicYN="N">Metalloproteases</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019715" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-1</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019716" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-2</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002578" MajorTopicYN="N">Uterine Cervical Dysplasia</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Tumor marker</Keyword>
            <Keyword MajorTopicYN="N">cervical cancer</Keyword>
            <Keyword MajorTopicYN="N">macrophage colony-stimulating factor</Keyword>
            <Keyword MajorTopicYN="N">matrix metalloproteinases</Keyword>
            <Keyword MajorTopicYN="N">tissue inhibitors of matrix metalloproteinases</Keyword>
            <Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704874</ArticleId>
            <ArticleId IdType="pii">39/11/6403</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13854</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704874</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6403-6412</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13854</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sidorkiewicz</LastName>
                    <ForeName>Iwona</ForeName>
                    <Initials>I</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0254-3095</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland iwona.sidorkiewicz@umb.edu.pl.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piskór</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dąbrowska</LastName>
                    <ForeName>Emilia</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guzińska-Ustymowicz</LastName>
                    <ForeName>Katarzyna</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pryczynicz</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zbucka-Krętowska</LastName>
                    <ForeName>Monika</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Reproduction and Gynecological Endocrinology, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ławicki</LastName>
                    <ForeName>Sławomir</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000628668">CSF1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560822">TIMP1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560823">TIMP2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019715">Tissue Inhibitor of Metalloproteinase-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C467484">VEGFA protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>127497-59-0</RegistryNumber>
                <NameOfSubstance UI="D019716">Tissue Inhibitor of Metalloproteinase-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>81627-83-0</RegistryNumber>
                <NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.35</RegistryNumber>
                <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045726" MajorTopicYN="N">Metalloproteases</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019715" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-1</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019716" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-2</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002578" MajorTopicYN="N">Uterine Cervical Dysplasia</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Tumor marker</Keyword>
            <Keyword MajorTopicYN="N">cervical cancer</Keyword>
            <Keyword MajorTopicYN="N">macrophage colony-stimulating factor</Keyword>
            <Keyword MajorTopicYN="N">matrix metalloproteinases</Keyword>
            <Keyword MajorTopicYN="N">tissue inhibitors of matrix metalloproteinases</Keyword>
            <Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704874</ArticleId>
            <ArticleId IdType="pii">39/11/6403</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13854</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704873</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Short- and Long-term Outcomes of 2-Step Stapled Intracorporeal <i>Versus</i> Extracorporeal Anastomosis in Laparoscopic Colectomy for Colon Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6393-6401</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13853</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Intracorporeal anastomosis (IA) in laparoscopic colectomy for colon cancer is technically difficult, and there is a lack of consensus on the risk of bacterial contamination and cancer cell dissemination. In this study, short- and long-term outcomes of IA were examined.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Short and long-term outcomes of those who underwent IA (n=44) or extracorporeal anastomosis (EA) (n=61) were compared.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">IA was better than EA for blood loss, incision length, and first stool. Maximum temperature and C-reactive protein on postoperative day 1 were higher for the IA group. The rate of positive cultures from intraoperative lavage was higher for IA. The rate of positive cultures improved to an equivalent level by replacing mechanical pretreatment with chemical pretreatment. IA and EA were equivalent for the results of ascites cytology from lavage.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">With the use of appropriate preoperative treatment, IA takes advantage of the minimally invasive nature of laparoscopic surgery.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kayano</LastName>
                    <ForeName>Hajime</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan h.kayano@tsc.u-tokai.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nomura</LastName>
                    <ForeName>Eiji</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueda</LastName>
                    <ForeName>Yasuhiko</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuramoto</LastName>
                    <ForeName>Toru</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Saiseikai Suita Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Machida</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mukai</LastName>
                    <ForeName>Masaya</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamamoto</LastName>
                    <ForeName>Seiichiro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Tokai University School of Medicine, Kanagawa, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makuuchi</LastName>
                    <ForeName>Hiroyasu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Tokai University Hachioji Hospital, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001201" MajorTopicYN="N">Ascites</DescriptorName>
                <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
                <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017792" MajorTopicYN="N">Surgical Stapling</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Anastomosis</Keyword>
            <Keyword MajorTopicYN="N">bacterial contamination</Keyword>
            <Keyword MajorTopicYN="N">cancer cell dissemination</Keyword>
            <Keyword MajorTopicYN="N">colon cancer</Keyword>
            <Keyword MajorTopicYN="N">intracorporeal</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704873</ArticleId>
            <ArticleId IdType="pii">39/11/6393</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13853</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704867</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6355-6358</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13847</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed. In patients developing pneumonitis, radiation and clinical parameters were investigated to identify potential risk factors.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven patients (1.8%) developed a pneumonitis grade ≥2. Mean doses to the ipsilateral lung were &gt;7 Gy in 5 patients (45%). Of the other patients, 5 had a chronic inflammatory disease. Six patients (55%) had another malignancy (4 previous contralateral breast cancers, 1 previous ovarian and thyroid cancer, 1 synchronous carcinoma-in-situ (pTis) at the contralateral breast). Five patients (45%) received chemotherapy including taxanes and 4 patients (36%) received trastuzumab.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prevalence of pneumonitis was 1.8%. Potential risk factors included mean radiation dose to ipsilateral lung &gt;7 Gy, systemic treatment with taxanes or trastuzumab, chronic inflammatory disease and history of another malignancy.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Werner</LastName>
                    <ForeName>Elisa M</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Eggert</LastName>
                    <ForeName>Marie C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bohnet</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pulmonology, University of Lübeck, Lübeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rades</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany dirk.rades@uksh.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
                <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P188ANX8CK</RegistryNumber>
                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002278" MajorTopicYN="N">Carcinoma in Situ</DescriptorName>
                <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
                <QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009378" MajorTopicYN="N">Neoplasms, Multiple Primary</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017564" MajorTopicYN="N">Radiation Pneumonitis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">irradiation</Keyword>
            <Keyword MajorTopicYN="N">pneumonitis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704867</ArticleId>
            <ArticleId IdType="pii">39/11/6355</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13847</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
	<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704859</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6291-6297</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13839</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Cyclins D1 and E play different roles in the cell cycle. Cyclin E promotes chromosome instability, whereas cyclin D1 regulates apoptosis of cells. This study evaluated the prognostic significance of G1 cyclins, p21 and pRb in tumor proliferation.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 102 patients with colon cancer were operated on and staged according to TNM. Follow-up was 2 to 68 months (mean 38.3±16.7 months). Expression of cyclin E and D1 were evaluated using immunohistochemistry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Levels of cyclin E expression were correlated with cyclin D1 expression (p=0.038), p21 expression (p=0.047), and pRb expression (p=0.004). The 5-year survival rate along with prognosis of patients with advanced stage (III, IV) colon cancer and cyclin D1 positive tumors, were significantly worse (p=0.009). Statistically significant association was observed between tumor proliferative capacity Ki-67, cyclin D1 (p=0.009), pRb (p=0.031) and p21 (p=0.050).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cyclin D1 is highly expressed in advanced stage colon cancer patients, implying a potential prognostic value.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Palaiologos</LastName>
                    <ForeName>Pantelis</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>2nd Department of Propedeutic Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chrysikos</LastName>
                    <ForeName>Dimosthenis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>University Department of Surgery, General and Oncologic Hospital of Kifissia 'Agii Anargiri', Athens, Greece dixrys@yahoo.gr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Theocharis</LastName>
                    <ForeName>Stamatios</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kouraklis</LastName>
                    <ForeName>Gregory</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>2nd Department of Propedeutic Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C530104">CCND1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C475820">CCNE1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493956">CDKN1A protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019927">Cyclin E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050759">Cyclin-Dependent Kinase Inhibitor p21</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015513">Oncogene Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>136601-57-5</RegistryNumber>
                <NameOfSubstance UI="D019938">Cyclin D1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019938" MajorTopicYN="N">Cyclin D1</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019927" MajorTopicYN="N">Cyclin E</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050759" MajorTopicYN="N">Cyclin-Dependent Kinase Inhibitor p21</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016193" MajorTopicYN="Y">G1 Phase</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015513" MajorTopicYN="N">Oncogene Proteins</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016160" MajorTopicYN="N">Retinoblastoma Protein</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cyclin D1</Keyword>
            <Keyword MajorTopicYN="N">Rb</Keyword>
            <Keyword MajorTopicYN="N">colon cancer</Keyword>
            <Keyword MajorTopicYN="N">cyclin E</Keyword>
            <Keyword MajorTopicYN="N">p21</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704859</ArticleId>
            <ArticleId IdType="pii">39/11/6291</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13839</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704855</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6259-6263</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13835</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a known cancer/testis antigen. Our group has previously shown KK-LC-1 gene expression in gastric cancer. However, could not be detected the KK-LC-1 protein due to the lack of an appropriate antibody. Here, we assessed our original monoclonal antibody (Kmab34B3) and, using it, assessed the expression of KK-LC-1 in gastric cancer.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We evaluated an original monoclonal antibody against KK-LC-1 (Kmab34B3), and used this antibody to compare KK-LC-1 protein expression in tumour and non-tumour stomach cells from gastric cancer patients.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Kmab34B3 stained testicular germ cells, and tumour cells in nine out of 11 (82%) specimens. In non-tumorous areas, Kmab34B3 stained 13 out of 29 (45%) pyloric gland specimens. Furthermore, Kmab34B3 also stained intestinal metaplasia positive and negative areas.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Kmab34B3 was able to detect KK-LC-1 protein within tumour cells and the pyloric gland where the gene has been shown to be expressed. Therefore, it might be an attractive tool for detecting KK-LC-1 expression in precancerous and cancerous stomach cells.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Takahashi</LastName>
                    <ForeName>Yoshihito</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of General, Pediatric and Hepatobiliary-Pancreatic Surgery, Kitasato University, Sagamihara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukuyama</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan fukuyam@insti.kitasato-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Futawatari</LastName>
                    <ForeName>Nobue</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General and Gastroenterological Surgery, Department of Surgery (Ohashi), Toho University, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ichiki</LastName>
                    <ForeName>Yoshinobu</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Thoracic Surgery, National Hospital Organization Saitama Hospital, Wako, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ohmiya</LastName>
                    <ForeName>Haruki</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biological Chemistry and Food Sciences, Faculty of Agriculture, Iwate University, Morioka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chuman</LastName>
                    <ForeName>Motohiro</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamashita</LastName>
                    <ForeName>Tetsuro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biological Chemistry and Food Sciences, Faculty of Agriculture, Iwate University, Morioka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hiki</LastName>
                    <ForeName>Naoki</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Upper Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumamoto</LastName>
                    <ForeName>Yusuke</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General, Pediatric and Hepatobiliary-Pancreatic Surgery, Kitasato University, Sagamihara, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamazaki</LastName>
                    <ForeName>Hitoshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nonoguchi</LastName>
                    <ForeName>Hiroshi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishi</LastName>
                    <ForeName>Yatsushi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Noritada</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000600054">kita-kyushu lung cancer antigen 1, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008679" MajorTopicYN="N">Metaplasia</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011230" MajorTopicYN="N">Precancerous Conditions</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011708" MajorTopicYN="N">Pylorus</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013270" MajorTopicYN="N">Stomach</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">Kita-Kyushu lung cancer antigen-1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704855</ArticleId>
            <ArticleId IdType="pii">39/11/6259</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13835</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704854</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6249-6257</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13834</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Therapeutic targeting of receptor protein tyrosine kinases (PTKs) has proven successful in treating cancer. However, reports about PTKs in treating prostate cancer are few. Elevated expression of the erythropoietin-producing hepatocellular receptor A2 (EPHA2) receptor tyrosine kinase, a transmembrane protein, is associated with poor prognosis of certain cancer types when the enzyme is dephosphorylated. This study investigated whether EPHA2 is useful in predicting the biochemical recurrence of prostate cancer.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Data from 241 patients who had undergone total prostatectomy between 2007 and 2011 were used. EPHA2 protein expression was categorized as high or low by two pathologists. The relationship was examined between EPHA2 expression level (high vs. low) and clinicopathological factors including biochemical recurrence. Correlations were examined between EPHA2, low-molecular-weight protein tyrosine phosphatase (LMW-PTP), E-cadherin, and Ki-67.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">EPHA2 expression was high in 121 (50.2%) and low in 120 (49.8%) patients. A log-rank test revealed early biochemical recurrence in the high-expression group. Gleason score, Ki-67 labeling index, and biochemical recurrence were more frequent in the high-expression group. Furthermore, multivariate analyses revealed that high EPHA2 expression was an independent prognostic factor for biochemical recurrence (hazard ratio=3.62, 95% confidence interval=2.39-5.61). Correlations between EPHA2 and both LMW-PTP and Ki-67 labeling index were positive, whereas EPHA2 and E-cadherin were negatively correlated.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">EPHA2 overexpression is predictive of aggressive prostate cancer behavior. EPHA2 may be a powerful prognostic biomarker for decision-making in postoperative follow-up after total prostatectomy, and regarding the need for palliative treatment. Additionally, it may be an important therapeutic target.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kurose</LastName>
                    <ForeName>Hirofumi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan kurose_hirofumi@med.kurume-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ueda</LastName>
                    <ForeName>Kosuke</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kondo</LastName>
                    <ForeName>Reiichiro</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ogasawara</LastName>
                    <ForeName>Sachiko</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusano</LastName>
                    <ForeName>Hironori</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sanada</LastName>
                    <ForeName>Sakiko</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naito</LastName>
                    <ForeName>Yoshiki</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakiri</LastName>
                    <ForeName>Makoto</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishihara</LastName>
                    <ForeName>Kiyoaki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kakuma</LastName>
                    <ForeName>Tatsuyuki</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biostatistics Center, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akiba</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Igawa</LastName>
                    <ForeName>Tsukasa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yano</LastName>
                    <ForeName>Hirohisa</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000623258">EphA2 receptor, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D036383">Ephrin-A2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019394">Ki-67 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.48</RegistryNumber>
                <NameOfSubstance UI="D017027">Protein Tyrosine Phosphatases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D036383" MajorTopicYN="N">Ephrin-A2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019394" MajorTopicYN="N">Ki-67 Antigen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017027" MajorTopicYN="N">Protein Tyrosine Phosphatases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">E-cadherin</Keyword>
            <Keyword MajorTopicYN="N">EPH receptor</Keyword>
            <Keyword MajorTopicYN="N">LMW-PTP</Keyword>
            <Keyword MajorTopicYN="N">biochemical recurrence</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">protein kinase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704854</ArticleId>
            <ArticleId IdType="pii">39/11/6249</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13834</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704852</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6231-6240</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13832</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The present study aimed to prospectively examine the usefulness of interferon-gamma (IFN-γ) release (IGR) as a biomarker in non-small-cell lung cancer patients receiving immune checkpoint inhibitor treatment (ICI-Tx).</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">IGR was measured using enzyme-linked immunosorbent assay at four time points: within 14 days before ICI-Tx (T1), and 8±3 (T2), 22±7 (T3), and 43±7 (T4) days after ICI-Tx.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-nine patients were divided into three groups based on IFN-γ levels in the IGR-positive control: Group-1 (n=8) with &lt;10 IU/ml at T1, Group-2 (n=12) with a decrease in IFN-γ levels to &lt;10 IU/ml at T3 and/or T4, and Group-3 (n=9) without changes in IFN-γ levels. Early progression and ICI-induced interstitial pneumonitis were frequently observed in Group-1 and Group-2, respectively. Group-3 exhibited more treatment cycles than the other groups. All three groups showed clear differences in clinical outcomes.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IFN-γ levels could be a biomarker for ICI-Tx.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hirashima</LastName>
                    <ForeName>Tomonori</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan hirashimat@ra.opho.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanai</LastName>
                    <ForeName>Tomohiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suzuki</LastName>
                    <ForeName>Hidekazu</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshida</LastName>
                    <ForeName>Hiroko</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsushita</LastName>
                    <ForeName>Akane</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawasumi</LastName>
                    <ForeName>Hiromi</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samejima</LastName>
                    <ForeName>Yumiko</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noda</LastName>
                    <ForeName>Yoshimi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nasu</LastName>
                    <ForeName>Shingo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Ayako</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morishita</LastName>
                    <ForeName>Naoko</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hashimoto</LastName>
                    <ForeName>Shoji</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Allergy, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kawahara</LastName>
                    <ForeName>Kunimitsu</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pathology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Yoshitaka</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okamoto</LastName>
                    <ForeName>Norio</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Toshio</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Allergy, Osaka Habikino Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>31YO63LBSN</RegistryNumber>
                <NameOfSubstance UI="D000077594">Nivolumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>52CMI0WC3Y</RegistryNumber>
                <NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>82115-62-6</RegistryNumber>
                <NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DPT0O3T46P</RegistryNumber>
                <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055985" MajorTopicYN="N">Latent Tuberculosis</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077594" MajorTopicYN="N">Nivolumab</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Non-small-cell lung cancer</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">immune checkpoint inhibitors</Keyword>
            <Keyword MajorTopicYN="N">immune-related adverse events</Keyword>
            <Keyword MajorTopicYN="N">interferon-gamma release assay</Keyword>
            <Keyword MajorTopicYN="N">interstitial pneumonitis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704852</ArticleId>
            <ArticleId IdType="pii">39/11/6231</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13832</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704850</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6217-6222</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13830</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Elderly cancer patients are more prevalent and require special attention. This study focused on the outcome of elderly (≥65 years) rectal cancer patients treated with tri-modality therapy.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 105 patients receiving neoadjuvant radio-chemotherapy and resection for locally advanced rectal cancers were retrospectively evaluated. Nine characteristics were analyzed for loco-regional control (LRC), metastases-free survival (MFS) and overall survival (OS) including tumor location, gender, age, performance status, radiotherapy technique, primary tumor/lymph node categories, downstaging and histological grading.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year rates of LRC, MFS and OS were 91%, 78% and 87%, respectively. Radio-chemotherapy was not completed in 12 patients (11%) due to toxicity; 18 patients (17%) experienced grade 3 toxicities. A total of 29 patients (28%) had surgical complications. On multivariate analyses, MFS was significantly associated with downstaging (p=0.003) and OS with lower histological grade (p=0.013).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Tri-modality therapy resulted in promising outcomes and was tolerated reasonably well by elderly patients. Prognostic factors were identified that may help personalize future treatment.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Treder</LastName>
                    <ForeName>Maxi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Janssen</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Private Practice of Radiation Oncology, Hannover, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schild</LastName>
                    <ForeName>Steven E</ForeName>
                    <Initials>SE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rades</LastName>
                    <ForeName>Dirk</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>04ZR38536J</RegistryNumber>
                <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
                <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6804DJ8Z9U</RegistryNumber>
                <NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017567" MajorTopicYN="N">Karnofsky Performance Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Rectal cancer</Keyword>
            <Keyword MajorTopicYN="N">elderly patients</Keyword>
            <Keyword MajorTopicYN="N">neoadjuvant radio-chemotherapy</Keyword>
            <Keyword MajorTopicYN="N">prognostic factors</Keyword>
            <Keyword MajorTopicYN="N">treatment outcomes</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704850</ArticleId>
            <ArticleId IdType="pii">39/11/6217</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13830</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704849</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6209-6216</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13829</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The appropriate extent of lymphadenectomy on gastric cancer patients with positive peritoneal cytology (CY1) is uncertain. This study retrospectively compared overall survival (OS) after standard and limited lymphadenectomy.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">The medical records from four institutions from 2004 to 2018 were reviewed and data for 91 patients with CY1, but no other distant metastases, who underwent gastrectomy were analyzed. D2 or greater lymphadenectomy and less than D2 lymphadenectomy were performed in 51 and 40 patients, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Full cohort analyses showed that patients who underwent D2 or greater lymphadenectomy had better prognostic nutritional indices and more such patients received postoperative chemotherapy. The OS in the group treated with D2 or greater lymphadenectomy was also significantly better (p=0.045). Twenty-seven pairs of patients were generated via propensity score matching, and analysis of their OS showed no significant difference between the groups according to lymphadenectomy (p=0.61).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The extent of lymphadenectomy may not affect the prognoses for patients with CY1 gastric cancer.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Endo</LastName>
                    <ForeName>Shunji</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yao Municipal Hospital, Osaka, Japan shunji.endo@hosp-yao.osaka.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishikawa</LastName>
                    <ForeName>Kazuhiro</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujitani</LastName>
                    <ForeName>Kazumasa</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsuyama</LastName>
                    <ForeName>Jin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikenaga</LastName>
                    <ForeName>Masakazu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Terumasa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery, Higashiosaka City Medical Center, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tamura</LastName>
                    <ForeName>Shigeyuki</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yao Municipal Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sasaki</LastName>
                    <ForeName>Y O</ForeName>
                    <Initials>YO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Yao Municipal Hospital, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005743" MajorTopicYN="N">Gastrectomy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009752" MajorTopicYN="N">Nutritional Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010537" MajorTopicYN="N">Peritoneum</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cell biology</Keyword>
            <Keyword MajorTopicYN="N">lymph node excision</Keyword>
            <Keyword MajorTopicYN="N">stomach neoplasms</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704849</ArticleId>
            <ArticleId IdType="pii">39/11/6209</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13829</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704846</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hookwire-guided Sentinel Lymph Node Biopsy Using Contrast-enhanced Ultrasonography Followed by a One-step Nucleic Acid Amplification (OSNA) Assay for Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6183-6192</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13826</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the feasibility of hookwire-guided sentinel lymph node biopsy (SLNB) using contrast-enhanced ultrasonography (CEUS) followed by a one-step nucleic acid amplification (OSNA) assay.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Clinical T1-2N0M0 breast cancer patients scheduled to undergo SLNB participated in this study. Both Sonazoid® and dye were used as tracers, and the most upstream sentinel lymph node (SLN) at each lymphatic flow detected by CEUS (First-SLN) was sampled under hookwire guidance, a procedure called &quot;Sona-Hook&quot;.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In each of the 50 cases, at least one First-SLN was extracted by &quot;Sona-Hook&quot;. All contrast-enhanced SLNs (CE-SLNs) were dye-positive, and the mean number of CE-SLNs sampled per patient was lower than that of dye-positive SLNs (1.48 vs. 1.88, p&lt;0.01). Through OSNA, qualitative assessment of tumor metastasis between First-SLNs and all SLNs completely matched together.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&quot;Sona-Hook&quot; for First-SLN followed by an OSNA assay may be a feasible minimally invasive SLNB strategy.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Miyake</LastName>
                    <ForeName>Tomohiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimazu</LastName>
                    <ForeName>Kenzo</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan kshimazu@onsurg.med.osaka-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanei</LastName>
                    <ForeName>Tomonori</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naoi</LastName>
                    <ForeName>Yasuto</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kagara</LastName>
                    <ForeName>Naofumi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimoda</LastName>
                    <ForeName>Masafumi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seung Jin</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noguchi</LastName>
                    <ForeName>Shinzaburo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018275" MajorTopicYN="N">Carcinoma, Lobular</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003287" MajorTopicYN="Y">Contrast Media</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061705" MajorTopicYN="N">Image-Guided Biopsy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D021141" MajorTopicYN="N">Nucleic Acid Amplification Techniques</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071036" MajorTopicYN="N">Sentinel Lymph Node</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016217" MajorTopicYN="N">Ultrasonography, Mammary</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">Sona-Hook</Keyword>
            <Keyword MajorTopicYN="N">contrast-enhanced ultrasonography (CEUS)</Keyword>
            <Keyword MajorTopicYN="N">hookwire</Keyword>
            <Keyword MajorTopicYN="N">one-step nucleic acid amplification (OSNA)</Keyword>
            <Keyword MajorTopicYN="N">sentinel lymph node biopsy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704846</ArticleId>
            <ArticleId IdType="pii">39/11/6183</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13826</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704841</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Suppression of Carnosine on Adhesion and Extravasation of Human Colorectal Cancer Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6135-6144</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13821</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To investigate the effect of carnosine, an active compound of dietary beef, fish and chicken, on the regulation of cell adhesion and extravasation during metastasis.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Cell adhesion and extravasation abilities, and related regulating molecular mechanisms were analyzed in human colorectal cancer cells (HCT-116) and human umbilical vein cells (EA.hy926).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Carnosine reduced the ability of HCT-116 cells to adhere to EA.hy926 cells. The expression levels of integrin-β1 in HCT-116 cells, as well as of intercellular adhesion molecule-1 and E-selectin in EA.hy926 cells, were reduced after carnosine treatment. After EA.hy926 cells were treated with carnosine, phosphorylation of vascular endothelia-cadherin (VE-cadherin), protein levels of Ras homologous (RHO) and RHO-associated coiled-coil containing protein kinase, and levels of reactive oxygen species were reduced. After treating EA.hy926 cells with carnosine, phosphorylation of inhibitor of kappa B (IκB) and DNA binding activity of nuclear factor-κB (NF-κB) were reduced.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Carnosine inhibits metastatic cell adhesion and extravasation by suppressing NF-κB signaling activation.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Chih-Chung</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition, Providence University, Taichung, Taiwan, R.O.C.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Po-Yu</ForeName>
                    <Initials>PY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan, R.O.C.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsieh</LastName>
                    <ForeName>Shuchen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemistry, National Sun Yat-Sen University, Kaohsiung, Taiwan, R.O.C.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Ching-Ching</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food Processing, National ChiaTung Agricultural Vocational Senior High School, Pingtung, Taiwan, R.O.C.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsieh</LastName>
                    <ForeName>Shu-Ling</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung, Taiwan, R.O.C. slhsieh@nkust.edu.tw slhsieh@ntu.edu.tw.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8HO6PVN24W</RegistryNumber>
                <NameOfSubstance UI="D002336">Carnosine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002336" MajorTopicYN="N">Carnosine</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Carnosine</Keyword>
            <Keyword MajorTopicYN="N">NF-κB signaling pathway</Keyword>
            <Keyword MajorTopicYN="N">cell adhesion</Keyword>
            <Keyword MajorTopicYN="N">extravasation</Keyword>
            <Keyword MajorTopicYN="N">permeability</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704841</ArticleId>
            <ArticleId IdType="pii">39/11/6135</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13821</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704840</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6125-6133</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13820</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of the study was to identify novel biomarkers that are vital for improving management of patients with gastric cancer (GC).</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">An RNA-sequencing analysis was conducted using gastric tissue from patients with metastatic GC. In vitro cell functions were evaluated by siRNA-mediated knockdown assays. A total of 230 pairs of gastric tissue were subjected to expression analysis of mRNA and protein in situ. The serum levels of the candidate biomarker were determined by ELISA.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MELTF was identified as a candidate biomarker. Inhibition of MELTF expression suppressed the invasion ability of GC cells. Increased tissue MELTF mRNA expression was associated with shorter survival. Furthermore, staining intensity of tissue MELTF protein was linked to recurrence rates. Serum MELTF levels gradually were increased from healthy controls to advanced GC. Patients with high serum MELTF levels had poor prognosis.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Both tissue and serum MELTF levels may serve as biomarkers of GC progression.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sawaki</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanda</LastName>
                    <ForeName>Mitsuro</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan m-kanda@med.nagoya-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Umeda</LastName>
                    <ForeName>Shinichi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miwa</LastName>
                    <ForeName>Takashi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Chie</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayashi</LastName>
                    <ForeName>Masamichi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Suguru</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakayama</LastName>
                    <ForeName>Goro</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omae</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Masahiko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kodera</LastName>
                    <ForeName>Yasuhiro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000599356">melanotransferrin protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">melanotransferrin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704840</ArticleId>
            <ArticleId IdType="pii">39/11/6125</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13820</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704839</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Shikonin-induced Apoptosis of Colon Cancer Cells Is Reduced by Peroxiredoxin V Expression.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6115-6123</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13819</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Colon cancer is the second most common deadliest malignancy in the world and better understanding of its underlying mechanisms is needed to improve clinical management. Natural plant extracts are gaining attention in the development of new therapeutic strategies against various cancer types. Shikonin is a naturally extracted naphthoquinone pigment with effects against cancer, including colon cancer.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In this study, we conducted a series of in vitro experiments to show the effects of Shikonin on colon cancer cell apoptosis. A colon cancer cell line with overexpression of peroxiredoxin V (PrxV) was constructed and the relationship of PrxV expression with Shikonin-induced cell apoptosis was investigated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Shikonin induced colon cancer cell apoptosis via regulation of mammalian target of rapamycin signaling. Shikonin-induced cell apoptosis was abrogated by overexpression of PrxV.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">According to the results obtained in this study, targeting PrxV may provide new insight for the successful management of colon cancer by inducing cell apoptosis.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chandimali</LastName>
                    <ForeName>Nisansala</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Hu-Nan</ForeName>
                    <Initials>HN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Disease Model Animal Research Center, College of Life Science and Technology, Heilongjiang Bayi Agricultural University, Daqing, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Ling-Zu</ForeName>
                    <Initials>LZ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhen</LastName>
                    <ForeName>Xing</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ren</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwon</LastName>
                    <ForeName>Taeho</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Primate Resources Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Dong-Sun</ForeName>
                    <Initials>DS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea dongsunlee@jejunu.ac.kr.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Practical Translational Research Center, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3IK6592UBW</RegistryNumber>
                <NameOfSubstance UI="C016101">shikonin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.15</RegistryNumber>
                <NameOfSubstance UI="D054464">Peroxiredoxins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009285" MajorTopicYN="N">Naphthoquinones</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054464" MajorTopicYN="N">Peroxiredoxins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Peroxiredoxin V</Keyword>
            <Keyword MajorTopicYN="N">ROS</Keyword>
            <Keyword MajorTopicYN="N">Shikonin</Keyword>
            <Keyword MajorTopicYN="N">colon cancer</Keyword>
            <Keyword MajorTopicYN="N">mTOR</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704839</ArticleId>
            <ArticleId IdType="pii">39/11/6115</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13819</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704838</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6107-6114</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13818</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The present investigation aimed to examine the therapeutic potential of the new coumarin derivative bis(4-hydroxy-2H-chromen-2-one) coumarin (4HC) against breast cancer.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">For this purpose, the effects of 4HC treatment on the proliferation of MCF-7 breast cancer cells and on MCF-10a non-cancerous cells were evaluated using a fluorescent assay. Cell cycle distribution and apoptosis were measured by image cytometry. The expression level of aromatase (CYP19A1) and apoptosis-related genes were determined by real-time PCR.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MCF-7 mammary cancer cell proliferation was significantly decreased within 24 h after treatment with 4HC at 50 μM, while no effect was observed on the viability of MCF-10a non-cancerous mammary cells. 4HC also increased the percentage of the cells in the G2/M phase, inducing apoptosis. Real-time PCR revealed that 4HC induced MCF-7 mortality through an up-regulation of Bax and a down-regulation of Bcl-2, resulting in an increase in caspase-3 gene expression. The increased expression of apoptosis-related genes was accompanied by a decrease in CYP19A1 gene expression.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">4HC selectively inhibits proliferation of MCF-7cells in vitro. Moreover, 4HC has inhibitory effects on aromatase gene expression and promoting effects on apoptosis, in MCF-7 cells.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ramdani</LastName>
                    <ForeName>Lamia Hamdan</ForeName>
                    <Initials>LH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Scientific and Technical Research Center in Physico-Chemical Analysis (CRAPC), Tipaza, Algeria lamia_pharm@yahoo.fr.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Talhi</LastName>
                    <ForeName>Oualid</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Scientific and Technical Research Center in Physico-Chemical Analysis (CRAPC), Tipaza, Algeria.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Organic Chemistry, Natural Products and Agrifood (QOPNA), Department of Chemistry &amp; QOPNA, University of Aveiro, Aveiro, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Decombat</LastName>
                    <ForeName>Caroline</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vermerie</LastName>
                    <ForeName>Marion</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berry</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Artur</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Organic Chemistry, Natural Products and Agrifood (QOPNA), Department of Chemistry &amp; QOPNA, University of Aveiro, Aveiro, Portugal.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bachari</LastName>
                    <ForeName>Khaldoun</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Scientific and Technical Research Center in Physico-Chemical Analysis (CRAPC), Tipaza, Algeria.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vasson</LastName>
                    <ForeName>Marie-Paule</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Anticancer Center Jean-Perrin, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delort</LastName>
                    <ForeName>Laetitia</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caldefie-Chézet</LastName>
                    <ForeName>Florence</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clermont Auvergne University, INRA, UNH, Human Nutrition unit, CRNH Auvergne, Clermont Ferrand, France.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CLARA, Lyon Auvergne Rhone Alpes canceropole, Lyon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003374">Coumarins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000593704">bis(4-hydroxy-2H-chromen-2-one)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A4VZ22K1WT</RegistryNumber>
                <NameOfSubstance UI="C030123">coumarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D001141">Aromatase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C561410">CYP19A1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001141" MajorTopicYN="N">Aromatase</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003374" MajorTopicYN="N">Coumarins</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bis(4-hydroxy-2H-chromen-2-one)</Keyword>
            <Keyword MajorTopicYN="N">Coumarin derivative</Keyword>
            <Keyword MajorTopicYN="N">MCF-7 breast cancer cells</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">aromatase inhibition</Keyword>
            <Keyword MajorTopicYN="N">breast cancer</Keyword>
            <Keyword MajorTopicYN="N">cell cycle</Keyword>
            <Keyword MajorTopicYN="N">cell proliferation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704838</ArticleId>
            <ArticleId IdType="pii">39/11/6107</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13818</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704837</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6097-6105</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13817</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Colorectal cancer (CRC) is one of the most common in the world and its prevalence is rapidly increasing. Jagged-1-activated Notch signaling by apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) promotes CRC, and high expression of Jagged-1 is associated with poor prognosis. However, its clinical implication is unknown. The aim of this study was to investigate the clinical role of Jagged-1-activated Notch signaling by APEX1.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) assay was used to evaluate the anti-cancer efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan. Tissue from CRC patients was analyzed to assess the clinical specificity of Jagged-1 activated by APEX1.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The half-maximal inhibitory concentration (IC<sub>50</sub>) in cells co-expressing APEX1 and Jagged-1 cells was higher than that in cells expressing only APEX1. These results indicated that the simultaneous expression of APEX1 and Jagged-1 might be associated with chemoresistance toward 5-FU, oxaliplatin, and irinotecan. Analysis of tissue from CRC patients revealed that high expression of Jagged-1 was associated with a statistically significantly low response to chemotherapy.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overexpression of Jagged-1 by APEX1 might serve as a predictor of response to chemotherapy and of poor prognosis, and moreover may be a therapeutic target for chemotherapy of advanced CRC.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Hong-Beum</ForeName>
                    <Initials>HB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Premedical Course, Chosun University School of Medicine, Gwangju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Hyun-Jong</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Gradulat School of Chosun University, Gwangju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Hee-Jeong</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jun Hee</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Otolaryngology Head and Neck Surgery, Chosun University Hospital, Gwangju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Sang-Gon</ForeName>
                    <Initials>SG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea sgpark@chosun.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000072100">Jagged-1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497761">NOTCH1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051881">Receptor, Notch1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>04ZR38536J</RegistryNumber>
                <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7673326042</RegistryNumber>
                <NameOfSubstance UI="D000077146">Irinotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.2.99.18</RegistryNumber>
                <NameOfSubstance UI="C085108">APEX1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.2.99.18</RegistryNumber>
                <NameOfSubstance UI="D043603">DNA-(Apurinic or Apyrimidinic Site) Lyase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D043603" MajorTopicYN="N">DNA-(Apurinic or Apyrimidinic Site) Lyase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077146" MajorTopicYN="N">Irinotecan</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072100" MajorTopicYN="N">Jagged-1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051881" MajorTopicYN="N">Receptor, Notch1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1)</Keyword>
            <Keyword MajorTopicYN="N">chemoresistance</Keyword>
            <Keyword MajorTopicYN="N">chemotherapy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704837</ArticleId>
            <ArticleId IdType="pii">39/11/6097</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13817</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704835</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6073-6086</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13815</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p&lt;0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ad6 was shown to be a promising agent for treating glioblastomas.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Romanenko</LastName>
                    <ForeName>Margarita V</ForeName>
                    <Initials>MV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dolgova</LastName>
                    <ForeName>Evgeniya V</ForeName>
                    <Initials>EV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osipov</LastName>
                    <ForeName>Ivan D</ForeName>
                    <Initials>ID</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ritter</LastName>
                    <ForeName>Genrikh S</ForeName>
                    <Initials>GS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sizova</LastName>
                    <ForeName>Mariya S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Proskurina</LastName>
                    <ForeName>Anastasia S</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Efremov</LastName>
                    <ForeName>Yaroslav R</ForeName>
                    <Initials>YR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bayborodin</LastName>
                    <ForeName>Sergey I</ForeName>
                    <Initials>SI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Potter</LastName>
                    <ForeName>Ekaterina A</ForeName>
                    <Initials>EA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taranov</LastName>
                    <ForeName>Oleg S</ForeName>
                    <Initials>OS</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Research Center of Virology and Biotechnology &quot;Vector&quot;, Koltsovo, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omigov</LastName>
                    <ForeName>Vladimir V</ForeName>
                    <Initials>VV</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Research Center of Virology and Biotechnology &quot;Vector&quot;, Koltsovo, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kochneva</LastName>
                    <ForeName>Galina V</ForeName>
                    <Initials>GV</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Research Center of Virology and Biotechnology &quot;Vector&quot;, Koltsovo, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grazhdantseva</LastName>
                    <ForeName>Antonina A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Research Center of Virology and Biotechnology &quot;Vector&quot;, Koltsovo, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zavyalov</LastName>
                    <ForeName>Evgeniy L</ForeName>
                    <Initials>EL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Razumov</LastName>
                    <ForeName>Ivan A</ForeName>
                    <Initials>IA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Netesov</LastName>
                    <ForeName>Sergey V</ForeName>
                    <Initials>SV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Novosibirsk State University, Novosibirsk, Russia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bogachev</LastName>
                    <ForeName>Sergey S</ForeName>
                    <Initials>SS</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2019-9382</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia labmolbiol@mail.ru.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000260" MajorTopicYN="N">Adenoviruses, Human</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014411" MajorTopicYN="N">Neoplastic Stem Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adenovirus</Keyword>
            <Keyword MajorTopicYN="N">DNA internalization</Keyword>
            <Keyword MajorTopicYN="N">TAMRA</Keyword>
            <Keyword MajorTopicYN="N">U87 cell line</Keyword>
            <Keyword MajorTopicYN="N">cancer stem cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704835</ArticleId>
            <ArticleId IdType="pii">39/11/6073</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13815</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704833</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6063-6066</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13813</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vycital</LastName>
                    <ForeName>Ondrej</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic vycitalo@fnplzen.cz.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pitule</LastName>
                    <ForeName>Pavel</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hosek</LastName>
                    <ForeName>Petr</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kriz</LastName>
                    <ForeName>Tomas</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treska</LastName>
                    <ForeName>Vladislav</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liska</LastName>
                    <ForeName>Vaclav</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Charles University, University Hospital Pilsen, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C102316">SERPINB9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015843">Serpins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015843" MajorTopicYN="N">Serpins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">immunosurveillance</Keyword>
            <Keyword MajorTopicYN="N">prognostic factor</Keyword>
            <Keyword MajorTopicYN="N">serpin B9</Keyword>
            <Keyword MajorTopicYN="N">visceral surgery</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704833</ArticleId>
            <ArticleId IdType="pii">39/11/6063</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13813</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704831</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of Volatile Anesthetics on Proliferation and Viability of SW480 Colon Cancer Cells <i>In Vitro</i>.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6049-6055</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13811</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">For patients undergoing cancer surgery, the risk for cancer progression is enhanced during the perioperative period. To what extent the type of anesthetic can affect the metastatic process and finally the outcome of patients with cancer is under debate. For this reason, the aim of this study was to investigate the effects of the volatile anesthetics sevoflurane and desflurane on colon cancer cells in vitro.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">SW480 colon carcinoma cells were exposed for 3 or 6 h to sevoflurane (1 or 2.5 vol%) or desflurane (6 or 12 vol%). Cell cycle distribution was analyzed by flow cytometry after a 24-72 h recovery and apoptosis was detected by annexin V staining after a 0-48 h recovery. Viability was tested by measuring ATP content after 0 and 24 h recovery.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with sevoflurane or desflurane caused no or only slight changes in cell-cycle distribution and apoptosis rate. Desflurane at 12vol% significantly reduced cell viability by 17±25% and 11±22% after 3 and 6 h incubation and 24 h recovery, respectively, while 2.5 vol% sevoflurane slightly increased viability.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">At clinically relevant concentrations, sevoflurane and desflurane had only slight effects on SW480 colon cancer cells in vitro.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bundscherer</LastName>
                    <ForeName>Anika C</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany anika.bundscherer@ukr.de.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ullrich</LastName>
                    <ForeName>Viktoria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Barmherzigen Brueder Hospital, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malsy</LastName>
                    <ForeName>Manuela</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gruber</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Graf</LastName>
                    <ForeName>Bernhard M</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brockhoff</LastName>
                    <ForeName>Gero</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology, University Medical Center, University of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sinner</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anesthesiology, University Hospital of Regensburg, Regensburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>38LVP0K73A</RegistryNumber>
                <NameOfSubstance UI="D000077149">Sevoflurane</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>CRS35BZ94Q</RegistryNumber>
                <NameOfSubstance UI="D000077335">Desflurane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018685" MajorTopicYN="N">Anesthetics, Inhalation</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077335" MajorTopicYN="N">Desflurane</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077149" MajorTopicYN="N">Sevoflurane</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Colon cancer</Keyword>
            <Keyword MajorTopicYN="N">apoptosis</Keyword>
            <Keyword MajorTopicYN="N">cell cycle</Keyword>
            <Keyword MajorTopicYN="N">desflurane</Keyword>
            <Keyword MajorTopicYN="N">sevoflurane</Keyword>
            <Keyword MajorTopicYN="N">volatile anesthetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704831</ArticleId>
            <ArticleId IdType="pii">39/11/6049</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13811</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704847</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6193-6196</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13827</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The median CA19-9 did not decrease in the cohort after IRE treatment (282 U/ml before versus 315 U/ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Månsson</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden christopher.mansson@surgsci.uu.se.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nilsson</LastName>
                    <ForeName>Anders</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Urdzik</LastName>
                    <ForeName>Jozef</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karlson</LastName>
                    <ForeName>Britt-Marie</ForeName>
                    <Initials>BM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018395">CA-19-9 Antigen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018395" MajorTopicYN="N">CA-19-9 Antigen</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018274" MajorTopicYN="N">Electroporation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CA19-9</Keyword>
            <Keyword MajorTopicYN="N">Pancreatic neoplasms</Keyword>
            <Keyword MajorTopicYN="N">electroporation</Keyword>
            <Keyword MajorTopicYN="N">interventional ultrasonography</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704847</ArticleId>
            <ArticleId IdType="pii">39/11/6193</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13827</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704829</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Integrated Small Dense Low-density Lipoprotein Profile in Cardiovascular Disease and Cancer: A Longitudinal Study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6035-6039</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13809</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Low-density lipoproteins (LDL) are a heterogeneous class of particles that differ in size and density from each other. Small dense LDL (sdLDL) particles are considered more atherogenic than larger particles. The aim of the study was to evaluate serum levels of sdLDL in patients who died from cardiovascular diseases (CVD) or cancer in a cohort of patients followed up in the De Bellis Research Hospital for 20 years.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">A total of 75 participants who died of cancer and 87 who died of CVD were enrolled and they were matched for age and sex with 135 healthy controls, i.e. without CVD or cancer and are still alive.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients who died from cancer had the highest value of LDL IV subfraction (0.25±1.16), followed by those who died from CVD (0.17±0.96).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The integrated profile of sdLDL between CVD and cancer suggests that therapeutic modulation of sdLDL may be associated with a risk reduction for these diseases.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Notarnicola</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DE Nunzio</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tutino</LastName>
                    <ForeName>Valeria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Veronese</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ambulatory of Clinical Nutrition, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guerra</LastName>
                    <ForeName>Vito</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Scientific Direction, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osella</LastName>
                    <ForeName>Alberto R</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Epidemiology and Biostatistics, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caruso</LastName>
                    <ForeName>Maria Gabriella</ForeName>
                    <Initials>MG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Ambulatory of Clinical Nutrition, National Institute of Gastroenterology-Research Hospital, Castellana Grotte, Italy gabriella.caruso@irccsdebellis.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>MICOL GROUP</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008077">Lipoproteins, LDL</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008077" MajorTopicYN="N">Lipoproteins, LDL</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">cardiovascular disease</Keyword>
            <Keyword MajorTopicYN="N">sdLDL</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704829</ArticleId>
            <ArticleId IdType="pii">39/11/6035</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13809</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704825</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5999-6005</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13805</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A patient CRC tumor previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice. Harvested tumor fragments were transplanted orthotopically in non-transgenic nude mice. Mice were randomized into three groups: Group 1 (G1), untreated-control; Group 2 (G2), OXA+5-FU; Group 3 (G3), TRAB+OXA+5-FU. Tumor width, length, and mouse body weight were measured twice a week.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Both treatment groups inhibited tumor growth compared to the untreated control group. The combination of TRAB, OXA and 5-FU was significantly more efficacious than OXA+5-FU and arrested tumor growth. No significant changes were observed in body-weight in any of the three groups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TRAB, OXA and 5-FU combination has clinical potential for this and other CRC patients.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Guangwei</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastrointestinal Surgery 2 Section, The First Hospital Affiliated to Fujian Medical University, Fuzhou, P.R. China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Qinghong</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tan</LastName>
                    <ForeName>Yuying</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Y U</ForeName>
                    <Initials>YU</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bouvet</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Shree Ram</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Jianxin</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastrointestinal Surgery 2 Section, The First Hospital Affiliated to Fujian Medical University, Fuzhou, P.R. China all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                    <AffiliationInfo>
                        <Affiliation>AntiCancer, Inc., San Diego, CA, U.S.A. all@anticancer.com yejianxinfuyi@126.com singhshr@mail.nih.gov.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>04ZR38536J</RegistryNumber>
                <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>ID0YZQ2TCP</RegistryNumber>
                <NameOfSubstance UI="D000077606">Trabectedin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077606" MajorTopicYN="N">Trabectedin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-fluorouracil</Keyword>
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">PDOX</Keyword>
            <Keyword MajorTopicYN="N">combination therapy</Keyword>
            <Keyword MajorTopicYN="N">oxaliplatinum</Keyword>
            <Keyword MajorTopicYN="N">trabectedin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704825</ArticleId>
            <ArticleId IdType="pii">39/11/5999</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13805</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704822</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines <i>In Vitro</i> and <i>In Vivo</i>.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5973-5982</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13802</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Lenvatinib is a potent inhibitor of receptor tyrosine kinases, targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), KIT, and RET. Here, we investigated the antiproliferative effects of lenvatinib in liver cancer cells in vitro and in vivo.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Eleven hepatocellular carcinoma cell lines and two combined hepatocellular/cholangiocarcinoma cell lines were treated with 0-30 μM lenvatinib. Cell growth, apoptosis and the expression of FGFR1-4, FGF19, fibroblast growth factor receptor substrate (FRS)2α and RET were examined. Two HCC cell lines were subcutaneously implanted on nude mice and mice were treated with 3, 10, 30 mg/kg/day of lenvatinib or vehicle for 14 consecutive days. Tumor volume was measured every 3 days. Mice were sacrificed on day 15 and tumors were processed for histological examination. Blood vessels, microvessel density, necrosis, and apoptosis were also examined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Lenvatinib dose- and time-dependently inhibited growth of all cell lines; however, sensitivity to lenvatinib varied. Apoptosis was not observed in any cell line, and expression of FGFR1, -2, -3 and -4, FGF19, FRS2α, and RET were observed in these cell lines. Cell lines with high expression of these factors showed higher response to lenvatinib. In mice, lenvatinib dose-dependently suppressed tumor growth. Blood vessels and microvessel density were significantly reduced and the rate of necrosis was significantly increased by lenvatinib; apoptosis was not observed.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Antiproliferative effects of lenvatinib on liver cancer cells were observed in vitro and in vivo. Lenvatinib may suppress tumor formation by inhibiting angiogenesis, and via an additional direct antiproliferative effect in some liver cancer cells.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ogasawara</LastName>
                    <ForeName>Sachiko</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan sachiko@med.kurume-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mihara</LastName>
                    <ForeName>Yutaro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kondo</LastName>
                    <ForeName>Reiichiro</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kusano</LastName>
                    <ForeName>Hironori</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akiba</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yano</LastName>
                    <ForeName>Hirohisa</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kurume University School of Medicine, Kurume, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010671">Phenylurea Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EE083865G2</RegistryNumber>
                <NameOfSubstance UI="C531958">lenvatinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010671" MajorTopicYN="N">Phenylurea Compounds</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Liver cancer</Keyword>
            <Keyword MajorTopicYN="N">angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">fibroblast growth factor</Keyword>
            <Keyword MajorTopicYN="N">lenvatinib</Keyword>
            <Keyword MajorTopicYN="N">tyrosine kinase inhibitor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704822</ArticleId>
            <ArticleId IdType="pii">39/11/5973</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13802</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704821</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5963-5971</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13801</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of this study was to investigate matrix metalloproteinase 11 (MMP11) as a promising biomarker in human pancreatic cancer.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A consecutive eliminating method was used to select biomarker candidates in pancreatic cancer. mRNA and protein expression levels of candidates were determined in tissues and whole blood samples of healthy donors and pancreatic cancer patients. The prognostic value of MMP11 was determined using various data-sets and Liptak's Z analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis using Gene Expression Omnibus (GEO) database showed significantly higher MMP11 mRNA expression in pancreatic cancer tissues compared to that in various normal tissues. MMP11 protein was specifically expressed in pancreatic cancer tissues, but not in various normal or other cancer tissues. Secreted MMP11 levels could be measured using easily accessible techniques and whole blood samples of pancreatic cancer. In addition, high levels of MMP11 were associated with poor prognosis of pancreatic cancer patients.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MMP11 may be a promising prognostic biomarker for pancreatic cancer patients.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jungwhoi</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Applied Life Science, SARI, Jeju National University, Jeju, Republic of Korea sdjd1108@kaist.ac.kr kimjh@jejunu.ac.kr.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jungsul</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bio and Brain Engineering, KAIST, Daejeon, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Jae Hoon</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Applied Life Science, SARI, Jeju National University, Jeju, Republic of Korea sdjd1108@kaist.ac.kr kimjh@jejunu.ac.kr.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Subtropical/tropical Organism Gene Bank, Jeju National University, Jeju, Republic of Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.-</RegistryNumber>
                <NameOfSubstance UI="C511771">MMP11 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.-</RegistryNumber>
                <NameOfSubstance UI="D053507">Matrix Metalloproteinase 11</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053507" MajorTopicYN="N">Matrix Metalloproteinase 11</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">MMP11</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
            <Keyword MajorTopicYN="N">whole blood</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704821</ArticleId>
            <ArticleId IdType="pii">39/11/5963</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13801</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704820</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5953-5962</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13800</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. The underlying mechanisms are not clearly understood.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The amount of ascites was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis in a retrospective cohort of 214 women with ovarian cancer, in an ordinal manner (amount of ascites: none, limited, moderate, abundant). In a prospective cohort comprising 45 women with ovarian cancer, IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-β (transforming growth factor) and CCL-2 [chemokine (C-C) motif ligand 2] were measured at diagnosis (and at interval debulking, when available).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p&lt;0.0001) and stronger immunosuppression (IL10 and VEGF). Neoadjuvant chemotherapy reduced immunosuppression, which was observed as a reduction in CCL-2, IL-10 and VEGF.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The amount of ascites is an independent predictor of survival and correlates with increased immunosuppression.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Coosemans</LastName>
                    <ForeName>A N</ForeName>
                    <Initials>AN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium an.coosemans@kuleuven.be.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baert</LastName>
                    <ForeName>Thais</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>D'Heygere</LastName>
                    <ForeName>Victoria</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Ear, Nose, and Throat Clinic, Uniklinik Essen, Essen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wouters</LastName>
                    <ForeName>Roxanne</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DE Laet</LastName>
                    <ForeName>Lara</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>VAN Hoylandt</LastName>
                    <ForeName>Anais</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thirion</LastName>
                    <ForeName>Gitte</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ceusters</LastName>
                    <ForeName>Jolien</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Laenen</LastName>
                    <ForeName>Annouschka</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biostatistics and Statistical Bioinformatics Centre of Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vandecaveye</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, University Hospitals Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vergote</LastName>
                    <ForeName>Ignace</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Leuven Cancer Institute, Laboratory of Gynecologic Oncology, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018262" MajorTopicYN="N">Adenocarcinoma, Clear Cell</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001201" MajorTopicYN="N">Ascites</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018284" MajorTopicYN="N">Cystadenocarcinoma, Serous</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>
            <Keyword MajorTopicYN="N">ascites</Keyword>
            <Keyword MajorTopicYN="N">immunosuppression</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704820</ArticleId>
            <ArticleId IdType="pii">39/11/5953</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13800</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704817</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of Afatinib and Lapatinib Against <i>HER2</i> Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5927-5932</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13797</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Trastuzumab is the only clinically approved targeted therapy for HER2 gene-amplified gastric cancer at present. However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We examined the anti-tumor activity of lapatinib and afatinib, that are reversible and irreversible TKIs, in HER2 gene-amplified trastuzumab-sensitive and - resistant gastric cancer cells (GLM-1 and GLM-1HerR2) in vitro and in vivo.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Afatinib inhibited the growth of GLM-1 and GLM-1HerR2 cells in vitro more efficiently than lapatinib by inducing G<sub>1</sub> cell-cycle arrest and apoptosis. Preclinical studies in mice revealed that afatinib inhibited growth of intraperitoneal GLM-1 and subcutaneous GLM-1HerR2 tumor more strongly than lapatinib. Afatinib was more effective than lapatinib in blocking PI3K/Akt and MAPK signaling in both GLM-1 and GLM-1HerR2 cells.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Afatinib could be a potential new molecular-targeted therapy for trastuzumab-sensitive and trastuzumab-resistant HER2 gene-amplified gastric cancers.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nakata</LastName>
                    <ForeName>Susumu</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan snakata@mb.kyoto-phu.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fujita</LastName>
                    <ForeName>Mitsugu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology, Faculty of Medicine, Kindai University, Osaka, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakanishi</LastName>
                    <ForeName>Hayao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Nagoya University, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0VUA21238F</RegistryNumber>
                <NameOfSubstance UI="D000077341">Lapatinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>41UD74L59M</RegistryNumber>
                <NameOfSubstance UI="D000077716">Afatinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P188ANX8CK</RegistryNumber>
                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000077716" MajorTopicYN="N">Afatinib</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005784" MajorTopicYN="N">Gene Amplification</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077341" MajorTopicYN="N">Lapatinib</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">HER2</Keyword>
            <Keyword MajorTopicYN="N">afatinib</Keyword>
            <Keyword MajorTopicYN="N">trastuzumab resistance</Keyword>
            <Keyword MajorTopicYN="N">tyrosine kinase inhibitor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704817</ArticleId>
            <ArticleId IdType="pii">39/11/5927</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13797</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704815</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Double-negative T Cells Inhibit Proliferation and Invasion of Human Pancreatic Cancer Cells in Co-culture.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5911-5918</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13795</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Double-negative T (DNT) cells are phenotypically CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup>T cells. This study aimed to investigate the anti-cancer activity of DNT cells against pancreatic cancer cells.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">DNT cells were isolated from human peripheral blood. The effect of DNT cells on proliferation and invasion of the human pancreatic cell line Panc-1 was assessed. Expression of Nrf2 and Fas in Panc-1 cells co-cultured with DNT cells was analyzed with RT-PCR. The supernatants of Panc-1 and DNT co-cultures were analyzed with ELISA for IFN-r and FasL levels.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The isolated DNT cell phenotype was CD4<sup>-</sup>CD8<sup>-</sup>CD56<sup>-</sup> CD3<sup>+</sup>TCR (T cell receptor) α/β<sup>+</sup> T cells with more than 90% purity. Panc-1 cell proliferation was significantly inhibited by co-culture with DNT cells. Panc-1 cells co-cultured with DNT cells showed significantly reduced cell invasion. Panc-1 cells co-cultured with DNT cells showed increased Nrf2 and Fas mRNA expression. Increased INF-r and FasL levels were detected in the supernatants of co-cultures of DNT and pancreatic cells.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">DNT cells inhibited proliferation and invasion of human pancreatic cancer cells. The INF-r, Fas/FasL pathway and Nrf2 may be involved in the anti-cancer effect of DNT cells against human pancreatic cancer.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Yin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Medical School of Shandong University, Jinan, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Pibo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Anhui Provincial Hospital, Hefei, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Haibo</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Anhui Provincial Hospital, Hefei, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Zhijian</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Origin Biosciences Inc., Nanjing, P.R. China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Y U</ForeName>
                    <Initials>YU</Initials>
                    <AffiliationInfo>
                        <Affiliation>Origin Biosciences Inc., Nanjing, P.R. China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of California, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Anticancer Inc, San Diego, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jiong</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Surgery, Anhui Provincial Hospital, Hefei, P.R. China ch_jiong@126.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C505661">FASLG protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016693">Receptors, Antigen, T-Cell, alpha-beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017471">Receptors, Interferon</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019014">fas Receptor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016693" MajorTopicYN="N">Receptors, Antigen, T-Cell, alpha-beta</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017471" MajorTopicYN="N">Receptors, Interferon</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019014" MajorTopicYN="N">fas Receptor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Double-negative T cell</Keyword>
            <Keyword MajorTopicYN="N">Nrf-2</Keyword>
            <Keyword MajorTopicYN="N">cell proliferation invasion</Keyword>
            <Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704815</ArticleId>
            <ArticleId IdType="pii">39/11/5911</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704814</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5903-5910</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13794</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastric cancer (GC) exhibits heterogeneous clinical and molecular features, requiring the development of new biomarkers to further understand this disease. Our transcriptomic analysis detected overexpression of melanoma-associated antigen A6 (MAGEA6) in metastatic GC, leading us to determine the clinical significance of MAGEA6 in GC.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Fourteen GC cell lines and 230 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. Polymerase chain reaction array analysis was performed to identify coordinately expressed cancer-related genes, and immunohistochemistry (IHC) was used to detected MAGEA6 expression in situ.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MAGEA6 mRNA levels were positively correlated with the expression of matrix metallopeptidase 9 mRNA. MAGEA6 mRNA levels were higher in GC tissues compared with those in normal adjacent tissues. Patients with high MAGEA6 expression had significantly worse prognosis. MAGEA6 protein levels in primary lesions predicted the likelihood of recurrence.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overexpression of MAGEA6 in GC tissues represents a promising biomarker for assessing the malignant phenotype of GC.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Endo</LastName>
                    <ForeName>Miyo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanda</LastName>
                    <ForeName>Mitsuro</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan m-kanda@med.nagoya-u.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawaki</LastName>
                    <ForeName>Koichi</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shimizu</LastName>
                    <ForeName>Dai</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Chie</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hattori</LastName>
                    <ForeName>Norifumi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayashi</LastName>
                    <ForeName>Masamichi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamada</LastName>
                    <ForeName>Suguru</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koike</LastName>
                    <ForeName>Masahiko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Omae</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima Medical University Hospital, Fukushima, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kodera</LastName>
                    <ForeName>Yasuhiro</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C095203">MAGEA6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002288" MajorTopicYN="N">Adenocarcinoma, Mucinous</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018279" MajorTopicYN="N">Carcinoma, Signet Ring Cell</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005743" MajorTopicYN="N">Gastrectomy</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">MAGE family member A6</Keyword>
            <Keyword MajorTopicYN="N">biomarker</Keyword>
            <Keyword MajorTopicYN="N">expression</Keyword>
            <Keyword MajorTopicYN="N">immunohistochemistry</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704814</ArticleId>
            <ArticleId IdType="pii">39/11/5903</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13794</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704812</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5879-5890</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13792</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of the study was to investigate the prognostic role of androgen receptor (AR), mineralocorticoid receptor (MR) and glucocorticoid receptor β (GRβ) expression in HER-2 negative breast cancer patients.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study population (n=152) was enriched with triple-negative breast cancers (TNBC) (n=96; 63.2%). The median follow-up time was 100 months. AR, MR and GRβ immunocytochemical staining was compared with that of epithelial-mesenchymal transition (EMT) markers (vimentin, SIP1, ZEB1).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">High expression of cytoplasmic MR was associated with dismal local relapse-free survival (RR=13.923; 95%CI=1.071-181.045; p=0.044) in tumours with non-TNBC phenotype. AR and GRβ were more frequently expressed in ER+/PR+/HER2- tumours, while cytoplasmic MR was more often expressed in TNBC tumours (for all, p&lt;0.0005). GRβ and AR were associated with decreased vimentin expression (p&lt;0.005), indicating their association with attenuated EMT.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cytoplasmic MR expression is a strong predictor of local recurrence in non-metastatic breast cancer patients with non-TNBC tumour phenotype.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jääskeläinen</LastName>
                    <ForeName>Anniina</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jukkola</LastName>
                    <ForeName>Arja</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Tampere University Hospital, Faculty of Medicine and Health Technology, University of Tampere, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haapasaari</LastName>
                    <ForeName>Kirsi-Maria</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Auvinen</LastName>
                    <ForeName>Päivi</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Cancer Center, Kuopio University Hospital, and Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soini</LastName>
                    <ForeName>Ylermi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Medical Research Center, Oulu University Hospital, Oulu, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karihtala</LastName>
                    <ForeName>Peeter</ForeName>
                    <Initials>P</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3490-3702</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland peeter.karihtala@oulu.fi.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011965">Receptors, Glucocorticoid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018161">Receptors, Mineralocorticoid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011980">Receptors, Progesterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C121943">glucocorticoid receptor beta</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011965" MajorTopicYN="N">Receptors, Glucocorticoid</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018161" MajorTopicYN="N">Receptors, Mineralocorticoid</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011980" MajorTopicYN="N">Receptors, Progesterone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Breast cancer</Keyword>
            <Keyword MajorTopicYN="N">immunohistochemistry</Keyword>
            <Keyword MajorTopicYN="N">mineralocorticoid receptor</Keyword>
            <Keyword MajorTopicYN="N">prognosis</Keyword>
            <Keyword MajorTopicYN="N">steroid receptor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704812</ArticleId>
            <ArticleId IdType="pii">39/11/5879</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13792</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704811</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5867-5877</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13791</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">The aim of this study was to examine clonal heterogeneity, to test the utility of liquid biopsy in monitoring disease progression and to evaluate the usefulness of ex vivo drug screening in a BRAF L597Q-mutated colorectal cancer (CRC) patient developing metastases during adjuvant therapy.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Next generation sequencing (NGS) and droplet digital PCR (ddPCR) were performed in samples from tumor tissues and liquid biopsies. Live cancer cells from a metastatic lesion were used in ex vivo drug sensitivity assays.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We found evidence of continued dependence of MEK/MAPK pathway activation, but different activating mutations in primary tumor and metastases. Liquid biopsy based BRAF L597Q ddPCR testing was a sensitive personalized biomarker predicting the rise of clinically aggressive metastatic disease. Ex vivo drug sensitivity assays with BRAF L597Q mutated cells showed response to MEK/MAPK targeted therapies.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The rare BRAF L597Q mutation may be associated with aggressive tumor behavior in CRC. Liquid biopsy can be used to capture clinically relevant tumor features.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lehtomaki</LastName>
                    <ForeName>Kaisa I</ForeName>
                    <Initials>KI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland kaisa.lehtomaki@tuni.fi.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tays Cancer Center, Tampere University Hospital, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lahtinen</LastName>
                    <ForeName>Laura I</ForeName>
                    <Initials>LI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Finland Central Hospital, Jyväskylä, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rintanen</LastName>
                    <ForeName>Nina</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Finland Central Hospital, Jyväskylä, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuopio</LastName>
                    <ForeName>Teijo</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Finland Central Hospital, Jyväskylä, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kholova</LastName>
                    <ForeName>Ivana</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Pathology, Fimlab Laboratories, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Makela</LastName>
                    <ForeName>Rami</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Misvik Biology Ltd, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rantala</LastName>
                    <ForeName>Juha K</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Misvik Biology Ltd, Turku, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>University of Sheffield, Sheffield, U.K.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kellokumpu-Lehtinen</LastName>
                    <ForeName>Pirkko-Liisa</ForeName>
                    <Initials>PL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Tays Cancer Center, Tampere University Hospital, Tampere, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kononen</LastName>
                    <ForeName>Juha</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Finland Central Hospital, Jyväskylä, Finland.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Docrates Cancer Center, Helsinki, Finland.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>04ZR38536J</RegistryNumber>
                <NameOfSubstance UI="D000077150">Oxaliplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6804DJ8Z9U</RegistryNumber>
                <NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.24</RegistryNumber>
                <NameOfSubstance UI="D020928">Mitogen-Activated Protein Kinases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.12.2</RegistryNumber>
                <NameOfSubstance UI="D048369">MAP Kinase Kinase 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.12.2</RegistryNumber>
                <NameOfSubstance UI="C482125">MAP2K1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060965" MajorTopicYN="N">Clonal Evolution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048369" MajorTopicYN="N">MAP Kinase Kinase 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020928" MajorTopicYN="N">Mitogen-Activated Protein Kinases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077150" MajorTopicYN="N">Oxaliplatin</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BRAFnonV600E mutations</Keyword>
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">MEK/MAPK pathway</Keyword>
            <Keyword MajorTopicYN="N">ctDNA</Keyword>
            <Keyword MajorTopicYN="N">ex vivo drug screening</Keyword>
            <Keyword MajorTopicYN="N">liquid biopsy</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704811</ArticleId>
            <ArticleId IdType="pii">39/11/5867</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13791</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31704810</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1791-7530</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Anticancer research</Title>
                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>5861-5866</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.13790</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We hypothesized that ancestry-mediated methylated DNA changes may drive racial and ethnic disparity in prostate cancer (PCa). To test this hypothesis, we analyzed genetic ancestry and association with DNA methylation changes in PCa disparity.</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Pyrosequencing and ancestry informative markers were used for DNA methylation and genetic ancestry testing, respectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Using Spearman rho rank correlation test, the data demonstrated significant (p&lt;0.05) and variable association between African-American ancestry and DNA methylation for all genes investigated in prostate tissues.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Genetic ancestry influences DNA methylation and this modifying factor must be considered in epigenetic association studies in populations of admixed patients.</AbstractText>
                <CopyrightInformation>Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Apprey</LastName>
                    <ForeName>Victor</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Family Medicine, Howard University, Washington, DC, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Songping</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology Howard University, Washington, DC, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Human Carcinogenesis, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kittles</LastName>
                    <ForeName>Rick A</ForeName>
                    <Initials>RA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Health Equities, Department of Population Sciences, City of Hope, Duarte, CA, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Southerland</LastName>
                    <ForeName>William M</ForeName>
                    <Initials>WM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology Howard University, Washington, DC, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ittmann</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, U.S.A.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwabi-Addo</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology Howard University, Washington, DC, U.S.A. bkwabi-addo@howard.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Anticancer Res</MedlineTA>
            <NlmUniqueID>8102988</NlmUniqueID>
            <ISSNLinking>0250-7005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019175" MajorTopicYN="Y">DNA Methylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054625" MajorTopicYN="Y">Healthcare Disparities</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AIMs</Keyword>
            <Keyword MajorTopicYN="N">DNA methylation</Keyword>
            <Keyword MajorTopicYN="N">disparity</Keyword>
            <Keyword MajorTopicYN="N">prostate cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31704810</ArticleId>
            <ArticleId IdType="pii">39/11/5861</ArticleId>
            <ArticleId IdType="doi">10.21873/anticanres.13790</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31702609</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>45</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17475</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017475</ELocationID>
            <Abstract>
                <AbstractText>The prognostic role of neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer remains inconsistent. This meta-analysis was conducted to evaluate the predictive value of this biomarker for prognoses in ovarian cancer patients.We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated.Ten studies involving 2919 patients were included in this meta-analysis. In multivariate analysis, the group with higher NLR had worse overall survival (OS) (HR = 1.34, 95% CI = 1.16-1.54) and shorter PFS (HR = 1.36, 95% CI = 1.17-1.57) than the control group. Furthermore, PLR values higher than the cut-off were associated with not only poorer OS (HR = 1.97, 95% CI = 1.61-2.40) but also more unfavorable PFS (HR = 1.79, 95% CI = 1.46-2.20). Univariate analysis also indicated the same results. Additionally, subgroup analysis showed that when the cut-off values for NLR and PLR were higher, their predictive effects became stronger.This comprehensive meta-analysis suggested that the values of inflammatory marker of NLR was associated with ovarian cancer survival. Therefore, inflammatory markers can potentially serve as prognostic biomarkers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Xinming</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gynaecology, Zhengjiang 4th Hospital of JiangSu Province, Zhengjiang.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Ling</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Huaian Maternity and Child Health Care Hospital of JiangSu Province, Huaian, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Huaian Maternity and Child Health Care Hospital of JiangSu Province, Huaian, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>HongBo</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Huaian Maternity and Child Health Care Hospital of JiangSu Province, Huaian, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
                <QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31702609</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017475</ArticleId>
            <ArticleId IdType="pii">00005792-201911080-00003</ArticleId>
            <ArticleId IdType="pmc">PMC6855616</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Zhonghua Fu Chan Ke Za Zhi. 2018 Mar 25;53(3):167-171</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29609230</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Transl Oncol. 2011 Jul;13(7):499-503</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21775277</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Biomark. 2016 Jun 7;17(1):33-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27314290</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2016 Feb;23(2):646-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26416715</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2014 May 15;134(10):2403-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24122750</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2015 Feb;75(2):255-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25428515</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Immunol Immunother. 2009 Jan;58(1):15-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18414853</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Opin Oncol. 2013 Jan;25(1):50-1</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23150341</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 2014 Mar;132(3):542-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24462730</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cancer. 2018 Mar 8;9(7):1127-1134</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29675093</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Surg Oncol. 2011 Oct;104(5):504-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21618251</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2015 Mar 7;21(9):2807-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25759553</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2015 Jul 24;5:12493</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26205001</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2018 Apr;97(16):e0358</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29668586</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 2018 Jul;150(1):31-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29751991</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2017 Nov 1;28(suppl_8):viii61-viii65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29232466</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Med Oncol. 2013 Mar;30(1):439</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23307251</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2017 Nov;96(45):e8101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29137007</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2001 Feb 17;357(9255):539-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11229684</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Chim Acta. 2016 May 1;456:163-169</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27006072</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Ovarian Res. 2019 Feb 11;12(1):16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30744662</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Med Assoc Thai. 2011 Jul;94(7):871-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21774296</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2017 Jan 22;482(4):1400-1406</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27956175</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Tumour Biol. 2015 Nov;36(11):8831-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26063409</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2018 Apr 18;18(1):443</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29669528</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2016 May 20;11(5):e0156101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27203425</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Open Med (Wars). 2017 May 7;12:131-137</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28730172</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genet Test Mol Biomarkers. 2017 Sep;21(9):547-554</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28799806</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Best Pract Res Clin Obstet Gynaecol. 2017 May;41:3-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27743768</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31676051</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1558-3171</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>99</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Surgical clinics of North America</Title>
                <ISOAbbreviation>Surg. Clin. North Am.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Surgical Management of Dysplasia and Cancer in Inflammatory Bowel Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1111-1121</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0039-6109(19)30107-0</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.suc.2019.08.006</ELocationID>
            <Abstract>
                <AbstractText>Patients with inflammatory bowel disease are at an increased risk of cancer secondary to long-standing intestinal inflammation. Surgical options must take into account the significant risk of synchronous disease at other colonic sites. Ileal pouch anal anastomosis is a viable option for patients with ulcerative colitis, but this should be restricted to early cancers that are unlikely to require preoperative or postoperative radiation treatment.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ansell</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grass</LastName>
                    <ForeName>Fabian</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merchea</LastName>
                    <ForeName>Amit</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, USA. Electronic address: Merchea.Amit@mayo.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Surg Clin North Am</MedlineTA>
            <NlmUniqueID>0074243</NlmUniqueID>
            <ISSNLinking>0039-6109</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003082" MajorTopicYN="N">Colectomy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011230" MajorTopicYN="N">Precancerous Conditions</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054047" MajorTopicYN="N">Surgical Stomas</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Crohn</Keyword>
            <Keyword MajorTopicYN="N">Dysplasia</Keyword>
            <Keyword MajorTopicYN="N">Ulcerative colitis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31676051</ArticleId>
            <ArticleId IdType="pii">S0039-6109(19)30107-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.suc.2019.08.006</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31675233</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-5118</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>67</Volume>
                    <Issue>46</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of agricultural and food chemistry</Title>
                <ISOAbbreviation>J. Agric. Food Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Wheat Bran for Colon Cancer Prevention: The Synergy between Phytochemical Alkylresorcinol C21 and Intestinal Microbial Metabolite Butyrate.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12761-12769</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jafc.9b05666</ELocationID>
            <Abstract>
                <AbstractText>There is convincing evidence that consuming whole grains (WGs) may decrease the risk of colorectal cancer (CRC). Wheat bran (WB) is a rich source of dietary fiber and phytochemicals with health-promoting properties. However, the active components especially the interaction between different components in WG wheat have not been fully explored. Here, we investigated whether one of the major WB phytochemicals, alkylresorcinol (AR) C21, and the major active intestinal microbial metabolite of fiber, butyrate, could synergistically suppress human colon cancer cells. Our results demonstrated for the first time that the combination of C21 and butyrate synergistically inhibited the growth of human colon cancer cells and induced apoptosis. Further mechanistic studies demonstrated that the cotreatment of C21 and butyrate induced significant up-regulations in cleaved Poly(ADP-ribose) polymerase (PARP), cleaved caspase 3, p53 upregulated modulator of apoptosis (PUMA), cytochrome C, lipid-conjugated membrane-bound form of microtubule-associated protein 1<i>A</i>/1B-light chain 3 (LC3-II), and C/EBP homologous protein (CHOP) expressions, indicating the synergistic anticancer effects of C21 and butyrate were associated with induction of apoptosis, autophagy, and ER stress pathways. Notably, the C21 concentrations in the large intestinal tract of mice treated with human relevant doses of C21, were from 0.86 to 1.78 μmol/g, suggesting the C21 doses used in vitro may be achievable after daily WG wheat intake. These results provide novel insights into the dietary prevention of CRC regarding the potential interaction of bioactive WG wheat phytochemicals and the microbial metabolites of fiber.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yantao</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory for Functional Foods and Human Health, Center for Excellence in Post-Harvest Technologies , North Carolina Agricultural and Technical State University, North Carolina Research Campus , 500 Laureate Way , Kannapolis , North Carolina 28081 , United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory for Functional Foods and Human Health, Center for Excellence in Post-Harvest Technologies , North Carolina Agricultural and Technical State University, North Carolina Research Campus , 500 Laureate Way , Kannapolis , North Carolina 28081 , United States.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery , General Hospital of Ningxia Medical University , Yinchuan 750004 , P. R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Changling</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory for Functional Foods and Human Health, Center for Excellence in Post-Harvest Technologies , North Carolina Agricultural and Technical State University, North Carolina Research Campus , 500 Laureate Way , Kannapolis , North Carolina 28081 , United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sang</LastName>
                    <ForeName>Shengmin</ForeName>
                    <Initials>S</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5005-3616</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratory for Functional Foods and Human Health, Center for Excellence in Post-Harvest Technologies , North Carolina Agricultural and Technical State University, North Carolina Research Campus , 500 Laureate Way , Kannapolis , North Carolina 28081 , United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Agric Food Chem</MedlineTA>
            <NlmUniqueID>0374755</NlmUniqueID>
            <ISSNLinking>0021-8561</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002087">Butyrates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004043">Dietary Fiber</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D064209">Phytochemicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012118">Resorcinols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.2.30</RegistryNumber>
                <NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YUL4LO94HK</RegistryNumber>
                <NameOfSubstance UI="C031389">resorcinol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002087" MajorTopicYN="N">Butyrates</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004043" MajorTopicYN="N">Dietary Fiber</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064209" MajorTopicYN="N">Phytochemicals</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011065" MajorTopicYN="N">Poly(ADP-ribose) Polymerases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012118" MajorTopicYN="N">Resorcinols</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">alkylresorcinols</Keyword>
            <Keyword MajorTopicYN="N">butyrate</Keyword>
            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">synergy</Keyword>
            <Keyword MajorTopicYN="N">wheat bran</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31675233</ArticleId>
            <ArticleId IdType="doi">10.1021/acs.jafc.9b05666</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31674041</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Smoking and gastrointestinal cancer patients-is smoking cessation an attainable goal?</ArticleTitle>
            <Pagination>
                <MedlinePgn>1335-1340</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25749</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Negative consequences of tobacco use during cancer treatment are well-documented but more in-depth, patient-level data are needed to understand patient beliefs about continued smoking (vs cessation) during gastrointestinal (GI) cancer treatment.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We conducted semi-structured interviews with 10 patients who were active smokers being treated for GI cancers and 5 caregivers of such patients. All interviews were audio-recorded, transcribed verbatim, and uploaded to NVivo. We consensus coded data inductively using conventional content analysis and iteratively developed our codebook. We developed data matrices to categorize the themes regarding patient perspectives on smoking as well as presumed barriers to smoking cessation during active therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our interviews revealed three consistent themes: (a) Smoking cessation is not necessarily desired by many patients who have received a cancer diagnosis; (b) Failure in past quit attempts may lead to feelings of hopeless about future attempts, especially during cancer treatment; (c) Patients perceived little to no access to smoking cessation treatment at the time of their cancer diagnosis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Well-designed systemic changes that promote the positive and efficacious effects of quitting smoking during cancer treatment, and that provide barrier-free access to such treatments may be helpful in promoting tobacco-free behavior during cancer treatment.</AbstractText>
                <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Barrett</LastName>
                    <ForeName>James R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cherney-Stafford</LastName>
                    <ForeName>Linda</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alagoz</LastName>
                    <ForeName>Esra</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piper</LastName>
                    <ForeName>Megan E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cook</LastName>
                    <ForeName>Jessica</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>William S. Middleton Memorial VA Hospital, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campbell-Flohr</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weber</LastName>
                    <ForeName>Sharon M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Winslow</LastName>
                    <ForeName>Emily R</ForeName>
                    <Initials>ER</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ronnkleiv-Kelly</LastName>
                    <ForeName>Sean M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abbott</LastName>
                    <ForeName>Daniel E</ForeName>
                    <Initials>DE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>T32 CA090217</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32CA090217</GrantID>
                    <Acronym>NH</Acronym>
                    <Agency>NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MSN205318</GrantID>
                    <Agency>University of Wisconsin Comprehensive Cancer Center Support Grant</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005770" MajorTopicYN="N">Gastrointestinal Neoplasms</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016540" MajorTopicYN="N">Smoking Cessation</DescriptorName>
                <QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">patient perceptions</Keyword>
            <Keyword MajorTopicYN="N">qualitative research</Keyword>
            <Keyword MajorTopicYN="N">tobacco cessation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2020</Year>
                <Month>12</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31674041</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25749</ArticleId>
            <ArticleId IdType="pmc">PMC6889952</ArticleId>
            <ArticleId IdType="mid">NIHMS1056431</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Intern Med. 1993 Sep 1;119(5):383-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8393311</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2014 Dec 10;32(35):3989-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25385740</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Qual Health Res. 2005 Nov;15(9):1277-88</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16204405</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2014 Nov;15(12):e568-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25439699</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Best Pract Res Clin Gastroenterol. 2017 Oct;31(5):569-577</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29195677</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Immunol. 1996 Apr 1;156(7):2384-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8786295</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2009 Nov 10;27(32):5312-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19738113</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2017 May 19;17(1):348</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28526000</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2287-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16214906</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Pharmacotherapy. 2012 Oct;32(10):920-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23033231</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Intern Med. 2004 Nov 8;164(20):2206-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15534156</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2006 Jan 1;106(1):17-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16311986</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Otolaryngol Head Neck Surg. 2013 Aug;149(2):200-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23715685</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cochrane Database Syst Rev. 2019 Jan 09;1:CD001118</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30623970</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2006 Jun 1;106(11):2428-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16634096</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Prev Med. 2004 Sep;39(3):449-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15313083</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2016 Apr 15;122(8):1247-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26881851</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 1997 Dec 3;89(23):1782-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9392619</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2003 Aug 1;98(3):632-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12879483</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2012 May;19(5):1430-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22065194</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31670920</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1421-9778</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>53</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>
                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>805-819</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.33594/000000174</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Despite effective therapeutic strategies for treating hormone receptor-positive (HR+) breast cancer, resistance to endocrine therapy that is either de novo or acquired still occurs. We investigated epidermal growth factor receptor (EGFR) as a therapeutic target for overcoming endocrine resistance in HR+ breast cancer models.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Using clinical data from 2,166 patients who had HR+ breast tumors and received tamoxifen, we analyzed survival rates. Levels of mRNA and protein expression were analyzed by real-time PCR and western blotting, respectively. Cell viability was analyzed by MTT assays and anchorage-independent growth by soft agar colony-formation assays. Efficacy of tamoxifen and/or gefitinib was analyzed using orthotopic xenograft mouse models.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">EGFR expression was significantly associated with more advanced stage and higher grade. EGFR expression was different in luminal A-like (Lum A, 1.3%) versus luminal B-like (Lum B, 11.4%) subtypes. On multivariate analyses for survival Lum B subtype EGFR+ tumors showed a hazard ratio (HR) of 5.22 (95% CI, 1.29-21.15, P = 0.020) for overall survival (OS) and HR of 2.91 (95% CI, 1.35-6.28, P = 0.006) for disease-free survival (DFS). Levels of EGFR inversely correlated with ER-α expression. Basal ER-α level was completely blocked by TGFA or EGF treatment. With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT). Conversely, downregulation of ER-α by TGFA was reversed by gefitinib with recovered sensitivity to 4-OHT. Tumorigenicity of EGFR and ER+ breast cancer cells were significantly decreased by combined tamoxifen and gefitinib.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Aberrant EGFR expression was associated with poor prognosis in ER+ breast cancers, especially the Lum B subtype. Loss of ER by EGFR activation induced tamoxifen resistance. Therefore, EGFR could be a therapeutic target for overcoming recurrence of ER+ breast cancer with high EGFR expression.</AbstractText>
                <CopyrightInformation>© Copyright by the Author(s). Published by Cell Physiol Biochem Press.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>Yisun</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Soo Youn</ForeName>
                    <Initials>SY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, Korea University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>You</LastName>
                    <ForeName>Daeun</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jung</LastName>
                    <ForeName>Seung Pil</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Breast and Endocrine Surgery, Department of Surgery, Korea University College of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Hee Jun</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Isaac</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Se Kyung</ForeName>
                    <Initials>SK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Jonghan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seok Won</ForeName>
                    <Initials>SW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Jeong Eon</ForeName>
                    <Initials>JE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sangmin</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea, sangmin3005.kim@samsung.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nam</LastName>
                    <ForeName>Seok Jin</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Cancer Center, Samsung Medical Center, Seoul, Korea, sjnam@skku.edu.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2016R1D1A1B01010508</GrantID>
                    <Agency>Basic Science Research Program, National Research Foundation of Korea (NRF) funded by the Ministry of Education</Agency>
                    <Country>Korea</Country>
                </Grant>
                <Grant>
                    <GrantID>2016R1A5A2945889</GrantID>
                    <Agency>National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP)</Agency>
                    <Country>Korea</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Cell Physiol Biochem</MedlineTA>
            <NlmUniqueID>9113221</NlmUniqueID>
            <ISSNLinking>1015-8987</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>094ZI81Y45</RegistryNumber>
                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>95K54647BZ</RegistryNumber>
                <NameOfSubstance UI="C475919">hydroxytamoxifen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Estrogen receptor; EGFR; Endocrine therapy; Tamoxifen resistance</Keyword>
        </KeywordList>
        <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31670920</ArticleId>
            <ArticleId IdType="doi">10.33594/000000174</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31670642</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1221-9118</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>114</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <MedlineDate>2019 Sept-Oct</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Chirurgia (Bucharest, Romania : 1990)</Title>
                <ISOAbbreviation>Chirurgia (Bucur)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Anaplastic Thyroid Cancer: A Rare Entity Presented Clinically Only with Fever and Elevated CRP.</ArticleTitle>
            <Pagination>
                <MedlinePgn>659-663</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.21614/chirurgia.114.5.659</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">14</ELocationID>
            <Abstract>
                <AbstractText>Anaplastic thyroid carcinoma (ATC) is a rare but almost invariably lethal disease. In this manuscript, we present a case where the dominant manifestation of ATC beside the goitre was elevated CRP values and a persistent low-grade fever. The patient underwent surgical removal of the tumour, chemotherapy and radiotherapy treatment. She is still alive and healthy 11 months after the surgery. We aim to demonstrate that ATC can be present with no specific symptoms or findings and to raise awareness towards an earlier diagnosis.</AbstractText>
                <CopyrightInformation>Celsius.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Garmpis</LastName>
                    <ForeName>Nikolaos</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Damaskos</LastName>
                    <ForeName>Christos</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garmpi</LastName>
                    <ForeName>Anna</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liakea</LastName>
                    <ForeName>Aliki</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mantas</LastName>
                    <ForeName>Dimitrios</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Romania</Country>
            <MedlineTA>Chirurgia (Bucur)</MedlineTA>
            <NlmUniqueID>9213031</NlmUniqueID>
            <ISSNLinking>1221-9118</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>9007-41-4</RegistryNumber>
                <NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065646" MajorTopicYN="N">Thyroid Carcinoma, Anaplastic</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CRP</Keyword>
            <Keyword MajorTopicYN="N">anaplastic</Keyword>
            <Keyword MajorTopicYN="N">cancer</Keyword>
            <Keyword MajorTopicYN="N">ferritin</Keyword>
            <Keyword MajorTopicYN="N">inflammatorymarkers</Keyword>
            <Keyword MajorTopicYN="N">thyroid</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31670642</ArticleId>
            <ArticleId IdType="pii">14</ArticleId>
            <ArticleId IdType="doi">10.21614/chirurgia.114.5.659</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31670285</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0304-4920</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>62</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <MedlineDate>2019 Sep-Oct</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>The Chinese journal of physiology</Title>
                <ISOAbbreviation>Chin J Physiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The association of matrix metalloproteinas-2 promoter polymorphisms with lung cancer susceptibility in Taiwan.</ArticleTitle>
            <Pagination>
                <MedlinePgn>210-216</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/CJP.CJP_43_19</ELocationID>
            <Abstract>
                <AbstractText>Matrix metalloproteinases-2 (MMP2) has been reported to be overexpressed in various types of cancer. However, the contribution of various genotypes of MMP2 to lung cancer is controversial and not yet been examined in Taiwan. Therefore, in the current study, we investigated the association of MMP2 genotypes with lung cancer risk among Taiwanese. In this hospital-based, case-control study, 358 lung cancer patients and 716 age- and gender-matched healthy controls were recruited, and the genotypic distributions of MMP2-1306 and MMP2- 735 were determined. Then, their association with lung cancer was evaluated, and their interaction with personal smoking status was also examined via stratification analysis. The results showed that the percentages of variant CT and TT at MMP2-1306 were 17.3% and 1.7% among the lung cancer patients, respectively, much lower than those of 28.7% and 2.4%, respectively, among the healthy controls (P for trend = 0.0001). The allelic frequency distribution analysis showed that the variant T allele at MMP2-1306 conferred a statistically significantly lower lung cancer risk than the wild-type C allele (adjusted odds ratio = 0.54, 95% confidence interval = 0.41-0.72, P = 0.0001). There was an obvious effect of MMP2-1306 genotype on lung cancer risk among the subpopulations of ever smokers but not nonsmokers. As for the genotypes of MMP2-735, there was no such differential distribution in the aspects of genotypic or allelic frequencies, or combinative effects with smoking status. The genotypes of MMP2-1306 may act as a biomarker in determining personal susceptibility to lung cancer in Taiwan. The contribution of MMP2 genotypes alone and its joint effects with personal cigarette smoking habit on lung cancer susceptibility should be taken into consideration of the clinical practices for early detection and prediction of lung cancer in Taiwan.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Guan-Liang</ForeName>
                    <Initials>GL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Biomedical Sciences, China Medical University; Taichung Armed Forces General Hospital, Taichung; National Defense Medical Center, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Shou-Cheng</ForeName>
                    <Initials>SC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Taichung Armed Forces General Hospital, Taichung; National Defense Medical Center, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Te-Chun</ForeName>
                    <Initials>TC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsai</LastName>
                    <ForeName>Chia-Wen</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Wen-Shin</ForeName>
                    <Initials>WS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hsin-Ting</ForeName>
                    <Initials>HT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Cheng-Nan</ForeName>
                    <Initials>CN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chao</LastName>
                    <ForeName>Che-Yi</ForeName>
                    <Initials>CY</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsia</LastName>
                    <ForeName>Te-Chun</ForeName>
                    <Initials>TC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bau</LastName>
                    <ForeName>Da-Tian</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Graduate Institute of Biomedical Sciences, China Medical University; Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital; Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Chin J Physiol</MedlineTA>
            <NlmUniqueID>7804502</NlmUniqueID>
            <ISSNLinking>0304-4920</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="C522361">MMP2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Genotype</Keyword>
            <Keyword MajorTopicYN="N">Taiwan</Keyword>
            <Keyword MajorTopicYN="N">lung cancer</Keyword>
            <Keyword MajorTopicYN="N">matrix metalloproteinase-2</Keyword>
            <Keyword MajorTopicYN="N">polymorphism</Keyword>
            <Keyword MajorTopicYN="N">smoking</Keyword>
        </KeywordList>
        <CoiStatement>None</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31670285</ArticleId>
            <ArticleId IdType="pii">ChinJPhysiol_2019_62_5_210_269834</ArticleId>
            <ArticleId IdType="doi">10.4103/CJP.CJP_43_19</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31664305</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1414-431X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>52</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas</Title>
                <ISOAbbreviation>Braz. J. Med. Biol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e8657</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0100-879X2019001100603</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1590/1414-431X20198657</ELocationID>
            <Abstract>
                <AbstractText>Although Taxol has improved the survival of cancer patients as a first-line chemotherapeutic agent, an increasing number of patients develop resistance to Taxol after prolonged treatment. The potential mechanisms of cancer cell resistance to Taxol are not completely clear. It has been reported that microRNAs (miRNAs) are involved in regulating the sensitivity of cancer cells to various chemotherapeutic agents. In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol. Cell apoptosis and autophagy, and the sensitivity of MCF-7 cells to Taxol were assessed with a series of in vitro assays. Our results showed that the inhibition of autophagy increased the Taxol-induced apoptosis and the sensitivity of MCF-7 cells to Taxol. Up-regulation of miR-129-5p also inhibited autophagy and induced apoptosis. Furthermore, miR-129-5p overexpression increased the sensitivity of MCF-7 cells to Taxol. High mobility group box 1 (HMGB1), a target gene of miR-129-5p and a regulator of autophagy, was negatively regulated by miR-129-5p. We found that interference of HMGB1 enhanced the chemosensitivity of Taxol by inhibiting autophagy and inducing apoptosis in MCF-7 cells. Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1. Using miR-129-5p/HMGB1/autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-8914-5510</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Weihua</ForeName>
                    <Initials>W</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0322-0223</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Lu</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1127-4480</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, Beijing Chaoyang Emergency Medical Center, Beijing, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yunfeng</ForeName>
                    <Initials>Y</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0001-6658-6276</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, Xiang Cheng City First Person Hospital, Zhoukou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ren</LastName>
                    <ForeName>Jingjing</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6774-9791</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Clinical Laboratory, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Braz J Med Biol Res</MedlineTA>
            <NlmUniqueID>8112917</NlmUniqueID>
            <ISSNLinking>0100-879X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C541915">Mirn129 microRNA, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31664305</ArticleId>
            <ArticleId IdType="pii">S0100-879X2019001100603</ArticleId>
            <ArticleId IdType="doi">10.1590/1414-431X20198657</ArticleId>
            <ArticleId IdType="pmc">PMC6826894</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Interferon Cytokine Res. 2014 Feb;34(2):71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24428799</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Res. 2009 Jan;19(1):92-105</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18955434</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Case Rep. 2014 Feb 24;15:85-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24587856</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Sep 25;12(9):e0184922</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28945807</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Med Sci Monit. 2015 Dec 31;21:4122-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26720492</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 May 22;12(5):e0177694</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28531218</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Annu Rev Med. 1997;48:353-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9046968</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2015 Oct 27;6(33):34423-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26460733</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Cycle. 2017 Mar 19;16(6):578-587</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28346809</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6103535</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Biol Ther. 2015;16(4):511-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25778491</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Onco Targets Ther. 2016 May 27;9:3067-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27313460</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Signal. 2015 Feb;27(2):189-203</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25435430</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 2004 Apr 9;279(15):14763-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14739282</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochem Cell Biol. 2018 Feb;96(1):19-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28482162</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Semin Cancer Biol. 2013 Aug;23(4):252-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23810837</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2015 Feb 20;6(5):2966-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25650662</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Onkologie. 2005 Feb;28(2):81-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15662111</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Autophagy. 2012 Feb 1;8(2):165-76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22248718</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Life Sci. 2016 Feb 15;147:143-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26829385</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Med Rep. 2016 Jan;13(1):188-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26573160</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS Biol. 2014 Oct 14;12(10):e1001967</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25313680</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Apr 26;7(17):24510-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27014910</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2009 May 20;27(15):2474-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19332727</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Exp Clin Cancer Res. 2018 Aug 29;37(1):205</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30157958</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2017 Aug 19;490(2):309-316</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28619508</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Compr Canc Netw. 2016 Mar;14(3):324-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26957618</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Autophagy. 2014 Mar;10(3):442-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24418846</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4257-4265</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27831649</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Chin J Cancer Res. 2015 Jun;27(3):267-78</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26157323</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 1979 Feb 22;277(5698):665-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">423966</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Transl Res. 2016 Apr 15;8(4):1886-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27186312</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Jul;44(4):400-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26555418</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Carcinog. 2017 Dec;56(12):2566-2577</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28667779</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Breast J. 2010 May-Jun;16(3):309-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20408821</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2014 Jan 22;14:37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24447372</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Biochem. 2018 Dec 2;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30506984</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer. 2016 Nov 10;15(1):70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27832783</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Biol Chem. 2004 May 14;279(20):20935-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15014079</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biomed Pharmacother. 2017 Mar;87:405-411</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28068630</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31663350</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0006-9248</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>120</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Bratislavske lekarske listy</Title>
                <ISOAbbreviation>Bratisl Lek Listy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Atorvastatin enhances anti-apoptotic effects of tamoxifen on melanoma cancer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>752-756</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4149/BLL_2019_125</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Tamoxifen engages mitochondrial estrogen receptor beta as an antagonist, increases mitochondrial cytotoxicity and induces tumor cell death. Tamoxifen also engages plasma membrane estrogen receptor alpha as an agonist, while it is suggested that in some users its activation is put into action by mechanism of resistance to tamoxifen. Apoptotic inducers have been shown to promote tamoxifen-induced cell death, which might be of great importance in overcoming tamoxifen resistance. Considering the pleiotropic effects of statins, in the present study, we investigated the effects of atorvastatin on tamoxifen-induced intrinsic apoptotic pathway activity in melanoma cells.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Melanoma B16F10 cells were treated for 24 and 48 h with various concentrations of tamoxifen, atorvastatin and combination of tamoxifen + atorvastatin. Cells with no treatment were considered a control group, and the study was then followed by quantitative RT- PCR assay. Bax and cytochrome c gene expressions were calculated by ΔΔct method.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Co-treatment of atorvastatin + tamoxifen could strongly enhance the expression of pro/apoptotic factors of Bax and cytochrome c in melanoma cells compared to the tamoxifen and atorvastatin groups.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In general, we conclude that the atorvastatin-induced increase in Bax and cytochrome c gene expression might be a permissive response to tamoxifen-induced cell death (Fig. 2, Ref. 37).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ghasemi</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malek</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Javanmard</LastName>
                    <ForeName>Sh Haghjooy</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghasemi</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Esfahani</LastName>
                    <ForeName>H Naji</ForeName>
                    <Initials>HN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vaseghi</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Slovakia</Country>
            <MedlineTA>Bratisl Lek Listy</MedlineTA>
            <NlmUniqueID>0065324</NlmUniqueID>
            <ISSNLinking>0006-9248</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494827">Bax protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>094ZI81Y45</RegistryNumber>
                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-43-6</RegistryNumber>
                <NameOfSubstance UI="D045304">Cytochromes c</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A0JWA85V8F</RegistryNumber>
                <NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069059" MajorTopicYN="N">Atorvastatin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045304" MajorTopicYN="N">Cytochromes c</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008546" MajorTopicYN="Y">Melanoma, Experimental</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Bax cytochrome c.</Keyword>
            <Keyword MajorTopicYN="N">atorvastatin</Keyword>
            <Keyword MajorTopicYN="N">melanoma</Keyword>
            <Keyword MajorTopicYN="N">tamoxifen</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31663350</ArticleId>
            <ArticleId IdType="doi">10.4149/BLL_2019_125</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31663299</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0393-974X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>33</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <MedlineDate>2019 Sep-Oct</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of biological regulators and homeostatic agents</Title>
                <ISOAbbreviation>J. Biol. Regul. Homeost. Agents</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1377-1385</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.23812/19-146-A</ELocationID>
            <Abstract>
                <AbstractText>MicroRNAs (miRNAs) function by negatively regulating their target genes. Aberrant expression of baculoviral IAP repeat containing 5 (BIRC5) is associated with the tumor growth and metastasis, however, the clinical significance of miRNAs/BIRC5 axis in gastric cancer (GC) remains unknown. The association of BIRC5 or miR-195-5p/-218-5p expression levels with the clinicopathological characteristics and prognosis in patients with GC was analysed by using a tissue microarray and TCGA dataset. Pearson correlation analysis was used for analysing the correlation of BIRC5 with miR-195-5p/-218-5p expression in GC tissues. Cox proportional hazard regression model was conducted to assess whether BIRC5 or miR-195-5p/-218-5p was an independent prognostic factor in patients with GC. We found that BIRC5 expression levels were increased in GC tissues as compared with the adjacent normal tissues, and acted as an independent prognostic factor of tumor recurrence in patients with GC. Increased expression of BIRC5 was traceable to the dysregulation of miR-195-5p/-218-5p rather than its genetic and epigenetic alterations in GC tissues. MiR-195-5p/-218-5p displayed a negative correlation with BIRC5 expression, and acted as independent prognostic factors of poor prognosis in patients with GC. In conclusion, dysregulation of miR-195-5p/-218-5p/BIRC5 axis predicts a poor prognosis in patients with gastric cancer.</AbstractText>
                <CopyrightInformation>Copyright 2019 Biolife Sas. www.biolifesas.org.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Zou</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y" EqualContrib="Y">
                    <LastName>Liao</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Baoan Central Hospital of Shenzhen, the Fifth Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>J Biol Regul Homeost Agents</MedlineTA>
            <NlmUniqueID>8809253</NlmUniqueID>
            <ISSNLinking>0393-974X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C107489">BIRC5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C552722">MIRN195 microRNA, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C547471">MIRN218 microRNA, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000077022">Survivin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013274" MajorTopicYN="N">Stomach Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077022" MajorTopicYN="N">Survivin</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BIRC5</Keyword>
            <Keyword MajorTopicYN="N">gastric cancer</Keyword>
            <Keyword MajorTopicYN="N">miR-195-5p</Keyword>
            <Keyword MajorTopicYN="N">miR-218-5p</Keyword>
            <Keyword MajorTopicYN="N">recurrence</Keyword>
            <Keyword MajorTopicYN="N">survival</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31663299</ArticleId>
            <ArticleId IdType="doi">10.23812/19-146-A</ArticleId>
            <ArticleId IdType="pii">36</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM">
        <PMID Version="1">31655836</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1698-6946</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>24</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Medicina oral, patologia oral y cirugia bucal</Title>
                <ISOAbbreviation>Med Oral Patol Oral Cir Bucal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Socio-demographic characteristics are related to the advanced clinical stage of oral cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e759-e763</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4317/medoral.23105</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Social determinants may be associated with the onset and progression of the clinical stage of oral cancer.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To evaluate the impact of socio-demographic characteristics on the prevalence of advanced clinical stage of oral cancer.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Information about 51,116 cases of oral cancer, from all Brazilian states, between 2000 and 2012, was obtained from the Cancer Registry Information System. The clinical stage of oral cancer (dependent variable) was classified as initial (stages I and II) or advanced (stages III and IV). The relationship between the clinical stage of oral cancer and the following independent variables was analyzed: sex, age, schooling, marital status, family history of cancer, and origin of referral. Analyses on frequency distribution and multivariate binary logistic regression model were performed (α&lt;0.05).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to individuals with no schooling, those who attended elementary to high school (OR=2.461) and college education (OR = 3.050) had a higher prevalence of advanced cases of oral cancer. Individuals without a partner (OR = 14,209) demonstrated a higher prevalence compared to married individuals. Subjects aged 20-44 years (OR = 4.081) and 45-64 years (OR = 14.875) had a higher prevalence compared to those aged 15-19 years. The variables gender, family history of cancer and origin of referral integrated the binary model of logistic regression, but did not present statistical significance.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Socioeconomic factors may be related to the advanced clinical stage of oral cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lins</LastName>
                    <ForeName>L-S</ForeName>
                    <Initials>LS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical and Social Dentistry Center for Health Sciences Federal University of Paraiba - Campus I University City Joao Pessoa PB Brazil. CEP 58051-900 yuri@ccs.ufpb.br.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bezerra</LastName>
                    <ForeName>N-V</ForeName>
                    <Initials>NV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Freire</LastName>
                    <ForeName>A-R</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Almeida</LastName>
                    <ForeName>L-D</ForeName>
                    <Initials>LD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lucena</LastName>
                    <ForeName>E-H</ForeName>
                    <Initials>EH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cavalcanti</LastName>
                    <ForeName>Y-W</ForeName>
                    <Initials>YW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Spain</Country>
            <MedlineTA>Med Oral Patol Oral Cir Bucal</MedlineTA>
            <NlmUniqueID>101231694</NlmUniqueID>
            <ISSNLinking>1698-4447</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>D</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009062" MajorTopicYN="Y">Mouth Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31655836</ArticleId>
            <ArticleId IdType="pii">23105</ArticleId>
            <ArticleId IdType="doi">10.4317/medoral.23105</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31654121</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1335</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>145</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and clinical oncology</Title>
                <ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2951-2967</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-019-03051-6</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide and new improvements are urgently needed. Several miRNA-targeted therapeutics have reached clinical development. MicroRNA-143 (miR-143) was found to significantly suppress the migration and invasion of NSCLC. It might be of great potential for NSCLC treatment. However, the therapeutic effect of miR-143 against NSCLC in vivo has not been explored until now.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The cationic liposome/pVAX-miR-143 complex (CL-pVAX-miR-143) was prepared and its biodistribution was assessed. The tumor suppression effects of CL-pVAX-miR-143 were evaluated in early-stage and advanced experimental lung cancer metastasis mice models by systemic delivery, respectively, and also in subcutaneous tumor models by intratumoral injection. The toxicity of CL-pVAX-miR-143 was assessed by H&amp;E analysis and biochemical measurements. The preliminary mechanism of CL-pVAX-miR-143 on tumor suppression was explored by immunochemistry and western blotting.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The assays on the stability and safety of CL-pVAX-miR-143 showed that it mainly accumulated in the lung after systemic administration. The intratumoral delivery of CL-pVAX-miR-143 effectively inhibited A549 subcutaneous tumor growth. Notably, systemic delivery of CL-pVAX-miR-143 significantly inhibited tumor metastasis and prolonged survival dose dependently in early-stage experimental lung cancer metastasis models. More importantly, same results were shown in advanced mice models with metastasis. CL-pVAX-miR-143 treatment did not induce obvious acute toxicity. The preliminary mechanism on inhibiting tumor metastasis might be induced by targeting CD44v3.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggested that CL-pVAX-miR-143 might be a promising strategy for clinical treatment of non-small cell lung cancer, especially for advanced NSCLC with metastasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Qianqian</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuan</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Xinmei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Su</LastName>
                    <ForeName>Xiaolan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Xueting</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Wen</ForeName>
                    <Initials>W</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9827-7766</Identifier>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University/Collaborative Innovation Center of Biotherapy, No. 1, Keyuan 4th Road, Gaopeng Street, High Technological Development Zone, Chengdu, 610041, Sichuan, China. zhuwen@scu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
            <NlmUniqueID>7902060</NlmUniqueID>
            <ISSNLinking>0171-5216</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002412">Cations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C542359">MIRN143 microRNA, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C532884">Mirn143 microRNA, mouse</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002412" MajorTopicYN="N">Cations</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Advanced cancer</Keyword>
            <Keyword MajorTopicYN="N">Cationic liposome</Keyword>
            <Keyword MajorTopicYN="N">Early-stage cancer</Keyword>
            <Keyword MajorTopicYN="N">NSCLC</Keyword>
            <Keyword MajorTopicYN="N">Tumor metastasis and growth</Keyword>
            <Keyword MajorTopicYN="N">miR-143</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31654121</ArticleId>
            <ArticleId IdType="doi">10.1007/s00432-019-03051-6</ArticleId>
            <ArticleId IdType="pii">10.1007/s00432-019-03051-6</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Radiat Res. 2011 Oct;176(4):486-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21663394</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 1991 Jan 3;324(1):1-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1701519</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Drug Discov Today. 2017 Feb;22(2):424-432</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27815139</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2011 Dec 23;12(1):39-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22193407</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Respir J. 2017 Mar 2;49(3):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28254765</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Gene Ther. 2004 Nov;11(11):733-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15486560</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Nanobiotechnology. 2016 Jun 21;14(1):47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27328938</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2013 Jun 15;132(12):2884-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23225545</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Gene Ther. 2010 Jun;17(6):398-408</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20094072</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lung Cancer. 2015 Jun;88(3):304-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25870155</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Control Release. 2017 Nov 28;266:287-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28987878</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Exp Cell Res. 2018 Oct 1;371(1):50-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30055135</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2017 Mar;16(3):203-222</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28209991</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Lung Cancer. 2018 Mar;19(2):e163-e169</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29233611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Death Differ. 2017 Sep;24(9):1502-1517</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28644440</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Death Dis. 2018 Feb 7;9(2):182</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29416013</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Semin Cancer Biol. 2019 Feb;54:63-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29199014</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Biol Sci. 2018 Mar 10;14(4):390-397</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29725260</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Pharm Biopharm. 2001 Sep;52(2):165-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11522482</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2016 Sep 3;388(10048):1012-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27598681</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Lett. 2017 Dec 1;410:212-227</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28965855</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2019 Jan;69(1):7-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30620402</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nanomedicine (Lond). 2012 Apr;7(4):475-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22296186</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Transl Med. 2013 Apr 03;11:86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23552524</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biotechnol Adv. 2017 May - Jun;35(3):350-360</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28286148</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Control Release. 2017 Jul 10;257:10-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28093296</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Death Dis. 2018 Jan 11;9(1):14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29323124</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Liposome Res. 2015;25(4):279-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25543847</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Genet. 2014 Aug;15(8):541-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25022906</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Discov. 2016 Feb;6(2):188-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26586766</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Physiol. 2018 Aug;233(8):5574-5588</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29521426</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Lett. 2011 Aug 28;307(2):211-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21550168</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Oncol. 2014 Nov 25;4:329</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25505733</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Ther. 2014 Oct;13(10):2352-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25053820</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Surg Oncol. 2017 Sep 19;15(1):175</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28927412</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS Genet. 2015 Feb 18;11(2):e1004873</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25693145</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Biomed Nanotechnol. 2016 Jul;12(7):1510-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29337490</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell Death Dis. 2017 Oct 12;8(10):e3101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29022908</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer. 2016 Jun 29;15(1):51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27358073</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cancer. 2017 Oct 17;8(18):3856-3861</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29151973</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Ther. 2001 Mar;3(3):337-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11273776</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1709-1716</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29630116</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Aging (Albany NY). 2016 May;8(5):1153-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27208668</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2017 Jan 21;389(10066):299-311</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27574741</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Ther Nucleic Acids. 2016 Aug 30;5(8):e357</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27574783</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Apoptosis. 2018 Aug;23(7-8):388-395</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29858716</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2013 Mar 27;13:158</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23530866</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2006 Aug;12(8):895-904</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16892035</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2003 Feb 15;63(4):887-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12591743</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Ther. 2011 Aug;10(8):1470-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21622730</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Biol Sci. 2013 Jul 18;9(7):680-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23904792</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2018 Jul 12;8(1):10495</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30002440</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Gene Ther. 2012 Jul;19(7):489-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22576699</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Acta Biomater. 2016 Mar;33:213-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26802444</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2016 Nov;27(11):2004-2016</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27502726</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2018 Jun 4;8(1):8549</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29867125</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2017 Oct;18(10):1386-1396</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28870611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651908</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The duration of endocrine therapy and breast cancer patients' survival: A nationwide population-based cohort study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17746</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017746</ELocationID>
            <Abstract>
                <AbstractText>As research progressed, the recommended duration of endocrine therapy for breast cancer patients has been extended from 5 to 10 years. This study aimed to investigate how the duration of endocrine medication and therapy affect survival rate in the real world. By using the National Health Insurance Research Database (NHIRD), this study examined 1002 breast cancer patients newly diagnosed between 2000 and 2005 as research subjects, and conducted follow-up until 2013. Among these subjects, 51 used aromatase inhibitors (AIs), 561 used tamoxifen, and 390 alternated between the use of tamoxifen and AIs. The mean follow-up period in this study was 9.63 years, and the mean duration of taking endocrine medication was 4.04 years. The tamoxifen group had the longest follow-up period (9.87 years), shortest endocrine therapy duration (3.29 years), and best survival rate (86.1%). Patients were divided into 3 groups based on the duration of endocrine therapy: under 2 years, 2 to 5 years, and over 5 years. It was found that patients who received medication for less than 2 years showed the lowest survival rate with statistically significant differences (P &lt; .001). Therefore, the extension of endocrine therapy duration is critical in improving breast cancer patients' survival rate.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Chuan-Hsun</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chun-Wen</ForeName>
                    <Initials>CW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Information Technology.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Chien-Ming</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Cheng Hsin General Hospital.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ou</LastName>
                    <ForeName>Tzu-Chi</ForeName>
                    <Initials>TC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Joint Commission of Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Chu-Chieh</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Care Management, National Taipei University of Nursing and Health Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>You-Min</ForeName>
                    <Initials>YM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Cheng Hsin General Hospital, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651908</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017746</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00076</ArticleId>
            <ArticleId IdType="pmc">PMC6824710</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2014 Jul 20;32(21):2255-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24868023</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2015 Sep;26 Suppl 5:v8-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26314782</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2008 Apr 20;26(12):1965-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18332472</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2008 Dec 2;99(11):1763-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18985046</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8901852</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trans Med Chir Soc Edinb. 1896;15:153-179</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29584099</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2001 Mar 21;93(6):456-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11259471</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2003 Nov 6;349(19):1793-802</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14551341</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):301-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25504903</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2001 May 2;93(9):684-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11333290</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2013 Mar 9;381(9869):805-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23219286</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2014 Feb 21;9(2):e87027</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24586261</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18073378</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2012 Mar 20;30(9):936-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22331951</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 1996 Oct;14(10):2738-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8874335</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651902</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17705</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017705</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this meta-analysis is to investigate the impact of Osimertinib on treatment efficacy in advanced nonsmall cell lung cancer (NSCLC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Trials comparing Osimertinib against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)/chemotherapy in patients with NSCLC with an epidermal growth factor receptor (EGFR) mutation were included, and the pooled data for progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Analysis results based on 6 eligible trials showed that Osimertinib significantly improved the overall PFS (hazard ratio [HR] = 0.38, 95% confidence interval [CI] = 0.29-0.50), improved the OS (HR = 0.66, 95% CI = 0.48-0.89), increased the ORR (odds ratio [OR] = 1.76, 95% CI = 1.14-2.72), increased the overall DCR (OR = 1.18, 95% CI = 1.02-1.37), and reduced the grade 3 or greater AEs (relative ratio [RR] = 0.50, 95% CI = 0.33-0.75) in all subgroups except in the ORR in the Exon 19 deletion (Ex19del) and/or L858R subgroup. Compared to patients with Ex19del and/or L858R mutation, patients with the T790M mutation had the benefits of a greater PFS (41.7%), a greater ORR (80.0%), a greater DCR (71.2%), and fewer grade 3 or greater AEs (70.7%) (each P &lt; .05). Race, sex, age, EGFR mutation, and smoking history may significantly predict additional benefits from Osimertinib, but there were no significant differences between subgroups stratified by these clinical characteristics.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Osimertinib showed greater treatment benefit for patients with NSCLC with EGFR mutation than EGFR-TKIs/chemotherapy, especially for T790M mutation-positive patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Xiao-Ping</ForeName>
                    <Initials>XP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jin-Feng</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Chun-Rong</ForeName>
                    <Initials>CR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Jun-Rong</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Laboratory, The Affiliated Tumor Hospital of Guangxi Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000178">Acrylamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000596361">osimertinib</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000178" MajorTopicYN="N">Acrylamides</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651902</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017705</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00070</ArticleId>
            <ArticleId IdType="pmc">PMC6824777</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res Treat. 2019 Apr;51(2):777-787</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30189719</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Chem Biol Drug Des. 2019 Jul;94(1):1306-1315</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30811850</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Thorac Dis. 2018 May;10(Suppl 13):S1556-S1563</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29951306</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2015 Jun 10;33(17):1958-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25897154</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Discov. 2014 Sep;4(9):1046-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24893891</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2019 Mar 15;125(6):892-901</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30512189</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>SAR QSAR Environ Res. 2011 Jun;22(3):239-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21400356</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biometrics. 1994 Dec;50(4):1088-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7786990</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30508196</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lung Cancer. 2018 Jul;121:5-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29858027</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2018 Aug 28;:JCO2018783118</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30153097</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2017 May 16;8(20):33922-33932</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28430611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2018 Jun;109(6):1930-1938</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29697876</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2018 Jan 11;378(2):113-125</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29151359</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2018 Mar 20;36(9):841-849</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28841389</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2018 Jan 24;553(7689):446-454</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29364287</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Oncol. 2010 Feb;11(2):121-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20022809</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9310563</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Oncol. 2016 Jun 1;2(6):805-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27100819</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30285222</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ther Adv Med Oncol. 2016 May;8(3):176-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27239236</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2017 Feb 16;376(7):629-640</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27959700</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30457891</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Drugs Today (Barc). 2018 Jun;54(6):369-379</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29998228</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2017 Jun 1;109(6):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28376144</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2018 Nov;68(6):394-424</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30207593</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2015 Sep;26(9):1883-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26105600</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Thorac Oncol. 2018 May;13(5):e77-e79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29703542</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651890</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Timescale of tumor volume of a young breast cancer patient with luminal B subtype: A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17659</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017659</ELocationID>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">It is largely unknown about the tumor growth of breast cancer naturally. We devised and analyzed an appropriate mathematical tool of the equations that describe how fast tumors grow without treatment on the basis of the ellipsoid shape of solid breast cancer.</AbstractText>
                <AbstractText Label="PATIENT CONCERNS" NlmCategory="UNASSIGNED">A 31-year-old woman presented with a painless palpable lump in her left breast for 5 months.</AbstractText>
                <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Infiltrated ductal breast cancer (histologic grade II) of luminal B INTERVENTIONS:: The patient did not receive any therapy due to her private reasons for 2 years, the analysis of the tumor volume growth was done regarding the growth rate of the tumor in the absence of intervention.</AbstractText>
                <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">After 2 years of diagnosis of breast cancer, the tumor mass occupied the whole left breast with skin implanted and nipple abnormality. As this case indicated that the tumor's early growth rate was very slow. When the tumor volume reached 300 cm, its fast growth began without treatment. Later growth approached the maximum, when the tumor volume was more than 800 cm.</AbstractText>
                <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">The tumor growth is segmental without therapy. Early diagnosis and treatment is the key to good prognosis for every breast cancer patient.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mao</LastName>
                    <ForeName>Xiaoyun</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Ming</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Mathematics, University of Rostock, Ulmenstrasse 69, Haus 3, Rostock, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Chuifeng</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, Liaoning, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018270" MajorTopicYN="N">Carcinoma, Ductal, Breast</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651890</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017659</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00058</ArticleId>
            <ArticleId IdType="pmc">PMC6824670</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 2015 Feb;1850(2):299-306</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25450183</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Dec 6;12(12):e0189127</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29211792</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 1964 Sep;13:490-502</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14219541</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lab Anim (NY). 2013 Jun;42(6):217-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23689461</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015 Dec 15;10(12):e0143811</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26669540</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Jpn J Cancer Res. 1990 May;81(5):454-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2116393</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Transplant. 2014 Jun;28(6):728-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24708263</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS Comput Biol. 2014 Aug 28;10(8):e1003800</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25167199</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 1983 Aug;71(2):407-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6576199</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015 Nov 05;10(11):e0142190</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26540189</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Jun 5;12(6):e0178691</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28582419</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2011 Aug;22(8):1736-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21709140</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1996;41(1):15-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8932872</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2014 Nov 15;74(22):6397-407</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25217520</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>IEEE Trans Med Imaging. 2006 Oct;25(10):1329-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17024836</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 1999 Oct 1;59(19):4770-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10519381</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Springerplus. 2016 Oct 7;5(1):1745</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27795888</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2879</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24814490</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Math Biosci. 2016 Dec;282:121-134</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27777048</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Math Med Biol. 2015 Jun;32(2):187-207</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24468637</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Breast J. 2001 May-Jun;7(3):184-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11469933</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2004 Jan 1;100(1):20-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14692020</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651881</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17636</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017636</ELocationID>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Colorectal cancer is the most common type of cancer leading to death; approximately 10% to 25% of rectal cancer patients present with synchronous colorectal liver metastases. However, the management of synchronous colorectal liver metastases is difficult, especially for patients unable to tolerate chemotherapy or surgery. To date, the optimum treatment of colorectal liver metastasis patients remains controversial, and the curative effect is unsatisfactory. Therefore, we established a novel therapeutic approach to treat colorectal liver metastases employing radiotherapy plus immunotherapy.</AbstractText>
                <AbstractText Label="PATIENT CONCERNS" NlmCategory="UNASSIGNED">A 56-year-old man presented with mucous bloody defecation occurring &gt;20 times a day and accompanied by fatigue and poor appetite. After 4 months, he was admitted to the hospital due to increased fecal blood volume.</AbstractText>
                <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">Highly differentiated adenocarcinoma was diagnosed based on rectal biopsy, and abdominal computed tomography (CT) showed multiple metastatic tumors in the liver.</AbstractText>
                <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The patient underwent 1 cycle of chemotherapy, which was terminated owing to severe gastrointestinal reactions. Several days later, he was administered cytokine-induced killer (CIK) cell therapy plus adjuvant radiotherapy.</AbstractText>
                <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Dynamic changes in the patient's tumor markers returned to normal levels, and abdominal CT and abdominal magnetic resonance imaging (MRI) revealed no metastatic liver tumors.</AbstractText>
                <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">Sequent therapy provided a curative effect for liver metastasis in a rectal cancer patient. Radiation may have activated the body to produce distant effects, eliminating the live metastasis. CIK cell-immunotherapy and radiotherapy may have synergistic therapeutic effects and could be combined for successful treatment of liver metastasis from rectal cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dang</LastName>
                    <ForeName>Yazheng</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Hongxiang</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiotherapy Oncology, Chang An Hospital, Xi'an, Shaan Xi.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Shigao</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Centre.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao SAR, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055612" MajorTopicYN="Y">Cytokine-Induced Killer Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651881</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017636</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00049</ArticleId>
            <ArticleId IdType="pmc">PMC6824631</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Lett. 2015 Aug 28;365(1):23-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25980820</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Treat Rev. 2015 Jun;41(6):503-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25872878</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Mol Sci. 2018 Jan 25;19(2):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29370095</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S76-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18006267</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2006 Sep 15;119(6):1377-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16642465</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Leuk Lymphoma. 2003 Sep;44(9):1457-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14565644</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncol Rep. 2011 Jan;25(1):33-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21109954</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Surg Oncol. 2006 Jun;32(5):473-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16580172</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bull Cancer. 2013 Apr 1;100(4):363-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23559319</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2014 Dec;93(28):e340</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25526496</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Opin Biol Ther. 2012 Jun;12(6):673-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22500889</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dis Colon Rectum. 2009 Jan;52(1):23-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19273952</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Lett. 2015 Jan 1;356(1):82-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24125863</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Immunother. 2001 Nov-Dec;24(6):502-10</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11759073</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2016 Mar 1;76(5):1009-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26833128</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ger Med Sci. 2007 Sep 10;5:Doc07</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19675715</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Immunol. 2007 May;27(3):317-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17468835</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Opin Biol Ther. 2012 May;12(5):565-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22444075</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2002 Jun;8(3):464-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12046071</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Zhonghua Xue Ye Xue Za Zhi. 2004 May;25(5):277-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15182535</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651875</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17617</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017617</ELocationID>
            <Abstract>
                <AbstractText>Esophageal cancer (EC) is one of the most common cancers in the world, with continuously growing diagnoses and morbidity. Because it is still unclear how to choose the best treatment for EC patients, a multimodal treatment is necessary to improve the prospect of the malignancy, including a sequence of surgery, chemotherapy, and radiotherapy, whether alone or combination. Therefore, this paper aims to analyze the effect of the sequence of chemotherapy, radiotherapy, and surgery on the prognosis and survival rate of patients with EC.The Surveillance, Epidemiology, and End Results (SEER) database was used to extract a dataset of patients who were diagnosed with EC from 1973 to 2015, with follow-up data for 6 years after diagnosis. The data were analyzed using correlation analysis, logistic regression Cox regression, and Kaplan-Meier analysis.EC patients who had radiation prior to surgery and chemotherapy had a better prognosis than the cases without chemotherapy. Based on univariate logistic regression, the odds radios of vital status recoded for &quot;radiation prior to surgery combined with chemotherapy&quot; is the lowest one among the 8 groups classified by radiation sequence with surgery and chemotherapy (P &lt; .001). Further, radiation prior to surgery and chemotherapy is an independent prognostic factor for better survival among EC patients.In conclusion, in the treatment of EC, administering radiation prior to surgery and chemotherapy is better than no radiotherapy, perioperative radiotherapy, postoperative radiotherapy, and other combinations without chemotherapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Nan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Shao-Wei</ForeName>
                    <Initials>SW</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004938" MajorTopicYN="N">Esophageal Neoplasms</DescriptorName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016629" MajorTopicYN="Y">Esophagectomy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651875</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017617</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00043</ArticleId>
            <ArticleId IdType="pmc">PMC6824783</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1117-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10613347</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1455880</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Surg Oncol Clin N Am. 2017 Jul;26(3):405-429</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28576180</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2015 Jun;94(25):e1002</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26107665</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Thorac Surg. 2010 Sep;90(3):892-8; discussion 898-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20732514</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncologist. 2013;18(3):281-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23429739</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2019 Jan;565(7739):301-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30643303</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2012 Dec 14;18(46):6737-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23239911</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2009 Oct 20;27(30):5062-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19770374</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dtsch Arztebl Int. 2018 Aug 6;115(31-32):513-519</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30149830</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2015 Jul 14;21(26):7933-43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26185366</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Cancer. 2011 Feb;47(3):354-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21084184</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Surg Oncol. 2012 Aug 25;10:173</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22920951</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Med. 2019 Jan;8(1):21-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30561117</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Compr Canc Netw. 2014 Dec;12(12):1697-705</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25505210</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2015 Dec 23;10(12):e0145097</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26699332</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Thorac Cancer. 2016 Mar;7(2):173-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27042219</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2018 Jan;154(2):360-373</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28823862</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2014 Oct 20;32(30):3400-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25225435</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2015 Dec;149(7):1700-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26376349</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2018 Jul 15;143(2):430-437</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29441562</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1340-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26065869</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2012 Jun 1;118(11):2820-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21990000</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 1981 Jul 1;48(1):63-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7237393</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Anticancer Res. 2018 Sep;38(9):5267-5273</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30194177</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Thorac Surg. 2008 Apr;85(4):1217-23; discussion 1223-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18355499</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Surg. 1987 Aug;11(4):426-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3630187</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2002 Feb 12;86(4):552-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11870536</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur Urol. 2012 Jun;61(6):1079-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22424666</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Thorac Oncol. 2016 Dec;11(12):2227-2237</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27544058</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2010 Mar;17(3):804-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19885698</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2018 Jan 20;36(3):268-275</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29161204</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Gastroenterol. 2017 Mar;51(3):223-227</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27306943</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Colorectal Dis. 2009 Jan;24(1):69-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18704459</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2018 Jan;154(2):390-405</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28780073</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2018 Jan;154(2):437-451</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29037469</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dis Esophagus. 2017 Jul 1;30(7):1-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28475725</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg. 2010 Jun;251(6):1056-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20485139</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2015 Mar;65(2):87-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25651787</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Surg Oncol. 2017 Apr;115(5):564-579</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28320055</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dis Esophagus. 2010 Feb;23(2):112-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19549208</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Med. 2016 Nov;5(11):3085-3093</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27726290</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2018 Aug;25(8):2441-2448</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29948420</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dis Esophagus. 2014 Apr;27(3):235-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23796070</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2009 Feb 20;27(6):851-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19139439</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Oct 10;12(10):e0185424</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29016614</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2017 Jun 7;23(21):3928-3933</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28638233</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2012 May 31;366(22):2074-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22646630</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651861</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17577</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017577</ELocationID>
            <Abstract>
                <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">Ovarian cancer often metastasizes, but it is unusual to transfer to the breast as an isolated mass. In particular, it is rare for patients to have breast metastases after 18 years of diagnosis of ovarian cancer. Therefore, accurate identification of ovarian cancer mammary gland metastasis can contribute to the treatment of the disease.</AbstractText>
                <AbstractText Label="PATIENT CONCERNS" NlmCategory="UNASSIGNED">This case report shows that an 82-year-old woman was diagnosed with breast metastases from ovarian cancer diagnosed 18 years ago. The patient underwent total uterine attachment, omentum, pelvic lymphadenectomy, pelvic floor tumor reduction, and chemotherapy 18 years ago.</AbstractText>
                <AbstractText Label="DIAGNOSIS" NlmCategory="METHODS">The pathological examination revealed metastatic adenocarcinoma. Immunohistochemical (IHC) staining results were negative for estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor-2 (Her-2), and thyroid transcription factor-1 (TTF-1); and positive for cytokeratin (CK) 5/6, CK7, and CA125.</AbstractText>
                <AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The patient underwent breast-conserving surgery and sentinel lymph node biopsy because of breast mass in November, 2018.</AbstractText>
                <AbstractText Label="OUTCOMES" NlmCategory="RESULTS">Currently, she has been followed for more than 1 month without any signs of recurrence.</AbstractText>
                <AbstractText Label="LESSONS" NlmCategory="CONCLUSIONS">Breast metastatic tumors should be distinguished from primary breast tumors to avoid any unnecessary surgery. The correct diagnosis is very important: surgical treatment of patients with secondary breast cancer may be diagnostic and palliative.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Zinan</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Breast, Yan'an Hospital of Kunming City, Kunming, Yunnan Province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Dezhong</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ruobing</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651861</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017577</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00029</ArticleId>
            <ArticleId IdType="pmc">PMC6824816</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Cancer. 2010 Jun 02;1:27-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20842221</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Am Coll Surg. 1998 Aug;187(2):178-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9704965</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 1972 Jun;29(6):1691-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">4337956</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Surg Oncol. 2010 Feb 1;101(2):137-40</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20082359</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Oncol (R Coll Radiol). 1999;11(6):419-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10663336</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 1990 Jun;37(3):432-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2190874</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31651857</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>43</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients: Protocol for a systematic review and meta-analysis of cohort studies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e17559</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000017559</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lung cancer is the leading cause of cancer-related deaths among males and the second leading cause among females worldwide. Numerous studies have linked estrogen status to lung cancer outcome. However, there are studies with conflicting results about the effect of ERβ on survival of lung cancer. The aim of this meta-analysis is to evaluate the prognostic impact of estrogen receptor beta expression on survival among NSCLC patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We will search 15 electronic databases, including PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI from inception to June 1, 2019. We will include all cohort studies comparing overall survival of NSCLC patients with high or low estrogen receptor beta expression. The database searches will be supplemented by searching through citations and references. Two reviewers will independently screen search results to identify eligible articles, complete data collection, and conduct quality assessment. All disagreements will be resolved by an independent third reviewer. Methodological quality of the included studies will be assessed using the Newcastle- Ottawa scale. Discrepancies will be resolved by consensus or by consulting a third author. Meta-analyses will be performed, and findings will be reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The results will be submitted to a peer-reviewed journal for publication.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This review will provide a comprehensive evaluation of the evidence on the prognostic impact of ERβ expression among NSCLC patients and will help clinicians find potential treatments based on estrogen signaling.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Haisheng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Mi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, The Second Hospital of Shandong University, Jinan, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Wenna</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duan</LastName>
                    <ForeName>Cunxian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fan</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Yanhong</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047629">Estrogen Receptor beta</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047629" MajorTopicYN="N">Estrogen Receptor beta</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31651857</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000017559</ArticleId>
            <ArticleId IdType="pii">00005792-201910250-00025</ArticleId>
            <ArticleId IdType="pmc">PMC6824691</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2005 Dec 15;65(24):11287-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16357134</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2007 Dec 20;25(36):5785-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18089876</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Bras Pneumol. 2008 Aug;34(8):595-600</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18797744</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2006 Jan 1;24(1):59-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16314616</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lung Cancer. 2011 Nov;74(2):318-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21511357</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):377-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20610980</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):102-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19460433</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Transl Lung Cancer Res. 2016 Apr;5(2):202-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27186517</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 2015 Jan 02;350:g7647</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25555855</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2005 Nov 20;117(4):662-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15929081</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Carcinogenesis. 2012 Nov;33(11):2181-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22859269</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2008 Jul 15;14(14):4417-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18579664</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncogene. 2019 Feb;38(8):1225-1238</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30250297</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Epidemiology. 2011 Jan;22(1):128; author reply 128</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21150360</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2009 Sep 15;115(18):4167-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19526591</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2005 Jul 15;11(14):5084-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16033821</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Clin Exp Med. 2015 Jun 15;8(6):8686-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26309520</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Endocrinol. 2009 Feb;23(2):146-56</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19106194</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Endocrinol. 2010 Sep;24(9):1737-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20660297</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9310563</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):113-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14734459</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2001 Jul 13;285(2):340-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11444848</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA. 2000 Apr 19;283(15):2008-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10789670</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Oncol Rep. 2004 Jul;6(4):259-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15161576</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2002 Apr 1;62(7):2141-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11929836</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Epidemiol. 2001 Oct;54(10):1046-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11576817</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Fam Med. 2005 May;37(5):360-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15883903</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2009 Oct 10;374(9697):1243-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19767090</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2010 Mar 20;28(9):1540-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20159813</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2018 Jul 1;110(7):734-742</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29346580</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Semin Oncol. 2014 Feb;41(1):5-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24565577</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2004 Jan 22;350(4):379-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14736930</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31650222</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1335</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>145</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and clinical oncology</Title>
                <ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>3005-3019</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-019-03041-8</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The role of tumour-associated macrophages (TAMs) in predicting the prognosis of colorectal cancer (CRC) remains controversial. This is especially so because the prognostic significance and clinicopathological relevance of different subtypes of TAMs in the immune microenvironment of CRC have not yet been established.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the clinicopathological and prognostic value of pan-macrophages, M1-macrophages or M2-macrophages in patients with CRC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Comprehensive searched on the Medline/PubMed, Web of Science (WoS) and Google Scholar databases was conducted to identify relevant studies published up to April 2019. The association between overall survival (OS), cancer-specific survival (CSS) or disease-free survival (DFS) and TAMs was analysed by meta-analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3749 patients from 17 studies were included. The pooled hazard ratios (HRs) indicated that high-density pan-macrophages improved OS (HR 0.67, P = 0.02). The pooled HR for M2-macrophages showed that high M2-macrophages infiltration was significantly associated with shorter OS (HR 2.93, P &lt; 0.0001) and DFS (HR 2.04, P = 0.02). The pooled odds ratios (ORs) revealed that high-density TAMs was associated with high CD8+ T cell infiltration (OR 2.04, P = 0.007), no distant metastasis (NDM) (OR 0.38, P &lt; 0.0001), microsatellite instability-high (MSI-H) (OR 0.38, P = 0.001), no lymph node metastasis (NLNM) (OR 0.54, P = 0.0002) and non-mucinous cancer (OR 0.39, P &lt; 0.00001).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Unlike other solid tumours, high-density CD68+ macrophage infiltration can be a good prognostic marker for CRC. However, when macrophages act as targets of combination therapy in CRC treatment, this might be more effective for CRC patients with high CD8+ T cell infiltrate, NDM, MSI-H, NLNM and non-mucinous cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yamei</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ge</LastName>
                    <ForeName>Xiaoxu</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Xiaoming</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Shaojun</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, People's Republic of China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-3455-2968</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, People's Republic of China. wangjian519@zju.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Lifeng</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4324-8818</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Colorectal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, People's Republic of China. sunlifeng@zju.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>No. 81472819</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>No. 81672342</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>No. LY19H030012</GrantID>
                    <Agency>Natural Science Foundation of Zhejiang Province</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>No. 2019QNA7028</GrantID>
                    <Agency>Fundamental Research Funds for the Central Universities</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>No. 2019FZJD009</GrantID>
                    <Agency>Fundamental Research Funds for the Central Universities</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
            <NlmUniqueID>7902060</NlmUniqueID>
            <ISSNLinking>0171-5216</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Clinicopathological</Keyword>
            <Keyword MajorTopicYN="N">Colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">Prognostic biomarkers</Keyword>
            <Keyword MajorTopicYN="N">Tumour-associated macrophages</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31650222</ArticleId>
            <ArticleId IdType="doi">10.1007/s00432-019-03041-8</ArticleId>
            <ArticleId IdType="pii">10.1007/s00432-019-03041-8</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Hematol Oncol. 2016 Feb 06;9:8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26851944</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2014 May 23;344(6186):921-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24812208</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2017 Aug 9;6(11):e1356148</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29147608</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 2017 Oct;147(1):181-187</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28698008</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2019 Apr 3;8(7):1593806</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">31143514</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Exp Metastasis. 2007;24(2):121-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17390111</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World J Gastroenterol. 2005 Feb 28;11(8):1210-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15754407</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer. 2003 Feb 15;97(4):960-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12569594</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2009 Jan 10;27(2):186-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19064967</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Adv Exp Med Biol. 2019 Apr 11;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30969400</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2010 Apr 2;141(1):39-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20371344</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2018 Mar;109(3):863-870</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29274107</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 2018 May 26;391(10135):2128-2139</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29754777</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Cell. 2014 Dec 8;26(6):880-895</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25490450</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Oral Pathol Med. 2018 May;47(5):460-467</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28940738</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genes Dev. 2018 Oct 1;32(19-20):1267-1284</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30275043</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2014 Mar 18;110(6):1595-605</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24504370</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Med. 2018 Sep;7(9):4496-4508</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30117315</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2017 Oct 11;7(2):e1380765</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29416940</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2015 Jun 25;372(26):2509-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26028255</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2017 Jun 5;17(1):404</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28583114</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Leukoc Biol. 2009 Aug;86(2):411-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19406830</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Immunol. 2018 Dec;19(12):1319-1329</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30397348</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2014 Sep 25;513(7519):559-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25043024</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Microenviron. 2014 Aug;7(1-2):61-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24771466</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trials. 2007 Jun 07;8:16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17555582</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2016 May 24;5(8):e1189052</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27622061</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2014 Apr 25;9(4):e95893</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24770346</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2019 Jan;69(1):7-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30620402</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2010 Aug;101(8):1913-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20545696</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Hum Immunol. 2009 May;70(5):325-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19236898</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Immunol. 2004 Dec;25(12):677-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15530839</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2007 Mar 1;13(5):1472-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17332291</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2018 Aug 1;7(9):e1470729</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30228938</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Histopathology. 2018 Oct;73(4):663-671</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29906313</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Invest. 2004 Sep;114(5):623-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15343380</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Immunol. 2012 Mar;33(3):119-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22277903</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Surg Oncol. 2015 May;111(6):752-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25752960</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2007 Aug 10;7:156</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17692120</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Immunol Res. 2019 Feb 25;2019:2368249</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30931335</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2013 Aug 20;109(4):1013-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23868006</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2005 Aug 22;93(4):387-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16106245</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Med Oncol. 2011 Dec;28(4):1447-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20676804</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Res. 2006 Jan 15;66(2):605-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16423985</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2012 Aug 15;131(4):864-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21952788</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncologist. 2008;13 Suppl 3:21-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18458121</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Immunity. 2012 Dec 14;37(6):1076-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23219392</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J BUON. 2015 Jan-Feb;20(1):114-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25778305</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Dev Immunol. 2012;2012:948098</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22778768</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Biosci. 2008 Jan 01;13:453-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17981560</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2016 Feb;95(6):e2636</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26871785</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Immunol. 2015 Dec;15(12):731-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26603899</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Transl Med. 2007 Nov 29;5:62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18047662</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Science. 2011 Jan 21;331(6015):337-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21205640</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Immunity. 2014 Jul 17;41(1):14-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25035950</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2012;7(12):e50946</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23284651</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Blood. 2006 Mar 1;107(5):2112-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16269622</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2019 Mar;18(3):197-218</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30610226</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Mol Histol. 2013 Dec;44(6):679-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23801404</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2015 Nov 9;5(4):e1106677</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27141391</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28767130</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Immunol. 2011 Aug 04;12:43</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21813021</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Pharmacol. 2019 Feb 28;10:139</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30873025</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Transl Med. 2010 Feb 08;8:13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20141634</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2012;7(10):e47045</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23077543</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Immunity. 2014 Jul 17;41(1):49-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25035953</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Jan;4(1):71-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14708027</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2018 Jan 1;110(1):</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28922789</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Immunol. 2010 Oct;11(10):889-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20856220</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Immunol. 2005 Dec;5(12):953-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16322748</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Surg Oncol. 2017 Jul;24(7):1835-1842</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28213791</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23420197</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Hematol Oncol. 2017 Feb 28;10(1):58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28241846</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer. 2019 Mar 30;18(1):64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30927925</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2009 Oct 30;139(3):485-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19836068</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Exp Med. 2008 Jun 9;205(6):1261-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18490490</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Semin Cancer Biol. 2012 Aug;22(4):289-97</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22349514</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncol Rep. 2003 Mar-Apr;10(2):309-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12579264</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Jan 12;12(1):e0170042</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28081243</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2013 Sep;104(9):1237-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23734742</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31647985</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-2561</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1872</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta. Reviews on cancer</Title>
                <ISOAbbreviation>Biochim Biophys Acta Rev Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.</ArticleTitle>
            <Pagination>
                <MedlinePgn>188315</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0304-419X(19)30123-4</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbcan.2019.188315</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">Breast cancer has, due to its high incidence, the highest mortality of cancer in women. The most common molecular type of breast cancer is the luminal subtype, which expresses estrogen and progesterone receptors and is typically treated with surgery and adjuvant endocrine therapy (ET). Estrogen receptor alpha (ERα), encoded by the estrogen receptor-1 (ESR1) gene, is expressed in approximately 70% of all breast cancers, and ET represents a major treatment modality in ERα-positive cancers. However, resistance to different ET evolves frequently, leading to disease progression or recurrence in ER+ breast cancer. Acquired mutations in the Ligand Binding Domain (LBD) of the ERα referred as ESR1 mutations; could be selected by ET itself leading to resistance over the course of ET therapy.</AbstractText>
                <AbstractText Label="OBJECTIVE">The goal of this review is to estimate the effect of Aromatase Inhibitors (AIs), Tamoxifen (TAM) and Fulvestrant (FUL) on the development of ESR1 mutations in hormone-sensitive advanced breast cancer.</AbstractText>
                <AbstractText Label="METHODS">A systematic review of qualitative studies published between January 1st, 2007 and March 1st, 2019 was conducted using the PubMed and Thomas Reuters Web of Science databases. Search terms included ESR1 mutations, estrogen receptor, breast cancer, recurrent, metastatic disease, aromatase inhibitors, fulvestrant and tamoxifen. Only full-text studies in English concerning the development of ESR1 mutations and their outcomes on disease progression were included. Selection of studies was performed using predefined data fields, taking study quality indicators into consideration. Inclusion criteria of the study populations were: Ghoncheh et al. (2016) [1] female patients above 18 years; Nielsen et al. (2011) [2] Estrogen-receptor positive (ER+) breast cancer in the advanced setting; Reinert et al. (2017) [3] previous exposure to endocrine therapy including SERDs (preferably Fulvestrant), SERMs (preferably Tamoxifen) or Aromatase Inhibitors.</AbstractText>
                <AbstractText Label="RESULTS">The current review enrolled 16 articles, including 4 multicentre double blinded RCTs and 12 cohorts and comprising a total of 2632 patients. The overall incidence rate of the ESR1 mutation was 24% (95% CI: 18%-31%). We observed that D538G was the most frequent ESR1 mutation. Several studies showed that prior endocrine therapy (AIs, TAM, FUL) could result in an ESR1 mutation and therapy resistance leading to disease progression or recurrence. Different mechanisms had been implied to explain the underlying ET resistance. One of the key findings of this work is the significant difference in ESR1 mutation incidence between patients with and without AI therapy (OR: 9.34, 95% CI: 3.28-26.62, P ≤.001).</AbstractText>
                <AbstractText Label="CONCLUSION">ESR1 mutations are not uncommon phenomenon in patients with hormone-sensitive advanced breast cancer. There is a significant higher incidence rate of ESR1 mutations in patients with previous AI-containing therapeutic regimens, compared to those who received non-AI containing regimes. These ESR1 mutations could lead to the development of complete endocrine resistance to AI, whereas only partial resistance is seen in case of TAM or FUL.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Najim</LastName>
                    <ForeName>Omar</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Antwerp, Belgium. Electronic address: omar.najim@uza.be.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seghers</LastName>
                    <ForeName>Sofie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sergoynne</LastName>
                    <ForeName>Laurine</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Gaver</LastName>
                    <ForeName>Hélène</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Faculty of Medicine, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Papadimitriou</LastName>
                    <ForeName>Konstantinos</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wouters</LastName>
                    <ForeName>Kristien</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trinh</LastName>
                    <ForeName>Xuan Bich</ForeName>
                    <Initials>XB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; Faculty of Medicine, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huizing</LastName>
                    <ForeName>Manon T</ForeName>
                    <Initials>MT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; Faculty of Medicine, University of Antwerp, Belgium; Biobank, Antwerp University Hospital, Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tjalma</LastName>
                    <ForeName>Wiebren</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Multidisciplinary Breast Clinic Antwerp University Hospital, University of Antwerp, Antwerp, Belgium; Faculty of Medicine, University of Antwerp, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Biochim Biophys Acta Rev Cancer</MedlineTA>
            <NlmUniqueID>9806362</NlmUniqueID>
            <ISSNLinking>0304-419X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C506487">estrogen receptor alpha, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>094ZI81Y45</RegistryNumber>
                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>22X328QOC4</RegistryNumber>
                <NameOfSubstance UI="D000077267">Fulvestrant</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077267" MajorTopicYN="N">Fulvestrant</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065228" MajorTopicYN="N">Non-Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">And metastasis</Keyword>
            <Keyword MajorTopicYN="Y">Aromatase inhibitors</Keyword>
            <Keyword MajorTopicYN="Y">Breast cancer</Keyword>
            <Keyword MajorTopicYN="Y">Disease progression</Keyword>
            <Keyword MajorTopicYN="Y">ESR1</Keyword>
            <Keyword MajorTopicYN="Y">Endocrine therapy</Keyword>
            <Keyword MajorTopicYN="Y">Fulvestrant</Keyword>
            <Keyword MajorTopicYN="Y">Mutation</Keyword>
            <Keyword MajorTopicYN="Y">Resistance</Keyword>
            <Keyword MajorTopicYN="Y">Tamoxifen</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31647985</ArticleId>
            <ArticleId IdType="pii">S0304-419X(19)30123-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbcan.2019.188315</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31647203</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1899-5276</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>28</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in clinical and experimental medicine : official organ Wroclaw Medical University</Title>
                <ISOAbbreviation>Adv Clin Exp Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1285-1292</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.17219/acem/104543</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Interleukin 9 (IL-9) has been implicated in the pathogenesis of several tumor types, but the role of anti-IL-9 in pancreatic cancer remains unclear.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to explore the mechanism and effects of blockading IL-9 in a pancreatic cancer mouse model.</AbstractText>
                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Panc02 cells were injected subcutaneously into mice to establish a mouse model. The mice were randomly categorized into 3 groups - the control group, the immunoglobulin G (IgG) group and the anti-IL-9 group - corresponding to intravenous tail injection of phosphate-buffered saline (PBS), IgG isotype antibody and anti-IL-9 antibody, respectively. Then, the expression of IL-9, interleukin-9 receptor (IL-9r), Janus kinase 1 (Jak1), Jak3, and signal transducer and activator of transcription 3 (Stat3) mRNA was tested with quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Interleukin 9 in the tumor tissue was detected using enzyme-linked immunosorbent assay (ELISA). Western blotting and immunocytochemistry were performed to detect STAT3 and phosphorylation signal transducers and activators of transcription-3 (pSTAT3). Matrix metalloproteinase 2 (MMP2), MMP9 and vascular endothelial growth factor (VEGF) levels were assessed using immunocytochemistry.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Tumor weight in the anti-IL-9 group was significantly lower than in the other groups (p &lt; 0.05). There was a remarkable survival benefit in the anti-IL-9 group compared to the other groups (p &lt; 0.05). The concentration of IL-9 in tumor tissue was significantly downregulated in the anti-IL-9-treated mice (p &lt; 0.05). The expression of Jak1 and Jak3 mRNA and pSTAT3, MMP2 and MMP9 proteins in the anti-IL-9 group was lower than that of the PBS or IgG groups (p &lt; 0.05), but the STAT3 and VEGF protein levels showed no significant difference (p &lt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Anti-IL-9 antibody could effectively restrain the growth of pancreatic cancer in mice, and this effect may partly occur by blocking the STAT3 pathway.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Dongcheng</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qin</LastName>
                    <ForeName>Qinyi</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lei</LastName>
                    <ForeName>Ronge</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Bangli</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qin</LastName>
                    <ForeName>Shanyu</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Poland</Country>
            <MedlineTA>Adv Clin Exp Med</MedlineTA>
            <NlmUniqueID>101138582</NlmUniqueID>
            <ISSNLinking>1899-5276</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016906">Interleukin-9</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494087">Stat3 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.24</RegistryNumber>
                <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016906" MajorTopicYN="N">Interleukin-9</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">IL-9 antibody</Keyword>
            <Keyword MajorTopicYN="N">JAK2/STAT3 pathway</Keyword>
            <Keyword MajorTopicYN="N">pancreatic cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31647203</ArticleId>
            <ArticleId IdType="doi">10.17219/acem/104543</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31646964</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2164</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Oct</Month>
                        <Day>23</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC genomics</Title>
                <ISOAbbreviation>BMC Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>769</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12864-019-6129-8</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Microsatellite instability (MSI) accounts for about 15% of colorectal cancer and is associated with prognosis. Today, MSI is usually detected by polymerase chain reaction amplification of specific microsatellite markers. However, the instability is identified by comparing the length of microsatellite repeats in tumor and normal samples. In this work, we developed a qualitative transcriptional signature to individually predict MSI status for right-sided colon cancer (RCC) based on tumor samples.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Using RCC samples, based on the relative expression orderings (REOs) of gene pairs, we extracted a signature consisting of 10 gene pairs (10-GPS) to predict MSI status for RCC through a feature selection process. A sample is predicted as MSI when the gene expression orderings of at least 7 gene pairs vote for MSI; otherwise the microsatellite stability (MSS). The classification performance reached the largest F-score in the training dataset. This signature was verified in four independent datasets of RCCs with the F-scores of 1, 0.9630, 0.9412 and 0.8798, respectively. Additionally, the hierarchical clustering analyses and molecular features also supported the correctness of the reclassifications of the MSI status by 10-GPS.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The qualitative transcriptional signature can be used to classify MSI status of RCC samples at the individualized level.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fu</LastName>
                    <ForeName>Yelin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Lishuang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Wenbing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Liangliang</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>You</LastName>
                    <ForeName>Tianyi</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Shuobo</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Yunyan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Wenyuan</ForeName>
                    <Initials>W</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-6477-9434</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China. zhaowenyuan@ems.hrbmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Zheng</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150086, China. guoz@ems.hrbmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioinformatics, Key Laboratory of Ministry of Education for Gastrointestinal Cancer, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350122, China. guoz@ems.hrbmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Medical Bioinformatics, Fujian Province, Fuzhou, 350122, China. guoz@ems.hrbmu.edu.cn.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>61601151</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>61701143</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>61673143</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81872396</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>81572935</GrantID>
                    <Agency>National Natural Science Foundation of China</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>C2016037</GrantID>
                    <Agency>Natural Science Foundation of Heilongjiang Province</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>2016Y9044</GrantID>
                    <Agency>Joint Scientific and Technology Innovation Fund of Fujian Province</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Genomics</MedlineTA>
            <NlmUniqueID>100965258</NlmUniqueID>
            <ISSNLinking>1471-2164</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053842" MajorTopicYN="Y">Microsatellite Instability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Gene expression profiles</Keyword>
            <Keyword MajorTopicYN="N">Microsatellite instability status</Keyword>
            <Keyword MajorTopicYN="N">Qualitative transcriptional signature</Keyword>
            <Keyword MajorTopicYN="N">Relative gene expression orderings</Keyword>
            <Keyword MajorTopicYN="N">Right-sided colon cancer</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31646964</ArticleId>
            <ArticleId IdType="doi">10.1186/s12864-019-6129-8</ArticleId>
            <ArticleId IdType="pii">10.1186/s12864-019-6129-8</ArticleId>
            <ArticleId IdType="pmc">PMC6813057</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Medicine (Baltimore). 2018 Oct;97(42):e12788</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30334969</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>FASEB J. 2019 Jan;33(1):151-162</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29957060</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Clin Exp Pathol. 2015 Jun 01;8(6):7173-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26261611</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2016 Jul 12;115(2):164-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27310704</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Genomics. 2018 Jan 29;19(1):99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29378509</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biomed Res Int. 2016;2016:9850690</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27699178</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Rev Anticancer Ther. 2008 Feb;8(2):207-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18279062</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2015 Feb 24;107(3):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25713148</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2017 Jan 20;35(3):376-377</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28095273</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2018 Sep;18(9):527-528</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30030494</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3219-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20498393</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncoimmunology. 2019 Apr 15;8(7):1596715</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">31143520</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2017 May 2;8(18):30265-30275</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28427173</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2016 Jun 20;34(18):2141-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27022117</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biostatistics. 2003 Apr;4(2):249-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12925520</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Oncol. 2017 Feb 1;3(2):194-201</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27722750</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Oncol. 2017 Nov 1;3(11):1529-1537</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28687838</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Apr 5;7(14):19060-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26967049</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Gastroenterology. 2014 Mar;146(3):643-646.e8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24333619</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Sci. 2018 Jun;109(6):1939-1948</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29700901</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Histopathology. 2006 Jun;48(7):787-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16722926</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stat Med. 2008 Aug 15;27(18):3598-611</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18338319</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Med. 2018 Mar;7(3):746-756</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29436178</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Biotechnol. 2014 Sep;32(9):903-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25150838</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Bioinformatics. 2018 Jun 26;19(1):244</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29940833</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Immunother Cancer. 2018 Apr 17;6(1):29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29665853</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Pathol Oncol Res. 2016 Jan;22(1):225-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26306467</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Br J Cancer. 2016 Dec 6;115(12):1513-1519</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27855439</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>DNA Repair (Amst). 2016 Feb;38:147-154</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26708048</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Crit Rev Oncol Hematol. 2017 Aug;116:38-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28693799</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2014 Dec 04;107(1):357</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25479802</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 2004 May 1;328(7447):1073</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15117797</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2017 Jan 24;8(4):6652-6662</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28036264</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Adv Biomed Res. 2018 Feb 16;7:28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29531926</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Hum Pathol. 2015 Nov;46(11):1582-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26297254</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stat Med. 1990 Jul;9(7):811-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2218183</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Diagn Mol Pathol. 2006 Jun;15(2):63-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16778585</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2003 Jul 17;349(3):247-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12867608</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Apr 26;7(17):24097-110</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27006471</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Pathol Lab Med. 2010 Jun;134(6):930-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20524870</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stat Appl Genet Mol Biol. 2004;3:Article19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16646797</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Oct 18;7(42):68909-68920</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27634898</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2017 Sep 21;8(49):86356-86368</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29156800</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Brief Bioinform. 2016 Mar;17(2):233-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26254430</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2016 Feb 23;7(8):8743-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26840027</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Pathol Lab Med. 2014 Mar;138(3):363-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24576032</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Treat Rev. 2016 Dec;51:19-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27838401</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Chem. 2018 Jun;64(6):950-958</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29632127</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Bioinformatics. 2005 Oct 15;21(20):3896-904</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16105897</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Brief Bioinform. 2019 Mar 20;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30895303</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Liver Int. 2018 Oct;38(10):1812-1819</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29682909</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Fam Cancer. 2013 Jun;12(2):241-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23435936</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Cancer Res. 2018 May;16(5):805-812</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29523759</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Genomics. 2017 Nov 28;18(1):913</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29179677</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Pathol. 2012 Dec;228(4):586-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22926706</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Cancer. 2017 Dec 13;17(1):844</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29237416</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2015 Dec 29;6(42):44593-608</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26527319</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31646652</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-9098</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>120</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of surgical oncology</Title>
                <ISOAbbreviation>J Surg Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1404-1411</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/jso.25733</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III) + (II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In a multivariable model based on preoperative plasma samples suPAR(I-III) + (II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95% confidence interval [CI], 1.78-5.28; P &lt; .0001) and 2.24 (95% CI, 1.59-3.16; P &lt; .0001) for suPAR(I-III) + (II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55% and 34% reduction in the risk estimate of death for suPAR(I-III) + (II-III) and uPAR(I), respectively.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.</AbstractText>
                <CopyrightInformation>© 2019 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rolff</LastName>
                    <ForeName>Hans C</ForeName>
                    <Initials>HC</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-1540-7148</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology and Transplantation, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christensen</LastName>
                    <ForeName>Ib J</ForeName>
                    <Initials>IJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svendsen</LastName>
                    <ForeName>Lars B</ForeName>
                    <Initials>LB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology and Transplantation, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilhelmsen</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lund</LastName>
                    <ForeName>Ida K</ForeName>
                    <Initials>IK</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biotech Research Innovation Center - BRIC, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thurison</LastName>
                    <ForeName>Tine</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biotech Research Innovation Center - BRIC, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Høyer-Hansen</LastName>
                    <ForeName>Gunilla</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biotech Research Innovation Center - BRIC, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Illemann</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Biotech Research Innovation Center - BRIC, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nielsen</LastName>
                    <ForeName>Hans J</ForeName>
                    <Initials>HJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Danish Collaborative Research Group on Colorectal Cancer</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D023361">Validation Studies</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Surg Oncol</MedlineTA>
            <NlmUniqueID>0222643</NlmUniqueID>
            <ISSNLinking>0022-4790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D055293">Receptors, Urokinase Plasminogen Activator</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055293" MajorTopicYN="N">Receptors, Urokinase Plasminogen Activator</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">biomarkers</Keyword>
            <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
            <Keyword MajorTopicYN="N">personalized medicine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31646652</ArticleId>
            <ArticleId IdType="doi">10.1002/jso.25733</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31646533</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1131</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Role of Mitochondrial Calcium Signaling in the Pathophysiology of Cancer Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>747-770</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-12457-1_30</ELocationID>
            <Abstract>
                <AbstractText>The pioneering work of Richard Altman on the presence of mitochondria in cells set in motion a field of research dedicated to uncovering the secrets of the mitochondria. Despite limitations in studying the structure and function of the mitochondria, advances in our understanding of this organelle prompted the development of potential treatments for various diseases, from neurodegenerative conditions to muscular dystrophy and cancer. As the powerhouses of the cell, the mitochondria represent the essence of cellular life and as such, a selective advantage for cancer cells. Much of the function of the mitochondria relies on Ca<sup>2+</sup> homeostasis and the presence of effective Ca<sup>2+</sup> signaling to maintain the balance between mitochondrial function and dysfunction and subsequently, cell survival. Ca<sup>2+</sup> regulates the mitochondrial respiration rate which in turn increases ATP synthesis, but too much Ca<sup>2+</sup> can also trigger the mitochondrial apoptosis pathway; however, cancer cells have evolved mechanisms to modulate mitochondrial Ca<sup>2+</sup> influx and efflux in order to sustain their metabolic demand and ensure their survival. Therefore, targeting the mitochondrial Ca<sup>2+</sup> signaling involved in the bioenergetic and apoptotic pathways could serve as potential approaches to treat cancer patients. This chapter will review the role of Ca<sup>2+</sup> signaling in mediating the function of the mitochondria and its involvement in health and disease with special focus on the pathophysiology of cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sterea</LastName>
                    <ForeName>Andra M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El Hiani</LastName>
                    <ForeName>Yassine</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada. yassine.elhiani@dal.ca.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002118" MajorTopicYN="Y">Calcium</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008928" MajorTopicYN="Y">Mitochondria</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Calcium signaling</Keyword>
            <Keyword MajorTopicYN="N">Calcium uptake</Keyword>
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Cancer treatment</Keyword>
            <Keyword MajorTopicYN="N">Mitochondria</Keyword>
            <Keyword MajorTopicYN="N">Mitochondrial dysfunction</Keyword>
            <Keyword MajorTopicYN="N">ROS</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31646533</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-12457-1_30</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31646523</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1131</Volume>
                    <PubDate>
                        <Year>2020</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels.</ArticleTitle>
            <Pagination>
                <MedlinePgn>505-517</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-12457-1_20</ELocationID>
            <Abstract>
                <AbstractText>Cancer cells acquire the ability to modify the calcium signaling network by altering the expression and functions of cation channels, pumps or transporters. Calcium signaling pathways are involved in proliferation, angiogenesis, invasion, immune evasion, disruption of cell death pathways, ECM remodelling, epithelial-mesenchymal transition (EMT) and drug resistance. Among cation channels, a pivotal role is played by the Transient Receptor Potential non-selective cation-permeable receptors localized in plasma membrane, endoplasmic reticulum, mitochondria and lysosomes. Several findings indicate that the dysregulation in calcium signaling induced by TRP channels is responsible for cancer growth, metastasis and chemoresistance. Drug resistance represents a major limitation in the application of current therapeutic regimens and several efforts are spent to overcome it. Here we describe the ability of Transient Receptor Potential Channels to modify, by altering the intracellular calcium influx, the cancer cell sensitivity to chemotherapeutic drugs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Santoni</LastName>
                    <ForeName>Giorgio</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Immunopathology and Molecular Medicine Laboratory, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morelli</LastName>
                    <ForeName>Maria Beatrice</ForeName>
                    <Initials>MB</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Immunopathology and Molecular Medicine Laboratory, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marinelli</LastName>
                    <ForeName>Oliviero</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Immunopathology and Molecular Medicine Laboratory, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nabissi</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Immunopathology and Molecular Medicine Laboratory, University of Camerino, Camerino, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santoni</LastName>
                    <ForeName>Matteo</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic and Oncology Unit, Macerata Hospital, Macerata, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amantini</LastName>
                    <ForeName>Consuelo</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy. consuelo.amantini@unicam.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050051">Transient Receptor Potential Channels</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SY7Q814VUP</RegistryNumber>
                <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050051" MajorTopicYN="Y">Transient Receptor Potential Channels</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Ca2+ dysregulation</Keyword>
            <Keyword MajorTopicYN="N">Cancer</Keyword>
            <Keyword MajorTopicYN="N">Chemoresistance</Keyword>
            <Keyword MajorTopicYN="N">TRPC5</Keyword>
            <Keyword MajorTopicYN="N">TRPC6</Keyword>
            <Keyword MajorTopicYN="N">TRPM7</Keyword>
            <Keyword MajorTopicYN="N">TRPM8</Keyword>
            <Keyword MajorTopicYN="N">TRPV1</Keyword>
            <Keyword MajorTopicYN="N">TRPV2</Keyword>
            <Keyword MajorTopicYN="N">TRPV6</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31646523</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-12457-1_20</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31646374</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1335</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>145</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and clinical oncology</Title>
                <ISOAbbreviation>J. Cancer Res. Clin. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2911-2920</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00432-019-03040-9</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (≤ 5 µm of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vim<sup>+</sup> CTCs). Liver metastases were reported in 7 (11.5%) patients and were significantly correlated to the presence of Vim<sup>+</sup> CTCs (p = 0.002), with a high positivity rate of 71.4% (5/7). Vim<sup>+</sup> CTCs were mostly in small cell size and Chr8 aneuploidy (77.0% and 82.05%, respectively). Baseline small cell CTCs ≥ 2/6 ml, triploid CTCs ≥ 2/6 ml, Vim<sup>+</sup> CTCs ≥ 1/6 ml were found to significantly correlate with poor progression-free survival (PFS) (p = 0.017, p = 0.009 and p = 0.001, respectively). After adjusting for clinically significant factors, baseline Vim<sup>+</sup> CTCs ≥ 1/6 ml was the only independent predictor of poor PFS [hazard ratio (HR):2.756, 95% confidence interval (CI): 1.239-6.131; p = 0.013].</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim<sup>+</sup> CTCs are in small size and Chr8 aneuploidy. Baseline presence of Vim<sup>+</sup> CTCs is correlated with liver metastases and may help predict poor PFS.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing, 100043, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Yanxia</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Lina</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gao</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Fanbin</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Peter Ping</ForeName>
                    <Initials>PP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cytelligen, San Diego, CA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Baolan</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China. libaolan1109@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Tongmei</ForeName>
                    <Initials>T</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-4271-3773</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No.9, Beiguan Street, Tongzhou District, Beijing, 101149, China. tongmeibj@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>171100001017038</GrantID>
                    <Agency>Beijing Municipal Science &amp; Technology Commission</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>YH201920</GrantID>
                    <Agency>Tongzhou lianggao talents project</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>KJ2019CX015</GrantID>
                    <Agency>Tongzhou district science and technology committee project</Agency>
                    <Country/>
                </Grant>
                <Grant>
                    <GrantID>11920703</GrantID>
                    <Agency>Beijing universities advanced subject construction project the joint project of capital medical university and Peking union medical college on clinical medicine</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>J Cancer Res Clin Oncol</MedlineTA>
            <NlmUniqueID>7902060</NlmUniqueID>
            <ISSNLinking>0171-5216</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014746">Vimentin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D002898" MajorTopicYN="N">Chromosomes, Human, Pair 8</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Advanced lung cancer</Keyword>
            <Keyword MajorTopicYN="N">Aneuploidy of Chr8</Keyword>
            <Keyword MajorTopicYN="N">Cell size</Keyword>
            <Keyword MajorTopicYN="N">Circulating tumor cells</Keyword>
            <Keyword MajorTopicYN="N">Progression-free survival</Keyword>
            <Keyword MajorTopicYN="N">Vimentin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31646374</ArticleId>
            <ArticleId IdType="doi">10.1007/s00432-019-03040-9</ArticleId>
            <ArticleId IdType="pii">10.1007/s00432-019-03040-9</ArticleId>
            <ArticleId IdType="pmc">PMC6861204</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Lung Cancer. 2014 Aug;85(2):314-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24882383</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Chin J Cancer Res. 2016 Dec;28(6):579-588</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28174486</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Cell. 2015 Jan 12;27(1):15-26</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25584892</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genet Mol Res. 2015 Sep 01;14(3):10352-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26345975</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2017 Oct;17(10):605-619</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28912577</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Med. 2013 Nov;19(11):1450-64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24202397</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Cancer. 2015 Mar 1;136(5):E359-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25220842</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>PLoS One. 2017 Jul 18;12(7):e0181211</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28719656</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Transl Med. 2015 Dec;4(1):38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26718583</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lung Cancer. 2018 Oct;124:270-278</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30268472</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Chonnam Med J. 2016 Sep;52(3):151-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27689025</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Pathol. 2000 Jan;156(1):57-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10623654</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Oncol. 2017 Jul;11(7):770-780</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28544498</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16857794</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Oncol. 2012 Nov;23(11):2937-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22689177</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Cancer Res. 2018 Nov 1;24(21):5261-5271</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30012565</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Invest. 2009 Jun;119(6):1429-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19487819</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26808342</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Lab. 2017 Oct 1;63(10):1575-1579</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29035448</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Rev Cancer. 2002 Jun;2(6):442-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12189386</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncol Lett. 2016 Dec;12(6):4720-4726</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28105179</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Cell Biol. 2011 Feb 7;192(3):373-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21300848</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int J Oncol. 2014 Jul;45(1):227-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24788213</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Biol Ther. 2019;20(4):546-551</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30572767</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Transl Med. 2010 Mar 31;2(25):25ra23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20424012</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biomed Res Int. 2018 May 31;2018:6387810</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29955607</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2012 Feb 10;30(5):525-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22253462</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cell. 2016 Jun 30;166(1):21-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27368099</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Diagnostics (Basel). 2018 Apr 18;8(2):null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29670052</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cancer Discov. 2017 Jul 20;:null</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28729406</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Oncotarget. 2017 Jul 25;8(30):49329-49337</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28521303</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31645497</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>12</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1672-7347</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>44</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Sep</Month>
                        <Day>28</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences</Title>
                <ISOAbbreviation>Zhong Nan Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Radiomics in predicting tumor molecular marker P63 for non-small cell lung cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1055-1062</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.11817/j.issn.1672-7347.2019.180752</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To establish a radiomics signature based on CT images of non-small cell lung cancer (NSCLC) to predict the expression of molecular marker P63.  Methods: A total of 245 NSCLC patients who underwent CT scans were retrospectively included. All patients were confirmed by histopathological examinations and P63 expression were examined within 2 weeks after CT examination. Radiomics features were extracted by MaZda software and subjective image features were defined from original non-enhanced CT images. The Lasso-logistic regression model was used to select features and develop radiomics signature, subjective image features model, and combined diagnostic model. The predictive performance of each model was evaluated by the receiver operating characteristic (ROC) curve, and compared with Delong test.  Results: Of the 245 patients, 96 were P63 positive and 149 were P63 negative. The subjective image feature model consisted of 6 image features. Through feature selection, the radiomics signature consisted of 8 radiomics features. The area under the ROC curves of the subjective image feature model and the radiomics signature in predicting P63 expression statue were 0.700 and 0.755, respectively, without a significant difference (P&gt;0.05). The combined diagnostic model showed the best predictive power (AUC=0.817, P&lt;0.01).  Conclusion: The radiomics-based CT scan images can predict the expression status of NSCLC molecular marker P63. The combination of the radiomics features and subjective image features can significantly improve the predictive performance of the predictive model, which may be helpful to provide a non-invasive way for understanding the molecular information for lung cancer cells.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Qianbiao</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013; Department of Radiology, People's Hospital of Hunan Province, First Affiiated Hospital, Hunan Normal University, Changsha 410002, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Zhichao</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Xiaoli</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>First Hospital of Hunan University of Chinese Medicine, Changsha 410007, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Mengtian</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mustafa Jumbe</LastName>
                    <ForeName>Mwajuma</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Muhimbili National Hospital, Dar es Salaam 65000, Tanzania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yan</LastName>
                    <ForeName>Haixiong</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, People's Hospital of Hunan Province, First Affiiated Hospital, Hunan Normal University, Changsha 410002, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rong</LastName>
                    <ForeName>Pengfei</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhong Nan Da Xue Xue Bao Yi Xue Ban</MedlineTA>
            <NlmUniqueID>101230586</NlmUniqueID>
            <ISSNLinking>1672-7347</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherAbstract Type="Publisher" Language="chi">
            <AbstractText>目的：建立基于非小细胞肺癌(non-small cell lung cancer，NSCLC)肿瘤CT图像的影像组学模型，预测NSCLC分子标志物P63的表达状态。方法：回顾性分析2014年1月至2018年3月接受CT扫描的245例NSCLC患者。患者均经组织病理学检查确诊，并在CT检查后2周内进行P63表达状态检测。通过MaZda软件提取CT平扫图像的影像组学特征，并且定义肿瘤CT图像的主观影像征象。使用Lasso-logistic回归模型进行特征筛选并分别建立影像组学模型、主观影像征象模型及融合诊断模型。通过受试者操作特征(receiver operator characteristic，ROC)曲线评估每个模型的预测性能，并采用Delong检验进行比较。结果：在245例患者中，P63阳性96例，P63阴性149例。主观影像征象模型由6个影像征象组成。通过特征选择，影像组学模型包括8个影像组学特征。主观影像征象模型和影像组学模型预测P63表达状态的ROC曲线下面积分别为0.700和0.755，二者差异无统计学意义(P&gt;0.05)。融合诊断模型较另2种模型具有最佳预测能力，ROC曲线下面积为 0.817(P&lt;0.01)。结论：基于CT图像的影像组学模型可以预测NSCLC分子标志物P63的表达状态；融合影像组学特征和主观影像征象的诊断模型可以显著提高模型的预测性能，有助于无创性了解肺癌细胞分子水平信息。.</AbstractText>
        </OtherAbstract>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31645497</ArticleId>
            <ArticleId IdType="doi">10.11817/j.issn.1672-7347.2019.180752</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


</PubmedArticleSet>